<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005392.pub2" GROUP_ID="COLOCA" ID="842005011316534425" MERGED_FROM="" MODIFIED="2009-05-13 16:22:11 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Exported from Review Manager 4.3.2&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;Old title: Anti-angiogenic therapy for colorectal cancer&lt;/p&gt;" NOTES_MODIFIED="2009-05-13 16:19:28 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="085" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2009-05-13 15:25:37 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-03-30 22:12:55 +0200" MODIFIED_BY="[Empty name]">Anti-angiogenic therapies for metastatic colorectal cancer</TITLE>
<CONTACT>
<PERSON ID="A7682B6682E26AA201ACDCB9E2764B22" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anna Dorothea</FIRST_NAME>
<MIDDLE_INITIALS>ADW</MIDDLE_INITIALS>
<LAST_NAME>Wagner</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Cheffe de Clinique</POSITION>
<EMAIL_1>Anna-Dorothea.Wagner@gmx.de</EMAIL_1>
<EMAIL_2/>
<URL>www.cancer-chuv.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Fondation du Centre Pluridisciplinaire d'Oncologie</DEPARTMENT>
<ORGANISATION>Centre Hospitalier Universitaire Vaudois</ORGANISATION>
<ADDRESS_1>Rue du Bugnon 46</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lausanne</CITY>
<ZIP>1011</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+ 41 21 314 0206</PHONE_1>
<PHONE_2/>
<FAX_1>+ 41 21 314 0200</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-05-13 11:22:30 +0200" MODIFIED_BY="[Empty name]">
<PERSON ID="A7682B6682E26AA201ACDCB9E2764B22" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anna Dorothea</FIRST_NAME>
<MIDDLE_INITIALS>ADW</MIDDLE_INITIALS>
<LAST_NAME>Wagner</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Cheffe de Clinique</POSITION>
<EMAIL_1>Anna-Dorothea.Wagner@gmx.de</EMAIL_1>
<EMAIL_2/>
<URL>www.cancer-chuv.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Fondation du Centre Pluridisciplinaire d'Oncologie</DEPARTMENT>
<ORGANISATION>Centre Hospitalier Universitaire Vaudois</ORGANISATION>
<ADDRESS_1>Rue du Bugnon 46</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lausanne</CITY>
<ZIP>1011</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+ 41 21 314 0206</PHONE_1>
<PHONE_2/>
<FAX_1>+ 41 21 314 0200</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B8751B4C82E26AA2014A5594DD911813" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Dirk</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Arnold</LAST_NAME>
<SUFFIX/>
<POSITION>MD</POSITION>
<EMAIL_1>dirk.arnold@medizin.uni-halle.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine IV</DEPARTMENT>
<ORGANISATION>Martin Luther University Halle Wittenberg</ORGANISATION>
<ADDRESS_1>Ernst Grube Str 40</ADDRESS_1>
<ADDRESS_2/>
<CITY>Halle/Saale</CITY>
<ZIP>06120</ZIP>
<REGION>Sachsen Anhalt</REGION>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 345 557 2924</PHONE_1>
<PHONE_2/>
<FAX_1>+49 345 557 2224</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16660" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Axel</FIRST_NAME>
<MIDDLE_INITIALS>AG</MIDDLE_INITIALS>
<LAST_NAME>Grothey</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Medicine</POSITION>
<EMAIL_1>grothey.axel@mayo.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Medical Oncology</DEPARTMENT>
<ORGANISATION>Mayo Clinic College of Medicine</ORGANISATION>
<ADDRESS_1>200 First Street SW</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rochester</CITY>
<ZIP>MN 55905</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 507 266 ext.0029</PHONE_1>
<PHONE_2/>
<FAX_1>+1 507 284 1803</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16661" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Johannes</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Haerting</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Department</POSITION>
<EMAIL_1>johannes.haerting@medizin.uni-halle.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Medical Epidemiology, Biostatistics and Informatics</DEPARTMENT>
<ORGANISATION>Martin Luther University Halle Wittenberg</ORGANISATION>
<ADDRESS_1>Magdeburger Str 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Halle (Saale)</CITY>
<ZIP>06112</ZIP>
<REGION>Sachsen Anhalt</REGION>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 345 557 ext: 3570</PHONE_1>
<PHONE_2/>
<FAX_1>+49 345 557 3850</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8DB2560482E26AA20022B7F8E830FD01" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Unverzagt</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Biometrician</POSITION>
<EMAIL_1>susanne.unverzagt@medizin.uni-halle.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Medical Epidemiology, Biostatistics and Informatics</DEPARTMENT>
<ORGANISATION>Martin Luther University Halle-Wittenberg</ORGANISATION>
<ADDRESS_1>Magdeburge Straﬂe 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Halle (Saale)</CITY>
<ZIP>06097</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 345 5574486</PHONE_1>
<PHONE_2/>
<FAX_1>+49 345 5573580</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-05-13 11:19:39 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="5" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="9" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2009-05-13 15:25:37 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 15:25:37 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>copy edited version</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Coordinating Centre for Clinical Trials, Martin-Luther University Halle-Wittenberg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Ministry for Education and Research (grant number: 01 KG 0603)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-13 16:19:28 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-05-13 15:56:03 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-05-13 15:56:03 +0200" MODIFIED_BY="[Empty name]">The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both progression-free survival as well as overall survival in first- and second line therapy.</TITLE>
<SUMMARY_BODY MODIFIED="2009-05-11 14:03:01 +0200" MODIFIED_BY="[Empty name]">
<P>Angiogenesis refers to the development of new blood vessels from the pre-existing vascular bed. Tumours are dependent on the formation of new blood vessels for their growth. Agents which inhibit the formation of new blood vessels are commonly referred to as "anti-angiogenic therapies". They are a new class of molecular designed drugs, among which one (bevacizumab) is already routinely used in clinical practice. Data from 5 randomized trials, which included a total of 3101 patients and evaluated the effect of bevacizumab, are currently available. Furthermore, data from one study, which included a total of 1168 patients and evaluated the effect of valatinib is published. The addition of bevacizumab to chemotherapy prolongs both progression-free survival from about 7.1 to 9.7 months when used as primary treatment and overall survival from about 17.7 to 20.5 months after prior use of chemotherapy (so called "second-line therapy") for metastatic colorectal cancer. However, the magnitude of the effect on progression-free survival is variable and probably depends on the type of chemotherapy to which it is associated. Vatalanib has no significant effect on progression-free and overall survival. Adverse effects of bevacizumab include increased frequencies of high blood pressure, arterial thromboembolic events and bowel perforations.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-13 11:45:29 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-05-11 12:17:11 +0200" MODIFIED_BY="[Empty name]">
<P>Angiogenesis inhibitors have been developed to block tumour angiogenesis and target vascular endothelial cells. While some of them have already been approved by the health authorities and are successfully integrated into patient care, many others are still under development, and the clinical value of this approach has to be established.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-05-11 14:02:25 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and toxicity of targeted anti-angiogenic therapies, in addition to chemotherapy, in patients with metastatic colorectal cancer. Primary endpoints are both progression-free and overall survival. Response rates, toxicity and secondary resectability were secondary endpoints. Comparisons were first-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor; and second-line chemotherapy, to the same chemotherapy without angiogenesis inhibitor.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-04-06 01:55:40 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials, MEDLINE, as well as proceedings from ECCO, ESMO and ASCO until November 2008. In addition, reference lists from trials were scanned, experts in the field and drug manufacturers were contacted to obtain further information. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-05-11 12:59:09 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials on targeted anti-angiogenic drugs in metastatic colorectal cancer (MCRC).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-05-11 13:00:17 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. Summary statistics for the primary endpoints were hazard ratios (HR's) and their 95% confidence intervals.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-05-13 11:45:29 +0200" MODIFIED_BY="[Empty name]">
<P>At present, eligible first line trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients) and vatalanib (1 trial which included 1168 patients). The overall HR¥s for PFS (0.61, 95% CI 0.45 - 0.83) and OS (0.81, 95% 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, confirms significant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity. For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95% CI 0.51 - 0.73) and OS (HR 0.75, 95% CI 0.63-0.89) was demonstrated in a single, randomized trial. While differences in treatment-related deaths and 60-day mortality were not significant, higher incidences in grade III/IV hypertension, arterial thrombembolic events and gastrointestinal perforations were observed in the patients treated with bevacizumab. For valatanib, currently available data showed a non-significant benefit in PFS and OS.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-04-06 06:16:54 +0200" MODIFIED_BY="[Empty name]">
<P>The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both PFS and OS in first-and second-line therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-13 16:15:52 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-05-11 16:28:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Epidemiology and Prognosis:</B>
</P>
<P>Colorectal cancer (CRC) currently ranks third in global cancer incidence (<LINK REF="REF-Parkin-2001" TYPE="REFERENCE">Parkin 2001</LINK>). In the U.S., 145.290 cases of colorectal cancer are expected to occur in 2005 (<LINK REF="REF-Am.-Cancer-Soc.-2005" TYPE="REFERENCE">Am. Cancer Soc. 2005</LINK>). Although surgery is the most common treatment, 40-50 % of patients who undergo potentially curative surgery ultimately relapse and die of metastatic disease (<LINK REF="REF-Obrand-1997" TYPE="REFERENCE">Obrand 1997</LINK>). In addition, 20-25% of patients with colorectal cancer already have metastases (stage IV) at diagnosis (<LINK REF="REF-Hamilton-1998" TYPE="REFERENCE">Hamilton 1998</LINK>). For these patients, systemic therapy is the primary treatment option.</P>
<P>
<BR/>
<B>Systemic chemotherapy:</B> 5-fluorouracil (5-FU), usually administered with folinic acid (FA), is the backbone of treatment for CRC. Historically, in patients with advanced disease, treatment with bolus administration of 5-FU/LV achieved an objective response rate of approximately 20% and was found to prolong median overall survival (OS) from approximately six months (best supportive care only) to 11 months (<LINK REF="REF-Scheithauer-1993" TYPE="REFERENCE">Scheithauer 1993</LINK>; <LINK REF="REF-CRC-Meta_x002d_anal.-2000" TYPE="REFERENCE">CRC Meta-anal. 2000</LINK>). In the mid 90¥s, the integration of oxaliplatin and irinotecan into infusional 5-FU/FA regimens resulted in a significant improvement of response rates (uniformly 45-54%) and prolongation of progression-free survival (from 4.5 to 8 months) (<LINK REF="REF-de-Gramont-2000" TYPE="REFERENCE">de Gramont 2000</LINK>; <LINK REF="REF-Douillard-2000" TYPE="REFERENCE">Douillard 2000</LINK>; <LINK REF="REF-Giacchetti-2000" TYPE="REFERENCE">Giacchetti 2000</LINK>; <LINK REF="REF-Grothey-2002" TYPE="REFERENCE">Grothey 2002</LINK>; <LINK REF="REF-Saltz-2000" TYPE="REFERENCE">Saltz 2000</LINK>). Furthermore, median overall survival in these trials was extended to 14-18 months. Further analyses have shown that survival is prolonged to more than 20 months when all three drugs are used at some point in the care of the patient (<LINK REF="REF-Grothey-2004" TYPE="REFERENCE">Grothey 2004</LINK>). Whereas 5FU/FA remains the backbone of the majority of treatment options, oral fluoropyrimidines like UFT (uracil-ftorafur)/FA or capecitabine demonstrate similar efficacy when compared to 5-FU/FA - as a single agent and in combination with oxaliplatin (<LINK REF="REF-Arkenau-2008" TYPE="REFERENCE">Arkenau 2008</LINK>).</P>
<P>
<B>
<BR/>Angiogenesis: </B>Angiogenesis refers to the development of new blood vessels from the pre-existing vascular bed. It is a highly complex, dynamic process, necessary for the supply of oxygen, nutrients, growth factors, hormones, proteolytic enzymes and dissemination of tumour cells to distant sites. Angiogenesis is regulated by a number of pro- angiogenic and anti-angiogenic molecules. Physiological angiogenesis is only transiently observed during embryogenesis, wound healing and reproductive functions in adults. In contrast, abnormal angiogenesis contributes to certain chronic diseases, such as diabetes, psoriasis, rheumatoid arthritis and malignant tumours (<LINK REF="REF-Folkman-1990" TYPE="REFERENCE">Folkman 1990</LINK>; <LINK REF="REF-Fidler-1994" TYPE="REFERENCE">Fidler 1994</LINK>). The dependence of tumour growth on the development of a neovasculature is now a well-established aspect of cancer biology (<LINK REF="REF-Folkman-1971" TYPE="REFERENCE">Folkman 1971</LINK>). A tumour requires angiogenesis to grow beyond 1-2 mm in size and to facilitate metastasis. During tumour progression, the pre-vascular and the vascular phase may be distinguished. In the initial pre-vascular phase, tumour growth is sustained by nutrients and oxygen through passive diffusion from the host vasculature. Cell proliferation and cell death are balanced, and the size of the tumour does not exceed a few mm. Once neovascularization occurs, the tumour acquires a rapid growth rate and increased metastatic potential (<LINK REF="REF-Hanahan-1996" TYPE="REFERENCE">Hanahan 1996</LINK>). Either genetic changes or local alterations including acidic pH, cytokines, growth factors or hypoxia may induce the change from a quiescent to an invasive phenotype, also called the "angiogenic switch" (<LINK REF="REF-Bergers-2003" TYPE="REFERENCE">Bergers 2003</LINK>). In addition, recruitment of circulating endothelial cells differentiated from stem cells into the newly formed blood vessels (<LINK REF="REF-Lyden-2001" TYPE="REFERENCE">Lyden 2001</LINK>), and intusseption, a process of splitting large "mother" blood vessels into smaller "daughter" vessels (<LINK REF="REF-Dvorak-2002" TYPE="REFERENCE">Dvorak 2002</LINK>), have been reported to participate in tumour vessel growth (<LINK REF="REF-Cao-2004" TYPE="REFERENCE">Cao 2004</LINK>). Tumour neovascularization exhibits fundamental morphological differences: in contrast to the normal blood vessel architecture, tumour vessels are irregular, heterogeneous, and leaky (<LINK REF="REF-McDonald-2002" TYPE="REFERENCE">McDonald 2002</LINK>). They do not exhibit a clear distinction between arterioles and venules, and their endothelial cells are disorganized, irregularly shaped, and sometimes overlap each other.</P>
<P>
<BR/>
<B>Angiogenesis Inhibitors</B> have been developed to block tumour angiogenesis and target vascular endothelial cells. Anti-angiogenic therapy presents various advantages as compared to conventional therapy. First, normal endothelial cells are quiescent under physiological conditions while tumour endothelial cells are actively proliferating and migrating (<LINK REF="REF-Longo-2002" TYPE="REFERENCE">Longo 2002</LINK>). Secondly, endothelial cells are genetically stable and represent a more uniform target as compared to the heterogeneous population of tumour cells (<LINK REF="REF-Rak-1996" TYPE="REFERENCE">Rak 1996</LINK>). Third, tumour endothelium can be easily reached by anti-angiogenic agents given by systemic administration. Finally, synergistic effects when combined with cytotoxic drugs and radiation therapy have been demonstrated for various compounds (<LINK REF="REF-Kakeji-1997" TYPE="REFERENCE">Kakeji 1997</LINK>).</P>
<P>Angiogenesis Inhibitors may be classified as direct, indirect or mixed inhibitors (<LINK REF="REF-Gasparini-2005" TYPE="REFERENCE">Gasparini 2005</LINK>):<BR/>
</P>
<UL>
<LI>Direct angiogenesis-inhibitors target the endothelial cells involved in the malignant disease by inhibiting their ability to proliferate, migrate, or form new blood vessels</LI>
<LI>Indirect angiogenesis-inhibitors interfere with the production of angiogenic factors by malignant, stromal or inflammatory cells or extracellular processes</LI>
<LI>Mixed angiogenesis-inhibitors, such as multi targeting kinase inhibitors, target both tumour endothelial and malignant cells</LI>
</UL>
<P>
<BR/>Principally, angiogenesis can be targeted by several mechanisms (<LINK REF="REF-Sivakumar-2005" TYPE="REFERENCE">Sivakumar 2005</LINK>):<BR/>
</P>
<UL>
<LI>binding of angiogenic factors, such as vascular endothelial growth factor (VEGF), e.g. anti-VEGF antibodies, VEGF trap</LI>
<LI>blockade of angiogenic factor receptors, e.g. anti-VEGF-receptor (R) antibodies</LI>
<LI>interruption of intracellular signalling pathways, e.g. tyrosine kinase inhibitors</LI>
<LI>mimetics of endogenous angiogenesis inhibitors, e.g. angiostatin-1 and -2, endostatin, thrombospondin 1</LI>
</UL>
<P>
<BR/>
<B>Vascular endothelial growth factor (VEGF)</B> deserves special attention in this context. It is one of the key regulators of angiogenesis. Activation of the VEGF-receptor pathway triggers a network of signalling processes that promotes endothelial cell growth, migration, and survival from pre-existing vasculature. In addition, VEGF mediates vessel permeability, has been associated with malignant effusions, and is involved in the mobilization of endothelial progenitor cells from the bone marrow to distant sites of neovascularization (<LINK REF="REF-Hicklin-2005" TYPE="REFERENCE">Hicklin 2005</LINK>; <LINK REF="REF-Zebrowski-1999" TYPE="REFERENCE">Zebrowski 1999</LINK>). Bevacizumab, an anti-VEGF-antibody is the first anti-angiogenic agent, which, when used in combination with chemotherapy, has been approved by the authorities (US: FDA; Europe: EMEA and others) for the treatment of metastatic CRC.</P>
<P>Currently, angiogenesis inhibitors are usually combined with chemotherapy. In addition to the scheduling of anti-angiogenic agents, the optimal scheduling of chemotherapy in combination with angiogenesis inhibitors and the optimal clinical setting remain to be determined (<LINK REF="REF-Gasparini-2005" TYPE="REFERENCE">Gasparini 2005</LINK>). Many available angiogenesis inhibitors have produced remarkable anti-tumour effects in animal models (<LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>). However, there are fundamental differences between experimental animal tumours and spontaneous human cancers (<LINK REF="REF-Cao-2004" TYPE="REFERENCE">Cao 2004</LINK>), and it is uncertain if angiogenesis inhibitors will produce similar effects in human cancer. Despite excellent preclinical data, some pivotal trials have had disappointing results (<LINK REF="REF-Miller-2005" TYPE="REFERENCE">Miller 2005</LINK>), and the clinical value of this strategy remains to be established. For this purpose, a systematic review of efficacy and toxicity of anti-angiogenic therapy for colorectal cancer is considered important. This review has focused on anti-angiogenic therapies for metastatic disease. The use of anti-angiogenic therapies as adjuvant treatment after curative resection will not be subject of this review.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-05-11 16:28:20 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>To evaluate, in terms of efficacy and toxicity, the effect of anti-angiogenic therapy - either alone or in combination with other targeted drugs - in addition to chemotherapy in patients with metastatic CRC.</P>
<P>Comparisons will be as follows:<BR/>
</P>
<UL>
<LI>1) First-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor</LI>
<LI>2) Second-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor</LI>
</UL>
<P>For each anti-angiogenic drug, all outcomes - as defined below - will be assessed for each individual trial. For progression-free-survival (PFS) and overall survival (OS), a statistical summary of the results of all individual trials performed with one angiogenesis-inhibitor will be calculated, which will be used to compare the results for different drugs. A large number of compounds with various mechanisms of action are currently under development. Future updates of this review will consider the mechanism of action, whether the drug is an antibody or a small molecule, and a direct, indirect or mixed inhibitor for classification, as well as different types of chemotherapy, schedules of anti-angiogenic agents, and combinations of different anti-angiogenic strategies. Studies using anti-angiogenic therapies as second line will be classified according their prior use in first line as well. This classification will be adopted depending on the availability of relevant studies in the future.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-13 16:05:00 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-05-13 15:59:53 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-05-13 15:59:53 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<UL>
<LI>INCLUSION CRITERIA: Randomised controlled trials with or without blinding. Abstracts or unpublished data are included only if sufficient information on study design, characteristics of participants, interventions and outcomes is available and if full information as well as final results are confirmed by contact to the first author.</LI>
<LI>EXCLUSION CRITERIA: Quasi-randomised studies, e.g. with treatment allocation alternate or by date of birth are excluded. Studies on perioperative therapy including patients with primarily resectable metastases should be considered separately and are not included in this review for this reason.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-05-13 11:47:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<UL>
<LI>Patients with histologically confirmed, metastatic CRC</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-05-13 11:47:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>Systemic, oral or intravenous, targeted anti-angiogenic therapies, in combination with chemotherapy. Agents targeting receptors not primarily involved in angiogenesis, such as the EGFR, are not included in this review. In addition, agents which have been developed for other indications, such as interferon or thalidomide, and were subsequently reported to have anti-angiogenic activity, are not considered. Trials evaluating anti-angiogenic therapies in combination with other targeted drugs are currently limited to combinations of bevacizumab and cetuximab. They will be subject of another review and are not included in our review for this reason.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-05-11 14:04:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>The <B>first primary endpoint is</B> <B>progression-free-survival (PFS)</B> to ensure a direct treatment effect. However, because PFS is a surrogate end point - although adequately validated and patient-relevant - an improved PFS alone is not considered as sufficient evidence of a patient benefit. For this reason, <B>overall survival (OS) is added as a hierarchical lower ranked primary endpoint</B>. A splitting of type I error &#945;=0.05 for the two-sided tests is not necessary (<LINK REF="REF-EMEA-2002" TYPE="REFERENCE">EMEA 2002</LINK>), as a significant effect on overall survival assumes a significant effect on progression-free survival.
<BR/>

<B>Definition of PFS: </B>Time from randomisation to either death or disease progression, whichever occurs first. Disease progression is defined according to RECIST, version 1.0 (<LINK REF="REF-Therasse-2000" TYPE="REFERENCE">Therasse 2000</LINK>) as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</P>
<P>
<B>Secondary endpoints are:<BR/>
</B>a) Median, 1-, 2-, 3-, as well as 5-year overall survival rates<BR/>b) Tumour response and time to progression according to RECIST version 1.0 (<LINK REF="REF-Therasse-2000" TYPE="REFERENCE">Therasse 2000</LINK>)<BR/>c) Rate of secondarily resectable patients<BR/>d) Toxicity, classified according to WHO- or National-Cancer-Institute Common Terminology Criteria (NCI-CTC), including the percentage of treatment-related deaths<BR/>Quality of life will be assessed if a sufficient number of studies with adequate quality-of-life assessment are or become available.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-11 16:36:56 +0200" MODIFIED_BY="[Empty name]">
<P>Searches were conducted September 2008 to identify published and unpublished randomised controlled trials. Due to the relatively recent availability of targeted anti-angiogenic drugs, a literature search starting in 2000 was considered sufficient for the purpose of this review.<BR/>1) The Cochrane Central Register of Controlled Trials (CENTRAL), Issue 3, 2008; MEDLINE (January 2000 to October 2008); EMBASE (January 2000 to October 2008), Cancer Lit (2000 to June 2008).<BR/>The following databases of ongoing trials were searched in December 2008:<BR/>http://www.controlled-trials.com<BR/>http://www.clinicaltrials.gov<BR/>http://www.eortc.be<BR/>http://www.update-software.com/National/nrr-frame.html<BR/>http://www.CenterWatch.com/</P>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows a flow chart of the searches.</P>
<P>2) Hand searching<BR/>Reference lists from trials selected by electronic searching were hand searched to identify further relevant trials. Published abstracts from conference proceedings from the European Society for Medical Oncology 2000 to 2008 (published in the Annals of Oncology); the European Council for Clinical Oncology 2000 to 2008 (published in the European Journal of Cancer), as well as the American Society for Clinical Oncology 2000 to 2008 were hand searched. The search strategy for the review has been constructed by using a combination of subject headings and text words relating to anti-angiogenic therapies in colorectal cancer. In addition, members of the Cochrane Colorectal Cancer Group, experts in the field and manufacturers of relevant drugs were asked to provide details of outstanding clinical trials and any relevant unpublished material.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-13 16:05:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>
<B>Trial selection: </B>In order to elect studies for further assessment, two independent reviewers (ADW, DA) scanned the title, abstract section and keywords of every record retrieved. Full articles were taken into account for further assessment if the information given suggests that the study:<BR/>
</P>
<UL>
<LI>Includes patients with histologically confirmed, metastatic CRC</LI>
<LI>Compares either</LI>
</UL>
<P>1) First-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor<BR/>2) Second-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor<BR/>
</P>
<UL>
<LI>Uses random allocation to the comparison groups</LI>
<LI>Trials which permit a cross-over for patients after disease progression may also be included. However, in these trials the number of patients who crossed over were considered in the interpretation of the results for overall survival.</LI>
</UL>
<P>
<B>
<BR/>Quality assessment of trials: </B>Two authors independently assessed the quality of the eligible studies (ADW, DA), with disagreements resolved by a third reviewer (SU) until consensus was obtained. Data extraction were performed using an assessment form, which was designed especially for the topic of this review (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Schulz-1994" TYPE="REFERENCE">Schulz 1994</LINK>; <LINK REF="REF-Reviewer_x00b4_s-Handbook" TYPE="REFERENCE">Reviewer¥s Handbook</LINK> ).</P>
<P>The following criteria were considered:<BR/>(1) Was the allocation truly random?<BR/>(2) Were groups similar at baseline regarding the most important prognostic factors?<BR/>(3) Were the number of withdrawals, dropouts and losses to follow-up in each group completely described?<BR/>(4) Was the analysis done by intention-to-treat?<BR/>(5) Were type and schedule of the follow up similar in the comparison group?</P>
<P>Answers to these questions were categorized as<BR/>- yes (a)<BR/>- no (b)<BR/>- unclear (c)</P>
<P>Based on these criteria, the studies were broadly subdivided into the following three categories of quality:<BR/>A - all of the criteria met: low risk of bias<BR/>B- all criteria of question 1. and 2. met, one of criteria 3 - 5 not met<BR/>C- criteria 1. and/or 2. not met; or more than one of criteria 3 - 5 not met<BR/>D- unclear: Insufficient information given. In these cases we contacted the first author of the study. This classification was used as the basis of a sensitivity analysis.</P>
<P>
<B>Definition of baseline comparability: </B>Activity index (Eastern Cooperative Oncology Group status 0 versus 1-3), and the number of organs involved in metastatic disease (one versus more than one) were considered as the most important prognostic factors. A difference of more than 15% between study arms was considered as an important difference. For age, baseline differences of five years have been considered as important.<BR/>
<B>Definition of intention-to-treat-analysis:</B> Patients have been analysed according to their allocated treatment, irrespective of whether they received that treatment.<B>
<BR/>Data extraction: </B>Two authors independently extracted details of study population, interventions and outcomes by using a standardized data extraction form (ADW, DA), which was tested in a pilot study. Differences in data extraction were resolved by consensus with a third author (SU), referring back to the original article. The data extraction form included at least the following items:</P>
<UL>
<LI>General information: title, authors, source, contact address, country, published/unpublished, language and year of publication, sponsoring of trial</LI>
<LI>Trial characteristics including study design, duration/follow up, quality assessment as specified above.</LI>
<LI>Patients: inclusion and exclusion criteria, sample size, baseline characteristics, similarity of groups at baseline, withdrawals and losses to follow up</LI>
<LI>Interventions: dose, route and timing of chemotherapy, anti-angiogenic therapy and comparison intervention</LI>
<LI>Outcomes: Hazard Ratio¥s and their 95% confidence intervals, log rank chi square, log rank p-values, number of events, number of patients per group, median, one, two, three and five year survival rates</LI>
</UL>
<P>Because this review was primarily planned as an individual patient data meta-analysis, the first authors have been contacted and asked to provide individual patient data (IPD) for the relevant trials. As a response we learned that - because the majority of the relevant trials were sponsored by the manufacturer of bevacizumab, Genentech (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>; <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>; <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>), or Roche (<LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>) - the decision to provide IPD from the respective trial sponsors could not be made by the authors, but by the sponsors. Unfortunately, despite negotiations for over one year, the IPD were not provided from the respective trial sponsors. According to the protocol, in the case that IPD were not provided, the meta-analysis could be performed on the basis or aggregate data. Nevertheless, we could obtain further information about the trial, such as on the method of randomization, number of patients censored, or lost to follow up.</P>
<P>
<B>Data analysis: </B>Because IPD could not be obtained, the meta-analysis had to rely on aggregate data. Summary statistics for the primary endpoints are hazard ratios (<LINK REF="REF-Cox-1972" TYPE="REFERENCE">Cox 1972</LINK>) and their 95% confidence intervals. In addition, median survival and survival rates were generated. Other secondary outcome measures were analysed descriptively.<BR/>
<BR/>
<B>Statistical methods for data analysis: </B>
</P>
<P>Because IPD could not be obtained for any of the studies, hazard ratios and their 95% confidence intervals were estimated directly or indirectly from the published data (<LINK REF="REF-Altman-2001" TYPE="REFERENCE">Altman 2001</LINK>). Hazard ratios can be estimated (with some assumptions) from log rank chi square, from log rank p-values, from observed to expected event ratios, from ratios of median survival times or time point survival rates (<LINK REF="REF-Machin-1997" TYPE="REFERENCE">Machin 1997</LINK>; <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). The meta analysis used the random effect model in case of significant heterogeneity and otherwise the fixed effect model to compare treatment differences. Statistical analysis of summary data was performed with RevMan.</P>
<P>
<B>Investigating heterogeneity:</B> Seeking statistical heterogeneity between studies, a Cochrane¥s Q-test was performed, with a significance threshold of alpha= 0.1. In case of significant heterogeneity, the extra variation was investigated by a sensitivity analysis after the main meta-analysis. Additionally, a random effects model was used to incorporate the heterogeneity in the analysis of PFS.<BR/>The following factors were considered as possible sources of heterogeneity:<BR/>
</P>
<UL>
<LI>Different applications of anti-angiogenic treatment (scheduling etc.)</LI>
<LI>Different types of angiogenesis inhibitors (as classified above)</LI>
<LI>Differences in prognostic factors between studies</LI>
<LI>Quality of studies</LI>
</UL>
<QUALITY_ASSESSMENT MODIFIED="2009-05-13 11:16:09 +0200" MODIFIED_BY="[Empty name]">
<P>Risk of bias will be assessed in terms of patients undergoing planned treatment.</P>
</QUALITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-13 11:44:38 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-05-13 11:18:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Included studies</B>
</P>
<P>At present, published randomised trials on targeted anti-angiogenic (according to our inclusion criteria) therapies are limited to a total of six trials, involving 4271 patients. These trials studied either bevacizumab (5 trials, 3103 patients) or vatalanib (1 trial, 1168 patients) in combination with chemotherapy.</P>
<P>Among these, four trials (2526 patients) compared first-line chemotherapy, in combination with bevacizumab, to the same chemotherapy alone (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>). The "chemotherapy backbone" in one of these trials was a combination of irinotecan and bolus 5-FU (so-called IFL-regimen) (<LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>). Two trials used a 5-FU/LV as a single agent (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>), and one trial used oxaliplatin, in combination with either capecitabine or 5-FU/LV (<LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>). A further trial, which included 577 patients, compared 5-FU/FA/oxaliplatin (FOLFOX-4) as second-line chemotherapy in combination with bevacizumab, to FOLFOX-4 alone (<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>). Vatalanib, a multi-targeted tyrosine-kinase inhibitor, in combination with FOLFOX-4 was compared to FOLFOX-4 and placebo in a further randomised phase III trial in first-line therapy (<LINK REF="STD-Hecht-2007" TYPE="STUDY">Hecht 2007</LINK>); another trial investigating vatalanib as second-line therapy was excluded as final results are still pending.</P>
<P>Two trials (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>) were designed as three-arm comparisons. The study by <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK> included one arm with bevacizumab 5mg/m2 and another arm with bevacizumab 10mg/m2. For the purpose of this analysis, these arms have been combined. The bevacizumab-only arm in <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK> was excluded as well from this meta-analysis because - according to the protocol - only anti-angiogenic treatments in combination with chemotherapy were considered. The trial by <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> was initially designed as a comparison of capecitabine-oxaliplatin to FOLFOX-6. After the results of the trial by Hurwitz became available, a second randomization with or without bevacizumab was added, which changed the trial design into a two-by-two factorial design. For the purpose of this meta-analysis, the results from the different chemotherapy arms have been condensed to two arms (oxaliplatin-based chemotherapy with versus without bevacizumab), as the definition of the primary endpoints and the main analysis plan of the trial did.</P>
<P>
<B>Excluded studies</B>
</P>
<P>One Chinese published trial compared chemotherapy in combination with thalidomide to the same chemotherapy without thalidomide (<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>). This study has been excluded because thalidomide is an agent not primarily targeting angiogenesis, but has been developed for another indication and was subsequently reported to have anti-angiogenic activity.</P>
<P>
<B>Participants</B>
</P>
<P>Median and/ or mean age of participants in the population of the first-line chemotherapy studies varied from approximately 60 years (<LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>) to 71 years (<LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>). This information was missing for the fourth trial (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>). The trial by <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK> was designed to include predominantly elderly or poor-performance-status patients. The proportion of participants with an activity index (ECOG) of less than 0 was between 41 and 43 % in <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK> and <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>. In <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, 72% of patients had an activity index of less than 0. Between 42% (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>) and 66% (<LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>) of patients had metastatic lesions in more than one organ.</P>
<P>As expected for a second-line-study (<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>), the percentage of participants with an activity index of less than 0 (50%), as well as the percentage of patients in whom more than one organ was involved (70%) was higher than in most of the first-line-trials and comparable to the poor-performance-status patients in <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>. Median age (61 years) was similar to the trials by <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, and <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>.</P>
<P>In the trial investigating the efficacy of vatalinib (<LINK REF="STD-Hecht-2007" TYPE="STUDY">Hecht 2007</LINK>), median age of the included patients was 60 years, 43% of participants had an activity index greater than 0, and in 52% of patients more than one organ was involved by metastatic disease.</P>
<P>When comparing the different arms of the studies, the mean or median age, activity index and number of metastases were well balanced in all included trials, with no differences greater than 15% between treatment arms.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-05-13 11:44:38 +0200" MODIFIED_BY="[Empty name]">
<P>According to our predefined criteria of quality assessment (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), the methodological quality of the included studies can in general be considered as adequate. The studies by <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>, as well as <LINK REF="STD-Hecht-2007" TYPE="STUDY">Hecht 2007</LINK> were placebo-controlled. The funnel plot for the primary outcomes progression-free survival (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) and overall survival (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>) did not suggest publication bias.</P>
<ALLOCATION MODIFIED="2009-04-06 06:46:09 +0200" MODIFIED_BY="[Empty name]">
<P>To guarantee allocation concealment, the allocation procedure in the trials by <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK> and <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> was performed with an Interactive Voice Response System (IVRS). Randomization lists in <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK> were generated by a computer random generator. In the study by <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, a dynamic randomization algorithm was utilized to balance baseline conditions.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-04-05 23:08:20 +0200" MODIFIED_BY="[Empty name]">
<P>An independent radiological review was performed in the studies by <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> and <LINK REF="STD-Hecht-2007" TYPE="STUDY">Hecht 2007</LINK>. For the study by <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK> this information was missing.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-03-31 22:52:02 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome data was complete.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-03-31 22:54:06 +0200" MODIFIED_BY="[Empty name]">
<P>A bias due to selecting reporting of outcomes was not identified.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-05-13 11:44:38 +0200" MODIFIED_BY="[Empty name]">
<P>A cross-over to bevacizumab from the control group was possible in <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK> and <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>. However, in the study by <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, cross-over patients received bevacizumab without chemotherapy. Bevacizumab alone provides probably only very limited clinical benefit as shown by <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>. In the trial by <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> only very few patients (3% in the bevacizumab and 5% in the placebo group) received bevacizumab in further treatment lines. Bias due to cross-over is therefore unlikely in both trials.</P>
<P>However, it should be noted that in the trial by <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK> the assessment of progression-free survival might be biased due to the fact that the frequency of tumour assessments was changed after 24 weeks from all 6 to all 12 weeks. Considering a median PFS of 10.6 and 6.2 months in the patients treated with and without bevacizumab it is likely that tumour progression was noticed at a later point of time in the group treated with bevacizumab. In addition, it should be noted that the IFL regimen, which was used as the "chemotherapy backbone" in this trial, cannot be considered as an acceptable standard for chemotherapy alone because the combination of irinotecan and bolus 5-FU was found to be associated with significant toxicity and a relatively low efficacy when compared to FOLFOX (<LINK REF="REF-Goldberg-2004" TYPE="REFERENCE">Goldberg 2004</LINK>). Another potential source of bias in this study is that tumour response was not reviewed by an independent radiologist.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-11 14:06:33 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1) First-line chemotherapy with versus without bevacizumab</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Progression-free-survival (PFS)</HEADING>
<P>A progression-free survival HR of 0.61 (95% confidence interval (CI) 0.45 to 0.83) in favour of the bevacizumab arm demonstrates a convincing benefit over chemotherapy alone (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). This correlates with an increase in median survival from 7.1 months without bevacizumab to 9.7 months in the bevacizumab groups and a difference in tumour response of 3% in favour of the patients treated with bevacizumab. However, we observed a significant statistical heterogeneity (measured by Cochrane's Q-Test with p=0.0004 and proportion of variability I<SUP>2 </SUP>of 84%) among the results of these trials. According to the protocol, different applications of anti-angiogenic treatment, types of angiogenesis inhibitors, differences in prognostic factors as well as the quality of the studies were considered as potential sources of heterogeneity. None of them were relevant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Overall survival (OS)</HEADING>
<P>The pooled HR for overall survival of 0.81 (95%CI 0.73 to 0.90) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) demonstrates a significant benefit in overall survival in the patients treated with bevacizumab. This corresponds to an increase in pooled median survival from 17.7 to 20.5 months. Survival rates of the bevacizumab containing group varied between 62% (1 year survival) and 26% (2 year survival) in <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK> and 78% (1 year survival) and 72% (2 year survival) in <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> were observed. In contrast, in the group without bevacizumab survival rates ranged from 53 % (1 year survival) and 24% (2 year survival) in <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK> and 72% (1 year survival) and 39% (2 year survival) in <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>. Information about later survival rates was not given in the text or provided by the authors in any of the four studies.</P>
<P>In contrast to the results for PFS, Cochrane's Q test as well as the proportion of variability I<SUP>2 </SUP>=49% did not show a statistically significant heterogeneity among the results for OS in <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. Both trials using a 5-FU/LV single-agent (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>) chemotherapy showed comparable results, with a pooled HR of 0.80 (95%CI 0.59 to 1.09) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). This corresponds to an increase in median OS from 13.1 to 17.5 months. The HR for OS in the trial using IFL chemotherapy (<LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>) was 0.66 (95%CI 0.54 to 0.81) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>), corresponding to an increase in median OS from 15.6 to 20.3 months. In contrast, the oxaliplatin based chemotherapy (<LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>) resulted in a HR of 0.89 (95% CI 0.78 to 1.02) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>), with corresponding median survival times of 19.9 and 21.3 months in the patients treated without and with bevacizumab.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome measures:</HEADING>
<P>(a)Tumour response - showed an absolute increase in tumour response of approximately 3% in favour of the patients treated with bevacizumab. This benefit was similar in the three studies by <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, and <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>. In contrast, in the trial by <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>, response rates were similar in both treatment arms. As expected, tumour response rates showed differences between 5-FU/LV single-agent chemotherapy (response rates between 15 and 18% in the chemotherapy-alone group) and 35% for IFL combination chemotherapy (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) without bevacizumab.</P>
<P>(b) Time to progression - Only one study (<LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>) reported time to progression (TTP) - although the authors did not provide their definition of TTP. Median TTP demonstrated a significant benefit for the addition of bevacizumab, with a median time of 5.2 months in the chemotherapy alone and 7.4 months in the bevacizumab group (HR 0.54, p=0.013 (Logrank test)).</P>
<P>(c) Secondary resectability - Information about secondarily resectable participants was given in the text or provided by the author for only one trial (<LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>). In this trial, 6.1 % of patients in the placebo containing arms and 8.4% of the patients in the bevacizumab containing arms were secondarily resectable. However, the rate of complete pathohistological resection (R0) was not provided.</P>
<P>(d)Toxicity - Results for toxicity showed non-significant differences for treatment related deaths (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) and 60-day-mortality (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) between the treatment and control group. However, the number of treatment interruptions due to adverse events was significantly higher in the patients treated with bevacizumab (21%) as compared to the chemotherapy alone group (15%) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The incidence of any grade 3 or 4 adverse events was approximately 8% higher among patients receiving chemotherapy plus bevacizumab than among those receiving chemotherapy alone (OR, calculated with the Mantel-Haenszel (MH) method=1.65, 95%CI 1.36 to 2.00) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). In detail, this higher incidence of toxicities had to be attributed to a statistically significant higher incidence of grade 3 or 4 hypertension (OR=4.86, 95%CI 2.99 to 7.90) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), grade 3 or 4 arterial thromboembolic events (OR=2.05, 95%CI 1.14 to 3.71) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>) and gastrointestinal perforations (OR=9.15, 95%CI 1.69 to 49.57) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>) in the bevacizumab group. In addition, statistically non-significant increased incidences of thromboembolic events, proteinuria and bleeding have been documented (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). Statistically significant heterogeneity was observed in the incidence of grade 3 or 4 adverse events with larger differences between the study arms in the trials by <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>, <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK> and <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>. In contrast, a relatively small difference in the incidence of grade 3 or 4 adverse events between the two treatment groups was observed in the trial by <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>.</P>
<P>(e ) Quality of life - Information was only available in <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>. Patients completed the Functional Assessment of Cancer Therapy&#8212;Colorectal (FACT-C), a validated instrument for assessing quality of life in CRC patients, at baseline and before each treatment cycle until disease progression. The median TDQ (time to deterioration in quality of life) was 3.0 months in the placebo group and 3.1 months in the bevacizumab group (HR 0.79; p=0.188).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 2) Second-line chemotherapy with versus without bevacizumab</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Progression-free-survival</HEADING>
<P>The addition of bevacizumab to second line chemotherapy with FOLFOX- 4 (<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>) shows a convincing benefit in progression-free survival (HR 0.61, 95% CI 0.51 to 0.73) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), which is statistically significant and clinically relevant. This corresponds to an increase in pooled median survival from 4.7 months to 7.3 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Overall survival</HEADING>
<P>The addition of bevacizumab to second line chemotherapy with FOLFOX- 4 (<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>) also demonstrates a significant benefit in overall survival (HR 0.75, 95%CI 0.63 to 0.89) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). This correlates with an increase of median survival from 10.8 to 12.9 months and in survival rates from 43% to 56% (1 year survival) and from 15% to 22% (2-year survival). Information about later survival rates was not given in the text or provided by the author.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome measures:</HEADING>
<P>(a) Tumour response - showed an approximately 15% increased response rate in favour of the patients treated with bevacizumab (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>(b) Time to progression - Information was not given in the text or provided by the author.</P>
<P>(c) Secondary resectability of metastases - Information was not given in the text or provided by the author.</P>
<P>(d) Toxicity - Treatment-related toxicities were higher in the bevacizumab arm. A statistically significant increase was observed in the incidence of grade 3 or 4 adverse events (OR=1.94, 95%CI 1.36 to 2.78) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). This had to be attributed to a higher incidence of grade 3 or 4 hypertension (OR=3.75, 95%CI 1.37 to 10.24) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>) and bleeding (10 patients in the bevacizumab group, as compared to one patient in the control group) (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>). Differences in all other toxicities were not statistically significant (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>, <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>, <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>, <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
<P>(e) Quality of life - Information was not given in the text or provided by the author.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 3) First-line chemotherapy with versus without vatalanib</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Progression-free-survival</HEADING>
<P>The addition of vatalanib (PTK/ZK) to first-line chemotherapy (<LINK REF="STD-Hecht-2007" TYPE="STUDY">Hecht 2007</LINK>) results in no improvement in progression-free survival (HR 0.89, 95% CI 0.78 to 1.03) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> and <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). Median progression-free survival times increased from 7.7 to 9.1 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Overall survival</HEADING>
<P>The addition of vatalanib (PTK/ZK) to first-line chemotherapy (<LINK REF="STD-Hecht-2007" TYPE="STUDY">Hecht 2007</LINK>) shows no benefit in overall survival (HR 1.08, 95% CI 0.94 to 1.24) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). Median survival times were 20.5 months for chemotherapy alone compared to 21.4 months with the addition of vatalanib. Survival rates showed no differences between treatment arms with and without vatalanib: 74% (1 year survival rate), approximately 43% (2-year survival) and approximately 25% (3 year survival). Information about later survival rates was not given in the text or provided by the author.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome measures:</HEADING>
<P>(a) Tumour response showed no differences between treatment groups (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>(b) Time to progression - information was not given in the text or provided by the author.</P>
<P>(c) Secondary resectability of metastases - information was not given in the text or provided by the author.</P>
<P>(d) Only all cause mortality within 28 days of last study drug administration was reported and showed a slight benefit in the vatalanib treated group (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). The incidence of 60 day mortality, treatment related deaths, treatment discontinuation and grade 3 or 4 adverse events was not reported. Treatment associated toxicities were higher in the bevacizumab arm. We observed a statistically significant increased risk of hypertension (OR=3.98, 95%CI 2.74 to 5.79) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) and pulmonary embolism (OR=3.52, 95%CI from 1.72 to 7.19) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). Other statistically significant differences in anti-angiogenic related events were not observed (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>, <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>, <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>, <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</P>
<P>(e) Quality of life - Information was not given in the text or provided by the author.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-13 16:15:52 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Summary of main results</HEADING>
<P>The introduction of Bevacizumab into the treatment of metastatic colorectal cancer (<LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>) was a milestone in clinical oncology. The magnitude of interest for this new therapeutic approach is reflected by the immense number of secondary publications on this topic (we identified 214 reviews or secondary publications), which is in contrast to the limited available primary data from randomised clinical trials comparing anti-angiogenic treatments, in combination with chemotherapy, to chemotherapy alone or chemotherapy and placebo.<BR/>At present, final results from randomised studies on targeted anti-angiogenic therapies, meeting the eligibility criteria for this review, are available only for trials including Bevacizumab (5 trials including a total of 3085 patients) and Vatalanib (1 trial including 1168 patients). A vigorous search for unpublished material or not finally published material was performed to minimize publication bias. The methodological quality of the included studies can in general be considered as adequate.<BR/>Results for both progression-free and overall survival of this comparison confirm the results of the individual trial by <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, which showed a statistically significant and clinically relevant benefit in progression-free and -overall survival for the addition of Bevacizumab to chemotherapy in patients with metastatic colorectal cancer.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">First-line chemotherapy with versus without bevacizumab</HEADING>
<P>
<B>Efficacy: </B>Results for both comparisons, progression-free and overall survival, confirm the results of the individual trials from <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>, which showed a significant benefit in both progression-free and overall survival for the addition of bevacizumab to chemotherapy in patients with metastatic colorectal cancer. However, the magnitude of this benefit seems to differ for the different chemotherapy &#8220;backbones":</P>
<P>In both trials, which compared a 5-FU bolus single-agent chemotherapy <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK>; <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK>, with or without bevacizumab, HR¥s for PFS were comparable (HR¥s 0.54, 95% CI 0.31 - 0.94 and 0.50, 95% CI 0.34 - 0.73) to the study using an irinotecan/bolus 5-FU-combination (0.54, 95% CI 0.45 - 0.65) <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>. In contrast, the difference in progression-free and overall survival in the trial using FOLFOX-4 or XELOX (capecitabine/oxaliplatin), with versus without bevacizumab was much smaller (HR 0.83, 95% CI 0.74 - 0.94) <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> for the pooled comparison of both arms (any fluoropyrimidine/oxaliplatin combination, with or without bevacizumab). Of interest, a planned subset analysis of the results for the individual chemotherapy backbones, with or without bevacizumab, showed that the gain in PFS due to bevacizumab was limited to the patients being treated with XELOX (HR 0.77; p=0.0026). In contrast, in the FOLFOX-4 &#8211; arms, no significant differences between patients treated with or without bevacizumab was seen (HR 0.89; p= 0.187) (<LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>). The reason for this difference is unclear. One hypothesis which is currently being discussed as a possible reason for the modest efficacy of the oxaliplatin/bevacizumab combinations in this trial, is that the extent of benefit from treatment with bevacizumab is correlated to the duration of its application. Only 29% and 47% of the patients in the bevacizumab and placebo arms in the <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK> trial were treated until disease progression, as planned according to the study design. Thirty and twenty percent of the patients in the bevacizumab and placebo arms discontinued both chemotherapy and bevacizumab already before disease progression due to mainly chemotherapy related adverse events, such as neurotoxicity, gastrointestinal events, general disorders and hematologic toxicity. Consequently, the overall duration of treatment with bevacizumab (median approximately 6 months) - as compared to previous trials (<LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>: median duration of therapy with bevacizumab approximately 10 months) - was much shorter.<BR/>If in fact treatment benefit from and duration of treatment with bevacizumab would be positively correlated, not only treatment until progression, but also treatment beyond progression would affect the treatment outcomes: The results of the BRiTE register (<LINK REF="REF-Grothey-2008" TYPE="REFERENCE">Grothey 2008</LINK>) observational cohort study, where the most favourable survival results were achieved by continuation of bevacizumab beyond progression, lend further support to this assumption.<BR/>However, a randomised trial addressing this issue is necessary - and currently recruiting - to confirm this hypothesis and exclude possible patient selection bias of this retrospective analysis (<LINK REF="REF-Arnold-2008" TYPE="REFERENCE">Arnold 2008</LINK>).</P>
<P>In fact, data on the combination of FOLFOX-4 and bevacizumab is controversial: The so-called TREE -study (<LINK REF="REF-Hochster-2008" TYPE="REFERENCE">Hochster 2008</LINK>), as well as the trials by <LINK REF="STD-Hecht-2009" TYPE="STUDY">Hecht 2009</LINK> and <LINK REF="STD-Tol-2009" TYPE="STUDY">Tol 2009</LINK> are of additional interest in this context: This trial by <LINK REF="REF-Hochster-2008" TYPE="REFERENCE">Hochster 2008</LINK> as well was planned before the approval of bevacizumab to evaluate the safety and efficacy of different combinations of oxaliplatin and fluoropyrimidines in metastatic CRC. Therefore, the first cohort of patients in this trial were randomised to receive either mFOLFOX-6 (bolus and infusional fluorouracil with oxaliplatin), b-FOL (bolus 5-FU and low-dose LV with oxaliplatin) or CapeOx, respectively. After the approval of bevacizumab, in the second cohort of patients, bevacizumab was added to each of these regimens. While overall survival in the first cohort was 19.2, 17.9 and 17.2 months, it increased two 26.1, 20.4 and 24.6 months after the addition of bevacizumab. There were no differences in prognostic factors between the two cohorts. Thus, although patients in this trial were not randomised to bevacizumab or placebo, a median survival of greater than 26 months for the patients receiving FOLFOX-4 and bevacizumab exceeds the results from all previous, large randomised trials in metastatic CRC. The two trials by <LINK REF="STD-Hecht-2009" TYPE="STUDY">Hecht 2009</LINK> and <LINK REF="STD-Tol-2009" TYPE="STUDY">Tol 2009</LINK>, which compared a combination of chemotherapy with bevacizumab to the triplet combination of chemotherapy, bevacizumab and an EGFR-antibody (either cetuximab or panitumumab) observed a PFS of greater than 10 months and OS of greater than 20 months in the patients treated with chemotherapy and bevacizumab. Of interest, the patients randomized to chemotherapy and bevacizumab in the trial by <LINK REF="STD-Hecht-2009" TYPE="STUDY">Hecht 2009</LINK> were enrolled - according to the investigators choice - to either an oxaliplatin or an irinotecan based chemotherapy. Baseline characteristics were comparable in both chemotherapy arms, as well as the results for PFS in the bevacizumab/oxaliplatin-based chemotherapy (median PFS 11.4 months) and bevacizumab/irinotecan-based chemotherapy (median PFS 11.7 months) arms. In contrast, OS was longer in the patients treated with the bevacizumab/oxaliplatin-based chemotherapy combination (median OS 24.5 months), as compared to bevacizumab/irinotecan-based chemotherapy (median OS 20.5 months). Important differences in performance status between trial populations, such as between the studies by <LINK REF="STD-Kabbinavar-2003" TYPE="STUDY">Kabbinavar 2003</LINK> (58% of patients with performance-status 0) and <LINK REF="STD-Kabbinavar-2005" TYPE="STUDY">Kabbinavar 2005</LINK> (28% of patients with performance status 0) do not seem to have an impact on the effect of bevacizumab.</P>
<P>In terms of OS improvement, only one trial (<LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>) has shown a significant benefit (HR 0.66, 95% CI 0.54 - 0.81), whereas all other trials failed to demonstrate significant gains. However, a gain in OS is not commonly observed in an era where 3 subsequent treatment lines have demonstrated benefits in overall survival as compared to best supportive care. When considering the relatively short treatment duration of bevacizumab in first line therapy, as well as the number of subsequent therapy lines with additional impact on survival, a benefit in OS is probably neither a sensitive, nor a realistic endpoint for a first-line therapy study.</P>
<P>The impact of bevacizumab on tumor response is controversial: While similar response rates in the patients treated with and without bevacizumab were observed in the trial using oxaliplatin-based first-line therapy by <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>, a difference of 10% in tumor response in favor of the patients treated with bevacizumab has been observed in the second-line trial by <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>, as well as the study by <LINK REF="STD-Hurwitz-2004" TYPE="STUDY">Hurwitz 2004</LINK>.</P>
<P>
<B>Toxicity: </B>Results for toxicity showed<B> </B>non-significant differences in treatment related deaths and 60-day-mortality. However, the number of treatment interruptions was significantly higher in the patients treated with bevacizumab, as well as the number of arterial thromboembolic complications and gastrointestinal perforations.</P>
<P>Unfortunately, individual patient data were not available which would have allowed to calculate the risk of different toxicities in different age groups. However, the risk of thromboembolic complications was subject of a recent pooled analysis (<LINK REF="REF-Scappaticci-2007" TYPE="REFERENCE">Scappaticci 2007</LINK>), which included 5 trials in metastatic breast, colorectal and lung cancer and analysed the incidence of arterial and venous thromboembolism in relation to the following risk factors: use of bevacizumab, arterial hypertension, history of arterial thromboembolism, history of atherosclerosis, history of diabetes mellitus, history of myocardial infarction, history of transient ischemic attack, and history of venous† thrombosis. According to this analysis, the subgroups with the strongest trend towards an increased rate of arterial thromboembolic events per 100-person-years in the bevacizumab-treated group were patients aged 65 or older (4.7 versus 10.0 events in the control and bevacizumab-treated patients, p=.082); patients with a history of an arterial thromboembolic event (5.9 versus 24.4, p=.060); and patients with both risk factors (3.6 versus 27 events, p=.052). Importantly, patients with a history of stroke or myocardial infarction within 12 months prior to study enrolment have not been included in these trials. Therefore, the potential benefits of the use bevacizumab in patients older than 65 years, with a history of a thromboembolic event, or with both risk factors should be weighted up against this risk in every individual patient.</P>
<P>
<B>Comparison 2) Second-line chemotherapy with versus without bevacizumab. †</B>
</P>
<P>The addition of bevacizumab to second line chemotherapy with FOLFOX- 4 after progression on a chemotherapy regimen without bevacizumab, showed a statistically significant and clinically relevant benefit in both progression-free (HR 0.61, 95% CI 0.51- 0.73) and overall survival (HR 0.75, 95% CI 0.63 - 0.89) (<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>). The reason why the same chemotherapy backbone (FOLFOX-4), for which the addition of bevacizumab did not show any benefit in first line therapy (<LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>) demonstrated both, an increase in response rate by 10% and a survival benefit when used in second line therapy, is unclear. Whether the different treatment doses of bevacizumab (5mg/kg body weight every 2 weeks in the trial by <LINK REF="STD-Saltz-2008" TYPE="STUDY">Saltz 2008</LINK>, and the doubled dose in the <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK> trial) are relevant for this question must currently be considered as unclear.</P>
<P>In contrast, data for Vatalanib in first-line therapy shows a non-significant benefit on both - progression-free and overall survival. The results of a second trial on vatalanib in second-line therapy are not yet available.</P>
</SUBSECTION>
</SUBSECTION>
<SUMMARY_OF_RESULTS MODIFIED="2009-05-11 14:14:31 +0200" MODIFIED_BY="[Empty name]">
<P>At present, eligible trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients in total; with four trials on first-line therapy and one trial on second-line-therapy) and vatalanib (1 trial in first-line therapy, which included 1168 patients). Final results of a second trial using vatalanib as second line therapy are still pending. The overall HR¥s for PFS (0.61, 95% CI 0.45 - 0.83) and OS (0.81, 95% 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, demonstrate statistically significant and clinically relevant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity, which is probably attributable to differences in the treatment effect of bevacizumab in combination with different "chemotherapy backbones". For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95% CI 0.51 - 0.73) and OS (HR 0.75, 95% CI 0.63-0.89) was demonstrated as well in a single, large, randomised trial. For valatanib, currently available data is limited to a single trial in first line chemotherapy, which showed no benefit in progression-free or overall survival. Results for toxicity of bevacizumab showed non-significant differences in treatment-related deaths and 60-day mortality. Statistically significant differences in toxicity, with higher incidences in the patients treated with bevacizumab, were observed for grade III/IV hypertension, arterial thromboembolic events and gastrointestinal perforations.</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-05-13 14:08:40 +0200" MODIFIED_BY="[Empty name]">
<P>The risk of bias in all individual trials has been analysed in detail above. Overall, the quality of evidence for the use of bevacizumab in metastatic colorectal cancer must be considered as adequate. However, due to a significant heterogeneity in the effects of bevacizumab in combination with FOLFOX-4 on PFS, the evidence for the use of this regimen in first-line therapy must be considered as low.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-05-13 14:09:33 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-05-11 14:16:59 +0200" MODIFIED_BY="[Empty name]">
<P>Bevacizumab in combination with chemotherapy prolongs both progression-free and overall survival of patients with metastatic colorectal cancer, as compared to chemotherapy alone. However, the impact of adding bevacizumab to chemotherapy on PFS in first-line chemotherapy shows significant heterogeneity: While the effect of bevacizumab in combination with irinotecan and 5-FU in the IFL combination, or 5-FU as single-agent is clinically meaningful and consistent, the effect of bevacizumab in combination with capecitabine/oxaliplatin is much smaller. Importantly, currently available data from randomised trials does not suggest any benefit of adding bevacizumab to FOLFOX-4 in first-line therapy.</P>
<P>The benefit of adding bevacizumab to first and second-line chemotherapy in patients with colorectal cancer has to be weighted up against treatment-related toxicity. The analysis of toxicity did not reveal any unexpected findings. Major toxicities of bevacizumab are hypertension, gastrointestinal perforations, proteinuria and arterial thromboembolic events. Importantly, arterial thromboembolic events are significantly associated with a history of prior thromboembolic complications. Furthermore, age &gt; 65 is a risk factor for arterial thromboembolic complications. Bevacizumab should therefore be used with caution in patients with these risk factors. Importantly, it should be noted that thromboembolic complications within 6 months before treatment start was an exclusion criteria in at least some of the trials <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>. For these reasons, the patient population in these trials might not be representative for the overall population of colorectal cancer patients: Elderly patients and patients with co-morbidities were insufficiently represented.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-05-13 14:09:33 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>The optimum chemotherapy backbone(s), as well as treatment duration for bevacizumab needs to be established.</LI>
</UL>
<UL>
<LI>Further knowledge in the treatment effect in subgroups of patients, such as patients with cardiovascular disease, or a history of prior thromboembolic events, is required.</LI>
</UL>
<UL>
<LI>Mechanisms of primary and secondary resistance to angiogenesis-inhibitors need clarification, and strategies to overcome resistance need to be developed.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-13 16:19:28 +0200" MODIFIED_BY="[Empty name]">
<P>The excellent support from the Cochrane Colorectal Cancer Group was very much appreciated.</P>
<P>We would like to acknowledge Dr. Daniel Sargent for his valuable support for the development of the protocol.</P>
<P>Further, the contact author of this review, Dr. Anne Dorothea Wagner, would like to acknowledge Institute for Medical Biometry in Halle, Germany, where this review was initiated during my position here.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-04-17 11:23:07 +0200" MODIFIED_BY="[Empty name]">
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-13 14:10:46 +0200" MODIFIED_BY="[Empty name]">
<P>Anna Dorothea Wagner: protocol development, writing the review<BR/>Daniel Sargent: statistical advice for the development of the protocol<BR/>Susanne Unverzagt: protocol development, writing the review<BR/>Axel Grothey: clinical and scientific advice, protocol development, writing the review<BR/>Dirk Arnold: scientific advice, writing the review<BR/>Johannes Haerting: protocol development, statistical advice</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>This is an update of the original protocol published in 2005 issue 3, by Anna Dorothea Wagner et al.. In this update the authors suggested to include two more comparisons:</P>
<P>a) First-line chemotherapy in combination with angiogenesis inhibitor and Epidermal Growth-Factor-(EGF)-receptor-antibody, to chemotherapy with angiogenesis inhibitor alone<BR/>b) Second-line chemotherapy in combination with angiogenesis inhibitor and EGF-receptor-antibody, to chemotherapy with angiogenesis inhibitor alone</P>
<P>but to avoid overlap with another registered title on Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer, this will be elucidated before publishing the full review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-05-13 16:14:47 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-05-13 16:14:47 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Giantonio-2007" NAME="Giantonio 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giantonio B J, Catalano P J, Meropol N J, O'Dwyer P J, Mitchell E P, Alberts S R, Schwartz M A, Benson A B 3rd, Eastern Cooperative Oncology Group Study E3200</AU>
<TI>Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>12</NO>
<PG>1539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hecht-2007" MODIFIED="2009-05-11 17:05:01 +0200" MODIFIED_BY="[Empty name]" NAME="Hecht 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-05-11 17:05:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff RA, Lloyd K, Bodoky G, Borner M, Laurent D, Jacques C</AU>
<TO>Final overall survival results of CONFIRM 1, a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or (mCRC) recieving first-line chemotherapy with oxaliplatin/5-FU/Leucovorin (FOLFOX 4) and PTK/ZK 22584 (PTK/ZK) or placebo (PBO)</TO>
<SO>European Journal of Cancer Supplements</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>4</NO>
<PG>238</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurwitz-2004" NAME="Hurwitz 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F</AU>
<TI>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</TI>
<SO>The New England journal of medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>23</NO>
<PG>2335-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabbinavar-2003" NAME="Kabbinavar 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E</AU>
<TI>Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabbinavar-2005" MODIFIED="2009-03-24 16:44:29 +0100" MODIFIED_BY="[Empty name]" NAME="Kabbinavar 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF</AU>
<TI>Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial</TI>
<SO>Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16</NO>
<PG>3697-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-03-24 16:44:29 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Saltz-2008" NAME="Saltz 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T S, Rivera R, Couture F, Sirzen F, Cassidy J</AU>
<TI>Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>12</NO>
<PG>2013-2019</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2002" MODIFIED="2009-03-29 23:31:53 +0200" MODIFIED_BY="[Empty name]" NAME="Anonymous 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-29 23:31:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Pharmacia's SU5416 not effective.</TI>
<SO>Expert Rev Anticancer Ther</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bekaii_x002d_Saab-2008" NAME="Bekaii-Saab 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bekaii-Saab TS, Bendell JC, Cohn LA, Kozloff MF, Roach N, Sargent DJ, Tezcan H, Grothey A, Purdie DM, Sugrue MM</AU>
<TI>nitial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>May 20 Suppl</NO>
<PG>abstr 15002</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergsland-2004" MODIFIED="2009-03-29 23:35:13 +0200" MODIFIED_BY="[Empty name]" NAME="Bergsland 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-29 23:35:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergsland E K</AU>
<TI>Update on clinical trials targeting vascular endothelial growth factor in cancer.</TI>
<SO>Am J Health Syst Pharm</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>21 Suppl 5</NO>
<PG>S12-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergsland-2006" MODIFIED="2009-03-29 23:35:22 +0200" MODIFIED_BY="[Empty name]" NAME="Bergsland 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-29 23:35:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergsland EK</AU>
<TI>When does the presence of the target predict response to the targeted agent?</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berry-2008" NAME="Berry 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berry SR, Van Cutsem E, Kretzschmar A, Michael M, RiveraF, DiBartolomeo M, Mazier M, Andre N, Cunningham D</AU>
<TI>Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT.</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>26</YR>
<VL>May 20 suppl</VL>
<PG>abstr 4025</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buyse-2003" MODIFIED="2009-03-29 23:35:33 +0200" MODIFIED_BY="[Empty name]" NAME="Buyse 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-29 23:35:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buyse M</AU>
<TI>Phase III clinical trials in oncology: 20-21 January 2003, London, UK</TI>
<SO>IDrugs</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>3</NO>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CALGB_x002f_SWOG-2006" MODIFIED="2009-03-29 23:36:00 +0200" MODIFIED_BY="[Empty name]" NAME="CALGB/SWOG 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-29 23:36:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum</TI>
<SO>Clinical Advances in Hematology &amp; Oncology</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>6</NO>
<PG>452-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004" NAME="Chen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chen H X, Mooney M, Boron M, GrochowL, Zwiebel J, Vena D, Mosby K, Grandinetti C, Kaplan RS</AU>
<TI>Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301)</TI>
<SO>Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>14S (July 15 Supplement)</NO>
<PG>abstr 3515</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-2008" NAME="Cunningham 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham D, Wong RP, D'haens G, Douillard J, Robertson J, Saunders O, Stone AM, Van Cutsem E</AU>
<TI>A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>May 20 suppl.</NO>
<PG>abstr 4028</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fyfe-2004" NAME="Fyfe 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny WF</AU>
<TI>Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups</TI>
<SO>Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>No 14S (July 15 Supplement)</NO>
<PG>abstr 3617</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giantonio-2006" NAME="Giantonio 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giantonio B J</AU>
<TI>Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.</TI>
<SO>Semin Oncol</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>5 Suppl 10</NO>
<PG>S15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hecht-2009" MODIFIED="2009-05-13 13:57:00 +0200" MODIFIED_BY="[Empty name]" NAME="Hecht 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-05-13 13:57:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spiegel D, Marshall J, Cohn A, McCOllum D, Stella P, Deeter R, Shahin S, Amado R</AU>
<TI>A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metasatc colorectal cancer</TI>
<SO>Journal of nClinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>5</NO>
<PG>672-680</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hochster-2006" NAME="Hochster 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH</AU>
<TI>Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.</TI>
<SO>Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I.</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18S (June 20 Supplement)</NO>
<PG>abstr 3510</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurwitz-2005a" NAME="Hurwitz 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurwitz H, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F</AU>
<TI>Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>15</NO>
<PG>3502-3508</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-2002" NAME="King 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>King J, Clingan P, Morris DL</AU>
<TI>Placebo control double-blind randomised clinical trial of the matrix metalloproteinase inhibitor (MMP) marimastat in patients with inoperable liver metastases (CRCLM): significant survival advantage in patients with musculoskelosketal symptoms</TI>
<SO>Proc Am Soc Clin Oncol</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>abstr 537</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koopman-2007" NAME="Koopman 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers G JM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ</AU>
<TI>Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9582</NO>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koukourakis-2006" NAME="Koukourakis 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL</AU>
<TI>Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway - A report of the tumour angiogenesis research group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>26</NO>
<PG>4301-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kozloff-2006" NAME="Kozloff 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn J, Steis R, Ding W, Suzuki S, Sugrue M, Grothey A</AU>
<TI>Efficacy of bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE).</TI>
<SO>Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I.</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>No.18S (June 20 Supplement)</NO>
<PG>abstr 3537</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00f6_hne-2008" NAME="Kˆhne 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kˆhne C-H, De Greve J, Hartmann JH, Lang I, Vergauve P, Becker K,; Braumann D, Joosens E, M¸ller L, Janssens J, Bokemeyer C, Reimer P, Link H, Sp‰th-Schwalbe E, Wilke H-J, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E</AU>
<TI>Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015</TI>
<SO>Annals of Oncology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>5</NO>
<PG>920-926</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Punt-2008" NAME="Punt 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, Schrama JG, Erdkamp FL, Vos A, Mol L, Antonini NF</AU>
<TI>Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>May 20 suppl</NO>
<PG>abstr LBA4011</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinacher_x002d_Schick-2008" MODIFIED="2009-03-30 00:15:18 +0200" MODIFIED_BY="[Empty name]" NAME="Reinacher-Schick 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll HSchmiegel,W.</AU>
<TI>Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604).</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>May 20 suppl</NO>
<PG>abstr 4030</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltz-2005" NAME="Saltz 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Saltz LB, Lenz H, Hochster HS, WadlerS, Hoff P, Kemeny N</AU>
<TI>Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan-Refractory Colorectal Cancer</TI>
<SO>Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16S, Part I of II (June 1 Supplement)</NO>
<PG>abstr 3508</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltz-2007" NAME="Saltz 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow ME, Chao RC, Lenz HJ</AU>
<TI>Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>30</NO>
<PG>4793-4799</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobrero-2007" NAME="Sobrero 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sobrero A, Ackland S, Clarke S, Perez-Carrin R, Chiara S, Gapski J, Mainwaring P, Balcewicz M, Langer B, Young S</AU>
<TI>Final data from a large phase II trial of first-line bevacizumab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC)</TI>
<SO>European Journal of Cancer Supplements</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>4</NO>
<PG>254 (Poster 3060)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobrero-2007a" NAME="Sobrero 2007a" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sobrero AF, Young S, Balcewicz M, Chiarra S, Perez Carrion R, Mainwaring P, Clarke S, Langer B, Ackland S</AU>
<TI>Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI</TI>
<SO>Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I.</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>No.18S (June 20 Supplement)</NO>
<PG>abstr 4068</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tol-2009" MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]" NAME="Tol 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG et al.</AU>
<TI>Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>6</NO>
<PG>563-572</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wainberg-2006" MODIFIED="2009-03-29 23:59:38 +0200" MODIFIED_BY="[Empty name]" NAME="Wainberg 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-29 23:59:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wainberg Z, Hecht R</AU>
<TI>A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>363-367</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2006" MODIFIED="2009-03-29 23:58:35 +0200" MODIFIED_BY="[Empty name]" NAME="Zheng 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-29 23:58:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng H, Chen J, Liao W, Luo R</AU>
<TI>[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. [Chinese]</TI>
<SO>Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University. 26(5):689-91, 2006 May. Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University. 26(5):689-91, 2006 May. Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University.</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>5</NO>
<PG>689-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-05-13 16:10:02 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00f6_hne-2007" MODIFIED="2009-03-30 00:11:20 +0200" MODIFIED_BY="[Empty name]" NAME="Kˆhne 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kohne C, Bajetta E, Valle JW, Van Cutsem J, Hecht JR, Moore M et al.</AU>
<TO>Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients with metastatic colorectal cancer recieving FOLFOX 4 and PTK/ZK 222584 or placebo</TO>
<SO>Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I</SO>
<YR>2007</YR>
<VL>25 Suppl 18</VL>
<PG>Abstract 4033</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-2008" NAME="Price 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Price TJ, Gebski V, Van Hazel A, Robinson A, Brosd A, Ganju V, Cunningham D, Wilson K, Tunney V, Tebbutt NC</AU>
<TI>International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial.</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>May 20 suppl</NO>
<PG>abstr 4029</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-05-13 16:14:47 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-EORTC40051_x002d_BOS" MODIFIED="2009-03-29 22:30:00 +0200" MODIFIED_BY="[Empty name]" NAME="EORTC40051-BOS" YEAR="">
<IDENTIFIERS MODIFIED="2009-03-29 22:30:00 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00004252" NAME="NCT00004252" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00021281" NAME="NCT00021281" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00070122" NAME="NCT00070122" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00109070" NAME="NCT00109070" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-NCT00109226" NAME="NCT00109226" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00200200" NAME="NCT00200200" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00265850" NAME="NCT00265850" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00294359" NAME="NCT00294359" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00321100" NAME="NCT00321100" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00399035" NAME="NCT00399035" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00437268" NAME="NCT00437268" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00438737" NAME="NCT00438737" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00454116" NAME="NCT00454116" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00457691" NAME="NCT00457691" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00484939" NAME="NCT00484939" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00499369" NAME="NCT00499369" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00500292" NAME="NCT00500292" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00544700" NAME="NCT00544700" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00561470" NAME="NCT00561470" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00642577" NAME="NCT00642577" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00700102" NAME="NCT00700102" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00707889" NAME="NCT00707889" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00720512" NAME="NCT00720512" YEAR="">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-05-13 16:14:36 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-05-13 16:14:36 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-2001" NAME="Altman 2001" TYPE="BOOK">
<AU>Altman DG</AU>
<TI>Systematic reviews of evaluations of prognostic variables</TI>
<SO>Systematic reviews in health care</SO>
<YR>2001</YR>
<PG>228-47</PG>
<EN>2nd</EN>
<PB>BMJ</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Am.-Cancer-Soc.-2005" NAME="Am. Cancer Soc. 2005" TYPE="OTHER">
<AU>American Cancer Society</AU>
<TI>Cancer Facts and Figures</TI>
<SO>Cancer Facts and Figures</SO>
<YR>2005</YR>
<CY>Atlanta</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arkenau-2008" MODIFIED="2009-04-06 06:27:18 +0200" MODIFIED_BY="[Empty name]" NAME="Arkenau 2008" TYPE="JOURNAL_ARTICLE">
<AU>Arkenau HT, Arnold D, Casidy J, Douillard JY, Hochster H.</AU>
<TI>Efficacy of oxaliplatin plus capecitabine or infusional fluouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomised trials</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>36</NO>
<PG>59100-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnold-2008" MODIFIED="2009-05-13 16:14:34 +0200" MODIFIED_BY="[Empty name]" NAME="Arnold 2008" TYPE="CONFERENCE_PROC">
<AU>Arnold D, Reinacher-Schiek A, Mueller L, Steffens C, Krˆning H, Freier W, et al.</AU>
<TI>Bevacizumab (Bev) beyond progression (BP) in combination with second-line chemotherapy (CT) after failure of a Bev containing first-line CT in patients (pts) with metastatic colorectal cancer (mCRC). Preliminary baseline and safety results of the AIO0504/AGMT phase III study</TI>
<SO>Proceeding of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium</SO>
<YR>2008</YR>
<PG>Abstract 469</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergers-2003" NAME="Bergers 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bergers G, Benjamin LE</AU>
<TI>Tumorigenesis and the angiogenic switch</TI>
<SO>Nature Reviews Cancer</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>6</NO>
<PG>401-410</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="24"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cao-2004" NAME="Cao 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cao YH</AU>
<TI>Antiangiogenic cancer therapy</TI>
<SO>Seminars in Cancer Biology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>2</NO>
<PG>139-145</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="25"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cox-1972" NAME="Cox 1972" TYPE="JOURNAL_ARTICLE">
<AU>Cox DR</AU>
<TI>Regression models and life tables</TI>
<SO>Journal of the Royal Statistical Society</SO>
<YR>1972</YR>
<VL>34</VL>
<NO>Series B</NO>
<PG>187-220</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CRC-Meta_x002d_anal.-2000" NAME="CRC Meta-anal. 2000" TYPE="OTHER">
<AU>Colorectal Meta-analysis Collaboration</AU>
<TI>Palliative chemotherapy for advanced or metastatic colorectal cancer:</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Gramont-2000" NAME="de Gramont 2000" TYPE="JOURNAL_ARTICLE">
<AU>de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A</AU>
<TI>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>16</NO>
<PG>2938-2947</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Douillard-2000" NAME="Douillard 2000" TYPE="JOURNAL_ARTICLE">
<AU>Douillard JY, Cunningham D, Roth AD, Navarro M, James RD</AU>
<TI>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.</TI>
<SO>The Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9209</NO>
<PG>1041-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dvorak-2002" NAME="Dvorak 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dvorak HF</AU>
<TI>Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>21</NO>
<PG>4368-4380</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="23"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2002" NAME="EMEA 2002" TYPE="OTHER">
<TI>Points to consider on multiplicity issues in clinical trials</TI>
<SO>available under: http://www.emea.europa.eu/pdfs/human/ewp/090899en.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferrara-2004" NAME="Ferrara 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ferrara N, Hillan KJ, Gerber HP, Novotny W</AU>
<TI>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</TI>
<SO>Nature Reviews Drug Discovery</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>5</NO>
<PG>391-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="32"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fidler-1994" NAME="Fidler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fidler IJ, Ellis LM</AU>
<TI>The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis</TI>
<SO>Cell</SO>
<YR>1994</YR>
<VL>79</VL>
<NO>2</NO>
<PG>185-188</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="26"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Folkman-1971" NAME="Folkman 1971" TYPE="JOURNAL_ARTICLE">
<AU>Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, Goldberg A, Hiatt HH, Glass J, Henshaw E</AU>
<TI>Tumor Angiogenesis - Therapeutic Implications</TI>
<SO>New England Journal of Medicine</SO>
<YR>1971</YR>
<VL>285</VL>
<NO>21</NO>
<PG>1182-&amp;</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Folkman-1990" NAME="Folkman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Folkman J</AU>
<TI>What Is the Evidence That Tumors Are Angiogenesis Dependent</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1990</YR>
<VL>82</VL>
<NO>1</NO>
<PG>4-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gasparini-2005" NAME="Gasparini 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gasparini G, Longo R, Fanielli M, Teicher BA</AU>
<TI>Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges and Open Questions</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1295-1311</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="37"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giacchetti-2000" NAME="Giacchetti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C</AU>
<TI>Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>1</NO>
<PG>136-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2004" MODIFIED="2009-05-11 16:53:55 +0200" MODIFIED_BY="[Empty name]" NAME="Goldberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR.</AU>
<TI>A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer</TI>
<SO>J Clin Oncol</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2002" NAME="Grothey 2002" TYPE="CONFERENCE_PROC">
<AU>Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A et al.</AU>
<TI>Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC)</TI>
<SO>Proc. Annu.Meet.Am.Soc.Clin.Oncol</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>512</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2004" NAME="Grothey 2004" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Sargent D, Goldberg RM, Schmoll HJ</AU>
<TI>Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>7</NO>
<PG>1209-1214</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2008" MODIFIED="2009-04-06 06:30:28 +0200" MODIFIED_BY="[Empty name]" NAME="Grothey 2008" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Sugrue M, Purdie DM, Sargent D, Hedrick E, Kozloff M.</AU>
<TI>Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>33</NO>
<PG>5326-5334</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1998" NAME="Hamilton 1998" TYPE="BOOK_SECTION">
<AU>Hamilton JM, Grem JL</AU>
<TI>Chapter 9: Lower gastrointestinal cancer</TI>
<SO>Current Cancer Therapeutics</SO>
<YR>1998</YR>
<VL>3</VL>
<ED>Kirkwood JM, Lotze MT, and Yasko JM</ED>
<PB>Churchill Livingstone</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanahan-1996" NAME="Hanahan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hanahan D, Folkman J</AU>
<TI>Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis</TI>
<SO>Cell</SO>
<YR>1996</YR>
<VL>86</VL>
<NO>3</NO>
<PG>353-364</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hicklin-2005" NAME="Hicklin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hicklin DJ, Ellis LM</AU>
<TI>Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>5</NO>
<PG>1011-1027</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="30"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hochster-2008" MODIFIED="2009-04-06 06:33:48 +0200" MODIFIED_BY="[Empty name]" NAME="Hochster 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hochster H, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn Al et al.</AU>
<TI>Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE-study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>21</NO>
<PG>3523-3529</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad MS, Moore A, Carroll D. et al.</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding neccessary ?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kakeji-1997" NAME="Kakeji 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kakeji Y, Teicher BA</AU>
<TI>Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents</TI>
<SO>Investigational New Drugs</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>39-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="36"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Longo-2002" NAME="Longo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Longo R, Sarmiento M, Fanielli M, Capaccetti B, Gattuso D, Gasparini G</AU>
<TI>Anti-angiogenic therapy: Rationale, challenges and clinical studies</TI>
<SO>Angiogenesis</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>237-256</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="34"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lyden-2001" NAME="Lyden 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu ZP, Hackett NR, Crystal RG, Moore MAS, Hajjar KA, Manova K, Benezra R, Rafii S</AU>
<TI>Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth</TI>
<SO>Nature Medicine</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>11</NO>
<PG>1194-1201</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="22"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Machin-1997" NAME="Machin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Machin D, Stenning SP, Parmar MKP et al.</AU>
<TI>Thirty years of Medical Research Council randomized trials in solid tumors.</TI>
<SO>Clinical Oncology (R Coll Radiol)</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>100-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2002" NAME="McDonald 2002" TYPE="JOURNAL_ARTICLE">
<AU>McDonald DM, Baluk P</AU>
<TI>Significance of blood vessel leakiness in cancer</TI>
<SO>Cancer Research</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>18</NO>
<PG>5381-5385</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="28"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2005" NAME="Miller 2005" TYPE="JOURNAL_ARTICLE">
<AU>Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS</AU>
<TI>Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>4</NO>
<PG>792-799</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="31"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Obrand-1997" NAME="Obrand 1997" TYPE="JOURNAL_ARTICLE">
<AU>Obrand DI, Gordon PH</AU>
<TI>Incidence and patterns of recurrence following curative resection for colorectal carcinoma</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1997</YR>
<VL>40</VL>
<NO>1</NO>
<PG>15-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2001" NAME="Parkin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Bray F, Ferlay J, Pisani P</AU>
<TI>Estimating the world cancer burden: GLOBOCAN 2000</TI>
<SO>International Journal of Cancer</SO>
<YR>2001</YR>
<VL>94</VL>
<NO>2</NO>
<PG>153-156</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Steward L.</AU>
<TI>Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rak-1996" NAME="Rak 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rak J, Kerbel R</AU>
<TI>Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls</TI>
<SO>Cancer Metastasis Reviews</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>231-236</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="35"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reviewer_x00b4_s-Handbook" NAME="Reviewer¥s Handbook" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors.</AU>
<TI>Cochrane Reviewers¥ Handbook 4.2.0 (updated March 2003).</TI>
<SO>The Cochrane Library</SO>
<YR>2003</YR>
<NO>2</NO>
<CY>Oxford: Update Software</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2007" NAME="Riley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Riley RD, Simmonds MC, Look MP</AU>
<TI>Evidence combining individual patient data and aggregate data: a systematic review identified current practice and possible methods</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2007</YR>
<VL>60</VL>
<NO>5</NO>
<PG>431-439</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saltz-2000" NAME="Saltz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL</AU>
<TI>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>13</NO>
<PG>905-914</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Scappaticci-2007" MODIFIED="2009-04-06 06:36:34 +0200" MODIFIED_BY="[Empty name]" NAME="Scappaticci 2007" TYPE="JOURNAL_ARTICLE">
<AU>Scappaticci FA, Skillings JR, Holden SN, Gerber HP, MIller K, Kabbinavar F et al.</AU>
<TI>Arterial thrombembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<PG>1232-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scheithauer-1993" NAME="Scheithauer 1993" TYPE="JOURNAL_ARTICLE">
<AU>Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D</AU>
<TI>Randomized Comparison of Combination Chemotherapy Plus Supportive Care with Supportive Care Alone in Patients with Metastatic Colorectalcancer</TI>
<SO>British Medical Journal</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6880</NO>
<PG>752-755</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1994" NAME="Schulz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Grimes DA, Altman DG</AU>
<TI>Assessing the quality of randomization from reports of controlled trials published in Obstetrics and Gynecology Journals</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<NO>2</NO>
<PG>125-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8015122"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sivakumar-2005" NAME="Sivakumar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sivakumar B, Harry L.E., Paleolog EM</AU>
<TI>Modulating Angiogenesis</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>292</VL>
<NO>8</NO>
<PG>972-977</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="40"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Therasse-2000" NAME="Therasse 2000" TYPE="JOURNAL_ARTICLE">
<AU>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbecke M, van Osterom AT, Christian MC, Gwyther SG</AU>
<TI>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cance, National Cancer Institute of Canada, National Cancer Institute of the United States</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>3</NO>
<PG>205-216</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zebrowski-1999" NAME="Zebrowski 1999" TYPE="JOURNAL_ARTICLE">
<AU>Zebrowski BK, Yano S, Liu WB, Shaheen RM, Hicklin DJ, Putnam JB, Ellis LM</AU>
<TI>Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions</TI>
<SO>Clinical Cancer Research</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>11</NO>
<PG>3364-3368</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="27"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES>
<REFERENCE ID="REF-Benson-2003" NAME="Benson 2003" TYPE="CONFERENCE_PROC">
<AU>Benson AB, Catalano PJ, Meropol NJ, O'Dwyer PJ, Giantonio BJ</AU>
<TI>Bevacizumab (anti VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>Abstract 975</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergsland-2000" NAME="Bergsland 2000" TYPE="CONFERENCE_PROC">
<AU>Bergsland E, Hurwitz H, Fehrenbacher L, Meropol N, Novotny N, Gaudreault J et al.</AU>
<TI>A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-Fluorouracil/Leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>Abstract 939</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassidy-2006" NAME="Cassidy 2006" TYPE="CONFERENCE_PROC">
<AU>Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al.</AU>
<TO>First efficacy and safety results from XELOX-1/NO16966, a randomized 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC)</TO>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17 Suppl 9</VL>
<PG>late breaking abstract 3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2006" NAME="Chen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS</AU>
<TI>Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center trial TRC-0301</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>21</NO>
<PG>3354-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Castro-2006" NAME="de Castro 2006" TYPE="JOURNAL_ARTICLE">
<AU>de Castro Junior G, Puglisi F, de Azambuja E, El Saghir N S, Awada A</AU>
<TI>Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>1</NO>
<PG>40-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Des-2005" NAME="Des 2005" TYPE="JOURNAL_ARTICLE">
<AU>Des GG</AU>
<TI>Biotherapies dans le traitement des cancers colorectaux. [Biotherapy in colorectal cancer]</TI>
<SO>J Chir (Paris)</SO>
<YR>2005</YR>
<VL>142</VL>
<NO>5</NO>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eichhorn-2004" NAME="Eichhorn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Eichhorn ME, Strieth S, Dellian M</AU>
<TI>Anti-vascular tumor therapy: Recent advances, pitfalls and clinical perspectives</TI>
<SO>Drug Resistance Updates</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>2</NO>
<PG>125-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2003" NAME="Ellis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ellis L M</AU>
<TI>Antiangiogenic therapy: more promise and, yet again, more questions.</TI>
<SO>J Clin Oncol</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>21</NO>
<PG>3897-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2005" NAME="Ellis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ellis L M</AU>
<TI>Bevacizumab.</TI>
<SO>Nat-Rev-Drug-Discov. 2005 May; Suppl: S8-9</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2006" NAME="Ellis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ellis LM, Curley SA, Grothey A</AU>
<TI>In reply [2]</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>16</NO>
<PG>2593-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2006a" NAME="Ellis 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Ellis LM, Rosen L, Gordon MS</AU>
<TI>Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.</TI>
<SO>Clin Adv Hematol Oncol</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>1</NO>
<PG>suppl 1-10; quz 11-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giantonio-2005" NAME="Giantonio 2005" TYPE="CONFERENCE_PROC">
<AU>Giantonio BJ, Catalano PJ, Meropol NJ, O¥Dwyer PJ, Mitchell EP, Alberts SR et al.</AU>
<TO>High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results fro, the Eastern Cooperative Oncology Group study E3200</TO>
<SO>Journal of Clinical Oncology ASCO Annual Meeting Proceedings</SO>
<YR>2005</YR>
<VL>23 Supplement 16</VL>
<PG>Abstract 2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goel-2005" NAME="Goel 2005" TYPE="JOURNAL_ARTICLE">
<AU>Goel R, Chouinard E, Stewart D J, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L</AU>
<TI>An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.</TI>
<SO>Invest New Drugs</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>1</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2006" NAME="Goldberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg R M, Hurwitz H I, Fuchs C S</AU>
<TI>The role of targeted therapy in the treatment of colorectal cancer.</TI>
<SO>Clin Adv Hematol Oncol</SO>
<YR>2006</YR>
<VL>4 Suppl 17</VL>
<NO>8</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2006" NAME="Grothey 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A</AU>
<TI>Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.</TI>
<SO>Semin Oncol</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>5 Suppl 10</NO>
<PG>S41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2006a" NAME="Grothey 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A</AU>
<TI>Is There a Third-Line Therapy for Metastatic Colorectal Cancer?</TI>
<SO>Seminars in Oncology</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>SUPPL. 11</NO>
<PG>36-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2006b" NAME="Grothey 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A</AU>
<TI>Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer.</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>14 Suppl 10</NO>
<PG>21-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2007" NAME="Grothey 2007" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Marshall J L</AU>
<TI>Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>5</NO>
<PG>553-64, 566; discussion 566-8, 577-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hambleton-2004" NAME="Hambleton 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hambleton J, Novotny WF, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E</AU>
<TI>Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation [abstract]</TI>
<SO>Annual Meeting Proceedings of the American Society of Clinical Oncology</SO>
<YR>2004</YR>
<PG>252</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hao-2003" NAME="Hao 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, Rowinsky EK</AU>
<TI>A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor</TI>
<SO>Clinical Cancer Research</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>7</NO>
<PG>2465-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hecht-2005" NAME="Hecht 2005" TYPE="CONFERENCE_PROC">
<AU>Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K et al.</AU>
<TO>A randomized, double-bline, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-FU/leucovorin and PTK/zk or placebo (CONFIRM-1)</TO>
<SO>Journal of Clinical Oncology, ASCO Annual Meeting Proceedings</SO>
<YR>2005</YR>
<VL>23 Suppl 16</VL>
<PG>Abstract 3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedrick-2004" NAME="Hedrick 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hedrick EE, Hurwitz H, Sarkar S, Griffing S, Novotny W, Grothey A</AU>
<TI>Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC) [abstract]</TI>
<SO>Annual Meeting Proceedings of the American Society of Clinical Oncology</SO>
<YR>2004</YR>
<PG>249</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurwitz-2003" NAME="Hurwitz 2003" TYPE="CONFERENCE_PROC">
<AU>Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J et al.</AU>
<TO>Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results ofa phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluouracil, leucovorin) as first-line therapy in subjects with metastatic CRC</TO>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>Abstract 3646</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iqbal-2004" NAME="Iqbal 2004" TYPE="JOURNAL_ARTICLE">
<AU>Iqbal S, Lenz H J</AU>
<TI>Angiogenesis inhibitors in the treatment of colorectal cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>SUPPL. 17</NO>
<PG>10-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iqbal-2004a" NAME="Iqbal 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Iqbal S, Lenz H J</AU>
<TI>Integration of novel agents in the treatment of colorectal cancer</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>SUPPL. 1</NO>
<PG>S32-S39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jain-2006" NAME="Jain 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jain RK, Duda DG, Clark JW, Loeffler JS</AU>
<TI>Lessons from phase III clinical trials on anti-VEGF therapy for cancer</TI>
<SO>Nature Clinical Practice Oncology</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>1</NO>
<PG>24-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kabbinavar-2004" NAME="Kabbinavar 2004" TYPE="CONFERENCE_PROC">
<AU>Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B, Novotny W</AU>
<TI>Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>Abstract 3516</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kabbinavar-2004a" NAME="Kabbinavar 2004a" TYPE="CONFERENCE_PROC">
<AU>Kabbinavar F, Schulz J, McCleod M, Patel T, Hamm JT, Hecht R et al.</AU>
<TO>First-line bevacizumab with 5-fluorouracil prolongs progression-free survival in metastatic colorectal cancer patients who are not optimal candidates for irinotecan therapy</TO>
<SO>Annals of Oncology</SO>
<YR>2004</YR>
<VL>15 Supplement 3</VL>
<PG>Abstract 261 O</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kabbinavar-2005" NAME="Kabbinavar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S</AU>
<TI>Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer</TI>
<SO>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16</NO>
<PG>3706-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klem-2003" NAME="Klem 2003" TYPE="JOURNAL_ARTICLE">
<AU>Klem J</AU>
<TI>Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>3</NO>
<PG>147-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mancuso-2005" NAME="Mancuso 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mancuso A, Sternberg C N</AU>
<TI>Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?</TI>
<SO>Crit Rev Oncol Hematol</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>1</NO>
<PG>67-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinico-2006" NAME="Martinico 2006" TYPE="JOURNAL_ARTICLE">
<AU>Martinico SCM, Jezzard S, Sturt NJH, Michils G, Tejpar S, Phillips RK, Vassaux G</AU>
<TI>Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors</TI>
<SO>Cancer Research</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>16</NO>
<PG>8233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maruyama-2000" NAME="Maruyama 2000" TYPE="JOURNAL_ARTICLE">
<AU>Maruyama S, Yagita A, Sukegawa Y, Daido A, Takeuchi S</AU>
<TI>Effect of a new immunotherapy for advanced colorectal cancer</TI>
<SO>Biotherapy</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>5</NO>
<PG>460-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mason-2006" NAME="Mason 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mason MD</AU>
<TI>Oncology</TI>
<SO>Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>12</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mass-2004" NAME="Mass 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mass RD, Fyfe G, Hambleton J, Kabbinavar F, Hurwitz H, Novotny W, Sarkar S</AU>
<TI>Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis [abstract]</TI>
<SO>Annual Meeting Proceedings of the American Society of Clinical Oncology</SO>
<YR>2004</YR>
<PG>274</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matsumura-1998" NAME="Matsumura 1998" TYPE="JOURNAL_ARTICLE">
<AU>Matsumura M, Chiba Y, Lu C, Amaya H, Shimomatsuya T, Horiuchi T, Muraoka R, Tanigawa N</AU>
<TI>Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer</TI>
<SO>Cancer Letters</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>1</NO>
<PG>55-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matsushita-1999" NAME="Matsushita 1999" TYPE="JOURNAL_ARTICLE">
<AU>Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, Yanagitani S, Amoh Y, Takemoto H, Ogata N, Yamamoto C, Kubota Y, Seki T, Inokuchi H, Nishizawa M, Takada H, Sawamura T, Okamura A, Inoue K</AU>
<TI>Down-regulation of TGF-beta receptors in human colorectal cancer: Implications for cancer development</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>80</VL>
<NO>1-2</NO>
<PG>194-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matsuura-2000" NAME="Matsuura 2000" TYPE="JOURNAL_ARTICLE">
<AU>Matsuura T, Fukuda Y, Fujitaka T, Nishisaka T, Sakatani T, Ito H</AU>
<TI>Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>5</NO>
<PG>1007-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattern-1996" NAME="Mattern 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mattern J, Volm M</AU>
<TI>Microvessel density and vascular endothelial growth factor expression in human tumors of different localization</TI>
<SO>Oncology Reports</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>3</NO>
<PG>465-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayer-2002" NAME="Mayer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mayer Kuckuk P, Banerjee D, Kemeny N, Fong Y, Bertino JR</AU>
<TI>Molecular therapies for colorectal cancer metastatic to the liver</TI>
<SO>Molecular Therapy</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>5 I</NO>
<PG>492-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntyre-2004" NAME="McIntyre 2004" TYPE="JOURNAL_ARTICLE">
<AU>McIntyre JA, Martin L</AU>
<TI>Panitumumab: Oncolytic anti-EGFR human monoclonal antibody</TI>
<SO>Drugs of the Future</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>8</NO>
<PG>793-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McWilliams-2005" NAME="McWilliams 2005" TYPE="JOURNAL_ARTICLE">
<AU>McWilliams R R, Erlichman C</AU>
<TI>Novel therapeutics in colorectal cancer.</TI>
<SO>Dis Colon Rectum</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>8</NO>
<PG>1632-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Medinger-2004" NAME="Medinger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Medinger M, Steinbild S, Mross K</AU>
<TI>Adjuvant and palliative anticancer treatment of coloncarcinoma in 2004</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>40</NO>
<PG>1633-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Medinger-M_x002c_-Ste2" NAME="Medinger M, Ste2" TYPE="JOURNAL_ARTICLE">
<AU>Medinger M, Steinbild S, Mross K</AU>
<TI>Die systemische Therapie des Kolonkarzinoms 2004. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004]</TI>
<SO>Schweiz Rundsch Med Prax</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>40</NO>
<PG>1633-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Menges-2006" NAME="Menges 2006" TYPE="JOURNAL_ARTICLE">
<AU>Menges M, Gartner B, Georg T, Fischinger J, Zeitz M</AU>
<TI>Cost-benefit analysis of screening colonoscopy in 40- to 50-year-old first-degree relatives of patients with colorectal cancer</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>6</NO>
<PG>596-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merighi-2007" NAME="Merighi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi P G, Borea P A</AU>
<TI>Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.</TI>
<SO>Mol Pharmacol</SO>
<YR>2007</YR>
<VL>72</VL>
<NO>2</NO>
<PG>395-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meropol-2006" NAME="Meropol 2006" TYPE="JOURNAL_ARTICLE">
<AU>Meropol NJ</AU>
<TI>Turning point for colorectal cancer clinical trials</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>21</NO>
<PG>3322-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Messersmith-2003" NAME="Messersmith 2003" TYPE="JOURNAL_ARTICLE">
<AU>Messersmith W, Laheru D, Hidalgo M</AU>
<TI>Recent advances in the pharmacological treatment of colorectal cancer.</TI>
<SO>Expert Opin Investig Drugs</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>3</NO>
<PG>423-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meulenbeld-2007" NAME="Meulenbeld 2007" TYPE="JOURNAL_ARTICLE">
<AU>Meulenbeld HJ, Creemers G J</AU>
<TI>First-line treatment strategies for elderly patients with metastatic colorectal cancer</TI>
<SO>Drugs and Aging</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>3</NO>
<PG>223-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meyerhardt-2006" NAME="Meyerhardt 2006" TYPE="JOURNAL_ARTICLE">
<AU>Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS</AU>
<TI>Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meyerhardt-JA_x002c_-2" NAME="Meyerhardt JA, 2" TYPE="JOURNAL_ARTICLE">
<AU>Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS</AU>
<TI>Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1892-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miki-2004" NAME="Miki 2004" TYPE="JOURNAL_ARTICLE">
<AU>Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M</AU>
<TI>C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2004</YR>
<VL>49</VL>
<NO>6</NO>
<PG>970-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milano-2005" NAME="Milano 2005" TYPE="JOURNAL_ARTICLE">
<AU>Milano G</AU>
<TI>Outils pharmacologiques du ciblage du recepteur du facteur de croissance epidermique et du VEGF. [Pharmacological skills for targeting EGFR and VEGF]</TI>
<SO>Bull Cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>Spec no</NO>
<PG>S17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milano-2006" NAME="Milano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Milano M, Guerin O</AU>
<TI>Recent advances in targeted therapies for colorectal cancer.</TI>
<SO>J Oncol Pharm Pract</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-2005" NAME="Mitchell 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell E P</AU>
<TI>Prognostic impact of race and ethnicity in the treatment of colorectal cancer.</TI>
<SO>Med Clin North Am</SO>
<YR>2005</YR>
<VL>89</VL>
<NO>5</NO>
<PG>1045-57, 1054</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miyashita-2003" NAME="Miyashita 2003" TYPE="JOURNAL_ARTICLE">
<AU>Miyashita M, Tajiri T, Yanagi K, Shimizu T, Futami R, Sasajima K, Tokunaga A</AU>
<TI>Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors</TI>
<SO>Hepato Gastroenterology</SO>
<YR>2003</YR>
<VL>50</VL>
<NO>50</NO>
<PG>308-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mocellin-2005" NAME="Mocellin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mocellin S, Lise M, Nitti D</AU>
<TI>Targeted therapy for colorectal cancer: mapping the way.</TI>
<SO>Trends Mol Med</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>7</NO>
<PG>327-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moesinger-2006" NAME="Moesinger 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moesinger RC</AU>
<TI>Diagnosis and emerging therapies in the treatment of colorectal cancer</TI>
<SO>Advanced Studies in Medicine</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>1</NO>
<PG>30-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2006" NAME="Moore 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moore MJ</AU>
<TI>Drug safety: The oncology perspective</TI>
<SO>Canadian Journal of Clinical Pharmacology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>1</NO>
<PG>e41-e47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moosmann-2007" NAME="Moosmann 2007" TYPE="JOURNAL_ARTICLE">
<AU>Moosmann N, Heinemann V</AU>
<TI>Cetuximab in the treatment of metastatic colorectal cancer</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>2</NO>
<PG>243-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mooteri-1996" NAME="Mooteri 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T</AU>
<TI>Tumor angiogenesis in primary and metastatic colorectal cancers</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>10</NO>
<PG>1073-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morabito-2006" NAME="Morabito 2006" TYPE="JOURNAL_ARTICLE">
<AU>Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F</AU>
<TI>Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions</TI>
<SO>Oncologist</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>7</NO>
<PG>753-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morgan-2003" NAME="Morgan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Morgan B, Thomas A L, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield M A, Mross K, Ball H A, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman G R, Laurent D, Dugan M, Marme D, Steward W P</AU>
<TI>Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.</TI>
<SO>J Clin Oncol</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>21</NO>
<PG>3955-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morgan-2006" NAME="Morgan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Morgan B, Utting JF, Higginson A, Thomas AL, Steward WP, Horsfield MA</AU>
<TI>A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging</TI>
<SO>British Journal of Cancer</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>10</NO>
<PG>1420-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morgan-B_x002c_-Thoma2" NAME="Morgan B, Thoma2" TYPE="JOURNAL_ARTICLE">
<AU>Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP</AU>
<TI>Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>21</NO>
<PG>3955-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morrow-2006" NAME="Morrow 2006" TYPE="JOURNAL_ARTICLE">
<AU>Morrow M, Goldstein L</AU>
<TI>Surgery of the primary tumor in metastatic breast cancer: Closing the barn door after the horse has bolted?</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18</NO>
<PG>2694-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moss-2006" NAME="Moss 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moss RA, Petrylak DP</AU>
<TI>Cytotoxic chemotherapy for prostate cancer: Who and when?</TI>
<SO>Current Treatment Options in Oncology</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>5</NO>
<PG>370-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Motl-2005" NAME="Motl 2005" TYPE="JOURNAL_ARTICLE">
<AU>Motl S</AU>
<TI>Bevacizumab in combination chemotherapy for colorectal and other cancers.</TI>
<SO>Am J Health Syst Pharm</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1021-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mousa-2004" NAME="Mousa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mousa SA, Mousa AS</AU>
<TI>Angiogenesis inhibitors: Current &amp; future directions</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mross-2005" NAME="Mross 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho Y Y, Gunther C, Laurent D, Unger C</AU>
<TI>Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours</TI>
<SO>European Journal of Cancer</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>9</NO>
<PG>1291-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mukherjee-2005" NAME="Mukherjee 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee A, Westwell AD, Bradshaw TD, Stevens MFG, Carmichael J, Martin SG</AU>
<TI>Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: An in vitro study</TI>
<SO>British Journal of Cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>2</NO>
<PG>350-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulcahy-2002" NAME="Mulcahy 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mulcahy MF, Benson III AB</AU>
<TI>Recent and ongoing clinical trials for treating colorectal cancer</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>6</NO>
<PG>871-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulcahy-2005" NAME="Mulcahy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mulcahy M F, Benson A B 3rd</AU>
<TI>Bevacizumab in the treatment of colorectal cancer.</TI>
<SO>Expert Opin Biol Ther</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>7</NO>
<PG>997-1005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulcahy-MF_x002c_-Ben2" NAME="Mulcahy MF, Ben2" TYPE="JOURNAL_ARTICLE">
<AU>Mulcahy MF, Benson III AB</AU>
<TI>Bevacizumab in the treatment of colorectal cancer</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>7</NO>
<PG>997-1005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mullerat-2003" NAME="Mullerat 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mullerat J, Wong Te Fong LF, Davies SE, Winslet MC, Perrett CW</AU>
<TI>Angiogenesis in anal warts, anal intraepithelial neoplasia and anal squamous cell carcinoma</TI>
<SO>Colorectal Disease</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>4</NO>
<PG>353-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murakami-2005" NAME="Murakami 2005" TYPE="JOURNAL_ARTICLE">
<AU>Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I</AU>
<TI>Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A&lt;inf&gt;2&lt;/inf&gt;</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>2005</YR>
<VL>280</VL>
<NO>26</NO>
<PG>24987-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Musso-2001" NAME="Musso 2001" TYPE="JOURNAL_ARTICLE">
<AU>Musso O, Theret N, Heljasvaara R, Rehn M, Turlin B, Campion J P, Pihlajaniemi T, Clement B</AU>
<TI>Tumor hepatocytes and basement membrane-producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>4</NO>
<PG>868-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mysliwiec-2002" NAME="Mysliwiec 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mysliwiec AG, Ornstein DL</AU>
<TI>Matrix metalloproteinases in colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>4</NO>
<PG>208-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagashima-1997" NAME="Nagashima 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nagashima Y, Hasegawa S, Koshikawa N, Taki A, Ichikawa Y, Kitamura H, Misugi K, Kihira Y, Matuo Y, Yasumitsu H, Miyazaki K</AU>
<TI>Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors</TI>
<SO>International Journal of Cancer</SO>
<YR>1997</YR>
<VL>72</VL>
<NO>3</NO>
<PG>441-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nakasaki-2002" NAME="Nakasaki 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H</AU>
<TI>Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer</TI>
<SO>American Journal of Hematology</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>4</NO>
<PG>247-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nakayama-2000" NAME="Nakayama 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nakayama Y, Sako T, Shibao K, Onitsuka K, Nagashima N, Hirata K, Nagata N, Itoh H</AU>
<TI>Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer</TI>
<SO>Anticancer Research</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>6 A</NO>
<PG>4097-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nakayama-2002" NAME="Nakayama 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nakayama Y, Sako T, Shibao K, Okazaki K, Rempo N, Onitsuka K, Minagawa N, Akahane K, Nagashima N, Nagata N, Itoh H</AU>
<TI>Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer</TI>
<SO>Anticancer Research</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>2437-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nanashima-1998" NAME="Nanashima 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nanashima A, Ito M, Sekine I, Naito S, Yamaguchi H, Nakagoe T, Ayabe H</AU>
<TI>Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>12</NO>
<PG>2634-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nanda-2004" NAME="Nanda 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nanda A, Buckhaults P, Seaman S, Agrawal N, Boutin P, Shankara S, Nacht M, Teicher B, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B</AU>
<TI>Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R</TI>
<SO>Cancer Research</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>23</NO>
<PG>8507-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nanda-A_x002c_-St--Cr2" NAME="Nanda A, St  Cr2" TYPE="JOURNAL_ARTICLE">
<AU>Nanda A, St Croix B</AU>
<TI>Tumor endothelial markers: new targets for cancer therapy.</TI>
<SO>Curr Opin Oncol</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nguyen-2006" NAME="Nguyen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen Q D, Rodrigues S, Rodrigue CM, Rivat C, Grijelmo C, Bruyneel E, Emami S, Attoub S, Gespach C</AU>
<TI>Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts</TI>
<SO>Molecular Cancer Therapeutics</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>8</NO>
<PG>2070-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novakovic-2006" NAME="Novakovic 2006" TYPE="JOURNAL_ARTICLE">
<AU>Novakovic P, Stempak JM, Sohn K J, Kim Y I</AU>
<TI>Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells</TI>
<SO>Carcinogenesis</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>5</NO>
<PG>916-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novotny-2004" NAME="Novotny 2004" TYPE="JOURNAL_ARTICLE">
<AU>Novotny WF, Holmgren E, Nelson B, Mass R, Kabbinavar F, Hurwitz H</AU>
<TI>Bevacizumab (a mononucleal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer [abstract]</TI>
<SO>Annual Meeting Proceedings of the American Society of Clinical Oncology</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>252</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nozawa-2004" NAME="Nozawa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nozawa T, Enomoto T, Koshida Y, Sato Y, Kuranami M</AU>
<TI>Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>12</NO>
<PG>2093-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connell-2004" NAME="O'Connell 2004" TYPE="JOURNAL_ARTICLE">
<AU>O'Connell M J</AU>
<TI>Current status of adjuvant therapy for colorectal cancer.</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>6</NO>
<PG>751-5; discussion 755-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Dwyer-2001" NAME="O'Dwyer 2001" TYPE="JOURNAL_ARTICLE">
<AU>O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB</AU>
<TI>Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study</TI>
<SO>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>9</NO>
<PG>2413-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Dwyer-2007" NAME="O'Dwyer 2007" TYPE="JOURNAL_ARTICLE">
<AU>O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, Benson III AB, Rothenberg M, Petrelli N, Lenz H J, Diasio R, DuBois R, Sargent D, Sloan J, Johnson CD, Comis RL, O'Connell MJ</AU>
<TI>Priorities in colorectal cancer research: Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>16</NO>
<PG>2313-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Neil-2005" NAME="O'Neil 2005" TYPE="JOURNAL_ARTICLE">
<AU>O'Neil B H, Goldberg R M</AU>
<TI>Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).</TI>
<SO>Semin Oncol</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>1</NO>
<PG>35-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Obrecht-2000" NAME="Obrecht 2000" TYPE="JOURNAL_ARTICLE">
<AU>Obrecht JP</AU>
<TI>Chemotherapeutic developments of malignant neoplasia</TI>
<SO>Onkologie</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ochiumi-2006" NAME="Ochiumi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ochiumi T, Kitadai Y, Tanaka S, Akagi M, Yoshihara M, Chayama K</AU>
<TI>Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer.</TI>
<SO>Int J Oncol</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>1</NO>
<PG>105-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ogawa-2004" NAME="Ogawa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ogawa M, Yamamoto H, Nagano H, Miyake Y, Sugita Y, Hata T, Kim B N, Ngan CY, Damdinsuren B, Ikenaga M, Ikeda M, Ohue M, Nakamori S, Sekimoto M, Sakon M, Matsuura N, Monden M</AU>
<TI>Hepatic Expression of ANG2 RNA in Metastatic Colorectal Cancer</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>2</NO>
<PG>528-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohi-2000" NAME="Ohi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ohi M, Miki C</AU>
<TI>Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>4</NO>
<PG>413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okada-2004" NAME="Okada 2004" TYPE="JOURNAL_ARTICLE">
<AU>Okada K, Satoh T, Fujimoto K, Tokunaga O</AU>
<TI>Interaction between morphology and angiogenesis in human early colorectal cancers</TI>
<SO>Pathology International</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>7</NO>
<PG>490-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okaji-2004" NAME="Okaji 2004" TYPE="JOURNAL_ARTICLE">
<AU>Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Tsuchiya T, Sakurai D, Tsuchiya N, Tokunaga K, Takahashi K, Nagawa H</AU>
<TI>A novel method for isolation of endothelial cells and macrophages from murine tumors based on Ac-LDL uptake and CD16 expression</TI>
<SO>Journal of Immunological Methods</SO>
<YR>2004</YR>
<VL>295</VL>
<NO>1-2</NO>
<PG>183-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okaji-2006" NAME="Okaji 2006" TYPE="JOURNAL_ARTICLE">
<AU>Okaji Y, Tsuno NH, Kitayama J, Sakurai D, Tsuchiya N, Saito S, Takegami K, Tsuchiya T, Kawai K, Yazawa K, Asakage M, Yoneyama S, Yamada J, Tokunaga K, Takahashi K, Nagawa H</AU>
<TI>Effects of down-regulating the Id genes in human colorectal cancer cells on early steps of haematogenous metastasis</TI>
<SO>European Journal of Cancer</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>5</NO>
<PG>668-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okon-2006" NAME="Okon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Okon K, Klimkowska A, Wojcik P, Osuch C, Papla B, Stachura J</AU>
<TI>The relationship between MSI status and vessel density in colorectal carcinoma</TI>
<SO>Polish Journal of Pathology</SO>
<YR>2006</YR>
<VL>57</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olszewski-2005" NAME="Olszewski 2005" TYPE="JOURNAL_ARTICLE">
<AU>Olszewski A J, Grossbard M L, Kozuch P S</AU>
<TI>The horizon of antiangiogenic therapy for colorectal cancer.</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>297-306; discussion 306, 308, 317-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Omura-2003" NAME="Omura 2003" TYPE="JOURNAL_ARTICLE">
<AU>Omura K</AU>
<TI>[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy]</TI>
<SO>Nippon Geka Gakkai Zasshi</SO>
<YR>2003</YR>
<VL>104</VL>
<NO>10</NO>
<PG>730-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Onodera-2005" NAME="Onodera 2005" TYPE="JOURNAL_ARTICLE">
<AU>Onodera H, Mori A, Nagayama S, Fujimoto A, Tachibana T, Yonenaga Y, Tsuruyama T</AU>
<TI>Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>6</NO>
<PG>477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oosterling-2005" NAME="Oosterling 2005" TYPE="JOURNAL_ARTICLE">
<AU>Oosterling SJ, van der Bij GJ, van Egmond M, van der Sijp JRM</AU>
<TI>Surgical trauma and peritoneal recurrence of colorectal carcinoma</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>1</NO>
<PG>29-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paesmans-2006" NAME="Paesmans 2006" TYPE="JOURNAL_ARTICLE">
<AU>Paesmans M, Bleiberg H</AU>
<TI>Are we cautious enough when we interpret results of randomized but underpowered comparisons? [9]</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1964-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pantel-1999" NAME="Pantel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pantel K, Cote RJ, Fodstad O</AU>
<TI>Detection and clinical importance of micrometastatic disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>13</NO>
<PG>1113-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2002" NAME="Park 2002" TYPE="JOURNAL_ARTICLE">
<AU>Park DJ, Stoehlmacher J, Zhang W, Tsao Wei D, Groshen S, Lenz H J</AU>
<TI>Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>1</NO>
<PG>46-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parvez-2004" NAME="Parvez 2004" TYPE="JOURNAL_ARTICLE">
<AU>Parvez T, Mahrous A R, Fawazi A</AU>
<TI>Meta-analysis of new treatment strategies for metastatic colorectal cancer.</TI>
<SO>J Coll Physicians Surg Pak</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>10</NO>
<PG>638-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pass-2002" NAME="Pass 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pass HI</AU>
<TI>Biology of metastatic disease</TI>
<SO>Seminars in Thoracic and Cardiovascular Surgery</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>1</NO>
<PG>10-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patiyil-2006" NAME="Patiyil 2006" TYPE="JOURNAL_ARTICLE">
<AU>Patiyil S, Alberts SR</AU>
<TI>Metastatic colorectal cancer: Therapeutic options</TI>
<SO>Current Treatment Options in Oncology</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>5</NO>
<PG>389-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peeters-2004" NAME="Peeters 2004" TYPE="JOURNAL_ARTICLE">
<AU>Peeters CFJM, Westphal JR, De Waal RMW, Ruiter DJ, Wobbes T, Ruers TJM</AU>
<TI>Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients</TI>
<SO>International Journal of Cancer</SO>
<YR>2004</YR>
<VL>112</VL>
<NO>4</NO>
<PG>554-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peeters-2005" NAME="Peeters 2005" TYPE="JOURNAL_ARTICLE">
<AU>Peeters CFJM, De Geus L F, Westphal JR, De Waal RMW, Ruiter DJ, Wobbes T, Oyen WJG, Ruers TJ</AU>
<TI>Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases</TI>
<SO>Surgery</SO>
<YR>2005</YR>
<VL>137</VL>
<NO>2</NO>
<PG>246-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Penland-2004" NAME="Penland 2004" TYPE="JOURNAL_ARTICLE">
<AU>Penland S K, Goldberg R M</AU>
<TI>Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.</TI>
<SO>Clin-Colorectal-Cancer. 2004 Oct; 4 Suppl 2: S74-80</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Penne-2005" NAME="Penne 2005" TYPE="JOURNAL_ARTICLE">
<AU>Penne K, Bohlin C, Schneider S, Allen D</AU>
<TI>Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.</TI>
<SO>Cancer Nurs</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>6</NO>
<PG>481-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pessino-2006" NAME="Pessino 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pessino A, Sobrero A</AU>
<TI>Optimal treatment of metastatic colorectal cancer</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>5</NO>
<PG>801-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pestalozzi-2005" NAME="Pestalozzi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pestalozzi B C, Jager D, Knuth A</AU>
<TI>Systemtherapie des kolorektalen Karzinoms. [Systemic therapy for colorectal cancer]</TI>
<SO>Chirurg</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>6</NO>
<PG>570-2, 574</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2003" NAME="Peters 2003" TYPE="JOURNAL_ARTICLE">
<AU>Peters H D</AU>
<TI>Looking into the near and far future of cancer therapy: A selection of new treatment concepts and technologies</TI>
<SO>Onkologe</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>5</NO>
<PG>553-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2004" NAME="Peters 2004" TYPE="JOURNAL_ARTICLE">
<AU>Peters G J, Smorenburg C H, Van Groeningen C J</AU>
<TI>Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach.</TI>
<SO>J-Chemother. 2004 Nov; 16 Suppl 4: 25-30</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petrelli-2005" NAME="Petrelli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B</AU>
<TI>Hepatic resection: The last surgical frontier for colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>20</NO>
<PG>4475-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pfeiffer-2007" NAME="Pfeiffer 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pfeiffer P, Qvortrup C, Eriksen J G</AU>
<TI>Current role of antibody therapy in patients with metastatic colorectal cancer.</TI>
<SO>Oncogene</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>25</NO>
<PG>3661-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piga-1996" NAME="Piga 1996" TYPE="JOURNAL_ARTICLE">
<AU>Piga A, Cascinu S, Latini L, Marcellini M, Bavosi M, Acito L, Bascioni R, Giustini L, Francini G, Pancotti A, Rossi G, Del Papa M, Carle F, Cellerino R</AU>
<TI>A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer</TI>
<SO>British journal of cancer</SO>
<YR>1996</YR>
<VL>74</VL>
<NO>6</NO>
<PG>971-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polley-2006" NAME="Polley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Polley ACJ, Mulholland F, Pin C, Williams EA, Bradburn DM, Mills SJ, Mathers JC, Johnson IT</AU>
<TI>Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia</TI>
<SO>Cancer Research</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>13</NO>
<PG>6553-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Portier-2007" NAME="Portier 2007" TYPE="JOURNAL_ARTICLE">
<AU>Portier G</AU>
<TI>In reply [14]</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Posey-2003" NAME="Posey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF</AU>
<TI>A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma</TI>
<SO>Clinical Cancer Research</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>1323-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prabhudesai-2007" NAME="Prabhudesai 2007" TYPE="JOURNAL_ARTICLE">
<AU>Prabhudesai S G, Rekhraj S, Roberts G, Darzi A W, Ziprin P</AU>
<TI>Apoptosis and chemo-resistance in colorectal cancer.</TI>
<SO>J Surg Oncol</SO>
<YR>2007</YR>
<VL>96</VL>
<NO>1</NO>
<PG>77-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-2004" NAME="Price 2004" TYPE="JOURNAL_ARTICLE">
<AU>Price N</AU>
<TI>Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer</TI>
<SO>Clinical colorectal cancer</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>2</NO>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-N_x002c_-Chu-E_x002c_2" NAME="Price N, Chu E,2" TYPE="JOURNAL_ARTICLE">
<AU>Price N, Chu E, Jain VK</AU>
<TI>Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>2</NO>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pritchard-1995" NAME="Pritchard 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard AJ, Chatterjee T, Wilkinson M, Powe DG, Gray T, Hewitt RE</AU>
<TI>Evidence for a weak angiogenic response to human colorectal cancers</TI>
<SO>British Journal of Cancer</SO>
<YR>1995</YR>
<VL>71</VL>
<NO>5</NO>
<PG>1081-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Punt-2005" NAME="Punt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Punt CJA</AU>
<TI>Chemotherapy of patients with colorectal carcinoma</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2005</YR>
<VL>149</VL>
<NO>26</NO>
<PG>1441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quan-1997" NAME="Quan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Quan W D Jr, Palackdharry C S</AU>
<TI>Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV.</TI>
<SO>Dis Mon</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>11</NO>
<PG>745-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajpal-2006" NAME="Rajpal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rajpal S, Venook A P</AU>
<TI>Targeted therapy in colorectal cancer.</TI>
<SO>Clin Adv Hematol Oncol</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>2</NO>
<PG>124-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramalingam-2005" NAME="Ramalingam 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ramalingam S, Belani CP</AU>
<TI>Molecularly-targeted therapies for non-small cell lung cancer</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>15</NO>
<PG>2667-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramirez-2002" NAME="Ramirez 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ramirez de Molina A, Rodriguez Gonzalez A, Gutierrez R, Martinez Pineiro L, Sanchez JJ, Bonilla F, Rosell R, Lacal JC</AU>
<TI>Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers</TI>
<SO>Biochemical and Biophysical Research Communications</SO>
<YR>2002</YR>
<VL>296</VL>
<NO>3</NO>
<PG>580-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ranieri-2004" NAME="Ranieri 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ranieri G, Coviello M, Patruno R, Valerio P, Martino D, Milella P, Catalano V, Scotto F, De Ceglie A, Quaranta M, Ribatti D, Pellecchia A</AU>
<TI>Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients.</TI>
<SO>Oncol Rep</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>4</NO>
<PG>817-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ranieri-2006" NAME="Ranieri 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D</AU>
<TI>Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.</TI>
<SO>Curr Med Chem</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>16</NO>
<PG>1845-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ready-2005" NAME="Ready 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ready N</AU>
<TI>Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>SUPPL. 3</NO>
<PG>S35-S41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reang-2006" NAME="Reang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Reang P, Gupta M, Kohli K</AU>
<TI>Biological response modifiers in cancer.</TI>
<SO>MedGenMed</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>4</NO>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reardon-2006" NAME="Reardon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Reardon DA, Rich JN, Friedman HS, Bigner DD</AU>
<TI>Recent advances in the treatment of malignant astrocytoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1253-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Recchia-1996" NAME="Recchia 1996" TYPE="JOURNAL_ARTICLE">
<AU>Recchia F, Nuzzo A, Lalli A, Lombardo M, Di Lullo L, Fabiani F, Fanini R, Venturoni L, Torchio P, Peretti G</AU>
<TI>Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer</TI>
<SO>American journal of clinical oncology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-2005" NAME="Reddy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Reddy G K</AU>
<TI>The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>5</NO>
<PG>300-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-2007" NAME="Reddy 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reddy N, Yu J, Fakih M G</AU>
<TI>Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>5</NO>
<PG>362-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-G-K_x002c_-Gibs2" NAME="Reddy G K, Gibs2" TYPE="JOURNAL_ARTICLE">
<AU>Reddy G K, Gibson T B, Peck S, Tyagi P</AU>
<TI>Highlights from: the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Hollywood, FL, January 2005.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>6</NO>
<PG>367-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-GK_x002c_-Chu-E2" NAME="Reddy GK, Chu E2" TYPE="JOURNAL_ARTICLE">
<AU>Reddy GK, Chu E, Jain VK</AU>
<TI>Capecitabine/Oxaliplatin combinations in advanced colorectal cancer: Summary of recent randomized studies</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>4</NO>
<PG>242-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-1" NAME="Reference 1" TYPE="JOURNAL_ARTICLE">
<TI>Anti-angiogenics steal the show</TI>
<SO>Nature Reviews Drug Discovery</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>6</NO>
<PG>448</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-10" NAME="Reference 10" TYPE="JOURNAL_ARTICLE">
<TI>Pharmacia's SU5416 not effective</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-11" NAME="Reference 11" TYPE="JOURNAL_ARTICLE">
<TI>Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group</TI>
<SO>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>4</NO>
<PG>921-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-12" NAME="Reference 12" TYPE="JOURNAL_ARTICLE">
<TI>Vaccine developments on the horizon</TI>
<SO>Oncology Spectrums</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>2</NO>
<PG>84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-13" NAME="Reference 13" TYPE="JOURNAL_ARTICLE">
<TI>VEGF inhibition on the rocks as Genentech's Avastin fails</TI>
<SO>Current Drug Discovery</SO>
<YR>2002</YR>
<NO>OCT.</NO>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-2" NAME="Reference 2" TYPE="JOURNAL_ARTICLE">
<TI>Bevacizumab. Metastatic colorectal cancer: Good in theory, not in practice</TI>
<SO>Prescrire International</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>83</NO>
<PG>94-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-3" NAME="Reference 3" TYPE="JOURNAL_ARTICLE">
<TI>&lt; black-down-triangle &gt; Bevacizumab and &lt; black-down-triangle &gt; cetuximab for colorectal cancer</TI>
<SO>Drug and Therapeutics Bulletin</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>5</NO>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-4" NAME="Reference 4" TYPE="JOURNAL_ARTICLE">
<TI>Campath shows increased life expectancy for patients with advanced B-CLL</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>3</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-5" NAME="Reference 5" TYPE="JOURNAL_ARTICLE">
<TI>Highlights from: 38th Annual Meeting of the American Society of Clinical Oncology. Edrecolomab (PanorexR) in combination with 5-fluorouracil-Based Adjuvant chemotherapy in stage III colon cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>2</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-6" NAME="Reference 6" TYPE="JOURNAL_ARTICLE">
<TI>Highlights from: The 42nd annual meeting of the american society of clinical oncology Atlanta, GA, June 2006</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>2</NO>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-7" NAME="Reference 7" TYPE="JOURNAL_ARTICLE">
<TI>IDdb news focus</TI>
<SO>Current Drug Discovery</SO>
<YR>2002</YR>
<NO>JULY</NO>
<PG>12-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-8" NAME="Reference 8" TYPE="JOURNAL_ARTICLE">
<TI>Marimastat</TI>
<SO>Drugs in R and D</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>3</NO>
<PG>198-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-9" NAME="Reference 9" TYPE="JOURNAL_ARTICLE">
<TI>News focus</TI>
<SO>Current Drug Discovery</SO>
<YR>2002</YR>
<NO>MAR.</NO>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rehman-2005" NAME="Rehman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rehman S, Jayson GC</AU>
<TI>Molecular imaging of antiangiogenic agents</TI>
<SO>Oncologist</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>92-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rhee-2005" NAME="Rhee 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rhee J, Hoff P M</AU>
<TI>Angiogenesis inhibitors in the treatment of cancer.</TI>
<SO>Expert Opin Pharmacother</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>10</NO>
<PG>1701-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rini-2007" NAME="Rini 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rini BI</AU>
<TI>Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions</TI>
<SO>Clinical Cancer Research</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>4</NO>
<PG>1098-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rmali-2004" NAME="Rmali 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rmali KA, Watkins G, Harrison G, Parr C, Puntis MCA, Jiang WG</AU>
<TI>Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>9</NO>
<PG>948-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rmali-2006" NAME="Rmali 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rmali KA, Puntis MCA, Jiang WG</AU>
<TI>Level of the expression of VEGF-A, B, C, D and their receptors (FLT-1, KDR and FLT-4) and its correlation with prognosis in patients with colorectal cancer</TI>
<SO>International Journal of Cancer Research</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>1</NO>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-2005" NAME="Rosales 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rosales J, Leong LA</AU>
<TI>Chemotherapy for metastatic colorectal cancer</TI>
<SO>JNCCN Journal of the National Comprehensive Cancer Network</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>4</NO>
<PG>525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roskoski-2007" NAME="Roskoski 2007" TYPE="JOURNAL_ARTICLE">
<AU>Roskoski Jr R</AU>
<TI>Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor</TI>
<SO>Biochemical and Biophysical Research Communications</SO>
<YR>2007</YR>
<VL>356</VL>
<NO>2</NO>
<PG>323-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothenberg-2004" NAME="Rothenberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rothenberg ML</AU>
<TI>Current status of second-line therapy for metastatic colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>SUPPL. 1</NO>
<PG>S16-S21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rougier-2005" NAME="Rougier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rougier P, Lepere C</AU>
<TI>Second-line treatment of patients with metastatic colorectal cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>SUPPL. 9</NO>
<PG>S48-S54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roumen-2005" NAME="Roumen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Roumen R M, Slooter G D, Croiset van Uchelen F A, Huib L V</AU>
<TI>Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients.</TI>
<SO>Dis Colon Rectum</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>5</NO>
<PG>1070-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roumen-RMH_x002c_-Slo2" NAME="Roumen RMH, Slo2" TYPE="JOURNAL_ARTICLE">
<AU>Roumen RMH, Slooter GD, Van Uchelen FAAMC, Huib LV</AU>
<TI>Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>5</NO>
<PG>1070-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowinsky-2003" NAME="Rowinsky 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rowinsky EK</AU>
<TI>Signal Events: Cell Signal Transduction and Its Inhibition in Cancer</TI>
<SO>Oncologist</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>SUPPL. 3</NO>
<PG>5-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowinsky-2004" NAME="Rowinsky 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rowinsky EK</AU>
<TI>The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors</TI>
<SO>Annual Review of Medicine</SO>
<YR>2004</YR>
<VL>55</VL>
<PG>433-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saad-2004" NAME="Saad 2004" TYPE="JOURNAL_ARTICLE">
<AU>Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF</AU>
<TI>Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer</TI>
<SO>Modern Pathology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>2</NO>
<PG>197-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saif-2006" NAME="Saif 2006" TYPE="JOURNAL_ARTICLE">
<AU>Saif M W</AU>
<TI>Targeted agents for adjuvant therapy of colon cancer.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>1</NO>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saif-2007" NAME="Saif 2007" TYPE="JOURNAL_ARTICLE">
<AU>Saif M W, Elfiky A, Salem R R</AU>
<TI>Gastrointestinal perforation due to bevacizumab in colorectal cancer.</TI>
<SO>Ann Surg Oncol</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>6</NO>
<PG>1860-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saif-M-W_x002c_-Kang-2" NAME="Saif M W, Kang 2" TYPE="JOURNAL_ARTICLE">
<AU>Saif M W, Kang S P, Chu E</AU>
<TI>Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies.</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>14 Suppl 10</NO>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saif-M-W_x002c_-Merri2" NAME="Saif M W, Merri2" TYPE="JOURNAL_ARTICLE">
<AU>Saif M W, Merritt J, Robbins J, Stewart J, Schupp J</AU>
<TI>Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>229-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saif-MW_x002c_-Mehra-2" NAME="Saif MW, Mehra 2" TYPE="JOURNAL_ARTICLE">
<AU>Saif MW, Mehra R</AU>
<TI>Incidence and management of bevacizumab-related toxicities in colorectal cancer</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>4</NO>
<PG>553-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saif-MW_x002c_-Merrit2" NAME="Saif MW, Merrit2" TYPE="JOURNAL_ARTICLE">
<AU>Saif MW, Merritt J, Robbins J, Stewart J, Schupp J</AU>
<TI>Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactorR/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>229-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saito-2000" NAME="Saito 2000" TYPE="JOURNAL_ARTICLE">
<AU>Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T, Muto T</AU>
<TI>Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>1</NO>
<PG>42-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saito-2003" NAME="Saito 2003" TYPE="JOURNAL_ARTICLE">
<AU>Saito S, Tsuno NH, Sunami E, Hori N, Kitayama J, Kazama S, Okaji Y, Kawai K, Kanazawa T, Watanabe T, Shibata Y, Nagawa H</AU>
<TI>Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>3</NO>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sakamoto-2006" NAME="Sakamoto 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sakamoto J, Oba K, Matsui T, Kobayashi M</AU>
<TI>Evidence based medicine in biotherapy for malignant tumor</TI>
<SO>Biotherapy</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4</NO>
<PG>363-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salesi-2005" NAME="Salesi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Salesi N, Bossone G, Veltri E, Di Cocco B, Marolla P, Pacetti U, Larosa G, Muni R, Vecchione A</AU>
<TI>Clinical experience with bevacizumab in colorectal cancer.</TI>
<SO>Anticancer Res</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>5</NO>
<PG>3619-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salgado-2001" NAME="Salgado 2001" TYPE="JOURNAL_ARTICLE">
<AU>Salgado R, Vermeulen PB, Van Marck E, Benoy I, Dirix L, George M, Eccles S, Box G, Tutton M, Abulafi M, Swift I</AU>
<TI>Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? [1] (multiple letters)</TI>
<SO>Clinical Cancer Research</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>5</NO>
<PG>1481-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salgado-2002" NAME="Salgado 2002" TYPE="JOURNAL_ARTICLE">
<AU>Salgado R, Benoy I, Weytjens R, Van Bockstaele D, Van Marck E, Huget P, Hoylaerts M, Vermeulen P, Dirix L Y</AU>
<TI>Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer.</TI>
<SO>Br J Cancer</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>12</NO>
<PG>1437-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salgado-2004" NAME="Salgado 2004" TYPE="JOURNAL_ARTICLE">
<AU>Salgado R, Benoy I, Vermeulen P, Van Dam P, Van Marck E, Dirix L</AU>
<TI>Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer</TI>
<SO>Angiogenesis</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salgado-R_x002c_-Beno2" NAME="Salgado R, Beno2" TYPE="JOURNAL_ARTICLE">
<AU>Salgado R, Benoy I, Weytjens R, Van Bockstaele D, Van Marck E, Huget Ph, Hoylaerts M, Vermeulen P, Dirix LY</AU>
<TI>Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>12</NO>
<PG>1437-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saltz-2005" NAME="Saltz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Saltz L B</AU>
<TI>Metastatic colorectal cancer: is there one standard approach?</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>9</NO>
<PG>1147-54; discussion 1154, 1157-8, 1160</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanborn-2005" NAME="Sanborn 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sanborn R, Blanke CD</AU>
<TI>Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?</TI>
<SO>Seminars in Oncology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>1 SPEC. ISS.</NO>
<PG>69-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandler-2006" NAME="Sandler 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sandler AB</AU>
<TI>Advanced non-small-cell lung cancer: New data, therapy choices, and challenging decisions</TI>
<SO>ONCOLOGY</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>6</NO>
<PG>626-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanoff-2007" NAME="Sanoff 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sanoff HK, Bleiberg H, Goldberg RM</AU>
<TI>Managing older patients with colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>14</NO>
<PG>1891-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Santimaria-2003" NAME="Santimaria 2003" TYPE="JOURNAL_ARTICLE">
<AU>Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P</AU>
<TI>Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer</TI>
<SO>Clinical Cancer Research</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>2</NO>
<PG>571-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Santini-2007" NAME="Santini 2007" TYPE="JOURNAL_ARTICLE">
<AU>Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzi V, Spalletta B, Caricato M, Coppola R, Tonini G</AU>
<TI>Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: Phase II study</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2007</YR>
<VL>59</VL>
<NO>5</NO>
<PG>613-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarioglu-2001" NAME="Sarioglu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sarioglu S, Sokmen S, Terzi C, Ozer E, Fuzun M, Kupelioglu A</AU>
<TI>Relationship of angiogenesis and p53 protein expression in colorectal carcinomas</TI>
<SO>Colorectal Disease</SO>
<YR>2001</YR>
<VL>3</VL>
<NO>1</NO>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarraf-2005" NAME="Sarraf 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sarraf Yazdi S, Mi J, Clary B M</AU>
<TI>Hepatic tumor growth: target for angiogenesis inhibition?</TI>
<SO>World J Surg</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>3</NO>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sato-2003" NAME="Sato 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sato A, Shimada K, Taguchi S</AU>
<TI>[Controversy of treatment for advanced colorectal cancer--intermedisine]</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>9</NO>
<PG>1260-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sato-2004" NAME="Sato 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sato T, Yamaguchi A, Goi T, Hirono Y, Takeuchi K, Katayama K, Matsukawa S</AU>
<TI>Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>2004</YR>
<VL>87</VL>
<NO>4</NO>
<PG>174-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scappaticci-2003" NAME="Scappaticci 2003" TYPE="JOURNAL_ARTICLE">
<AU>Scappaticci FA, Contreras A, Boswell CA, Lewis JS, Nolan G</AU>
<TI>Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>19-20</NO>
<PG>2667-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scappaticci-2005" NAME="Scappaticci 2005" TYPE="JOURNAL_ARTICLE">
<AU>Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H</AU>
<TI>Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>2005</YR>
<VL>91</VL>
<NO>3</NO>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schalhorn-2005" NAME="Schalhorn 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schalhorn A</AU>
<TI>Monoclonal antibodies in the treatment of advanced colorectal cancer</TI>
<SO>Arzneimittel Forschung/Drug Research</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>11</NO>
<PG>709-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scharl-2006" NAME="Scharl 2006" TYPE="JOURNAL_ARTICLE">
<AU>Scharl A, Gohring U J, Bischoff J, Costa SD</AU>
<TI>Magic bullets in breast cancer. What is clinically up-to-date, what will future bring?</TI>
<SO>Gynakologische Praxis</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>4</NO>
<PG>601-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schiavon-2007" NAME="Schiavon 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schiavon G, Santini D, Vincenzi B, Tonini G</AU>
<TI>European Society for Medical Oncology 2006: Meeting highlights on targeted therapies - Istanbul, Turkey, 29 September - 3 October 2006</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>2</NO>
<PG>269-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schippinger-2005" NAME="Schippinger 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schippinger W, Jagoditsch M, Sorri C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlbvck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group</AU>
<TI>A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer</TI>
<SO>British journal of cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>9</NO>
<PG>1655-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitz-2004" NAME="Schmitz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz V, Wang L, Barajas M, Gomar C, Prieto J, Qian C</AU>
<TI>Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice</TI>
<SO>Gut</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>4</NO>
<PG>561-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitz-2005" NAME="Schmitz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz V, Kornek M, Hilbert T, Dzienisowicz C, Raskopf E, Rabe C, Sauerbruch T, Qian C, Caselmann WH</AU>
<TI>Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>28</NO>
<PG>4332-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-2002" NAME="Schmoll 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll HJ</AU>
<TI>The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: Prospects and future directions</TI>
<SO>Seminars in Oncology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>5 SUPPL. 15</NO>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-2005" NAME="Schmoll 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll H J</AU>
<TI>Lebensverlangerung bei fortgeschrittenem Darmkrebs. [Improving longevity in advanced intestinal cancer]</TI>
<SO>Krankenpfl J</SO>
<YR>2005</YR>
<VL>43</VL>
<NO>1-3</NO>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-2006" NAME="Schmoll 2006" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll H J, Arnold D</AU>
<TI>Update on capecitabine in colorectal cancer.</TI>
<SO>Oncologist</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1003-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-2005" NAME="Schneider 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schneider BP, Miller KD</AU>
<TI>Angiogenesis of breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1782-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-2004" NAME="Schwartz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz R N, Blanke C D, Pesko L J</AU>
<TI>Targeted therapies in the treatment of colorectal cancer: what managed care needs to know.</TI>
<SO>J Manag Care Pharm</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>5 Suppl B</NO>
<PG>S2-13; quiz S14-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senan-2007" NAME="Senan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Senan S, Smit EF</AU>
<TI>Design of clinical trials of radiation combined with antiangiogenic therapy</TI>
<SO>Oncologist</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>4</NO>
<PG>465-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seto-2000" NAME="Seto 2000" TYPE="JOURNAL_ARTICLE">
<AU>Seto S I, Onodera H, Kaido T, Yoshikawa A, Ishigami S I, Arii S, Imamura M</AU>
<TI>Tissue factor expression in human colorectal carcinoma: Correlation with hepatic metastasis and impact on prognosis</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>2</NO>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seymour-1996" NAME="Seymour 1996" TYPE="JOURNAL_ARTICLE">
<AU>Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, Perren TJ, McAdam WA, Harper PG, Neoptolemos JP, Nicholson M, Duffy AM, Stephens RJ, Stenning SP, Taylor I</AU>
<TI>Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council</TI>
<SO>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>8</NO>
<PG>2280-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seymour-2007" NAME="Seymour 2007" TYPE="JOURNAL_ARTICLE">
<AU>Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ</AU>
<TI>Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9582</NO>
<PG>143-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shahrzad-2005" NAME="Shahrzad 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shahrzad S, Quayle L, Stone C, Plumb C, Shirasawa S, Rak JW, Coomber BL</AU>
<TI>Ischemia-induced K-ras mutations in human colorectal cancer cells: Role of microenvironmental regulation of MSH2 expression</TI>
<SO>Cancer Research</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>18</NO>
<PG>8134-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shan-2003" NAME="Shan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Shan Y S, Lee J C, Chow N H, Yang H B, Wang S T</AU>
<TI>Immunohistochemical microvessel count is not a reliable prognostic predictor in colorectal carcinoma</TI>
<SO>Hepato Gastroenterology</SO>
<YR>2003</YR>
<VL>50</VL>
<NO>53</NO>
<PG>1316-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shankar-1998" NAME="Shankar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, Burnstock G, Taylor I</AU>
<TI>Raised endothelin 1 levels in patients with colorectal liver metastases</TI>
<SO>British Journal of Surgery</SO>
<YR>1998</YR>
<VL>85</VL>
<NO>4</NO>
<PG>502-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharieff-2004" NAME="Sharieff 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sharieff W</AU>
<TI>Bevacizumab in colorectal cancer.</TI>
<SO>N Engl J Med</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>16</NO>
<PG>1690-1; author reply 1690-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shi-2002" NAME="Shi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Shi W, Teschendorf C, Muzyczka N, Siemann DW</AU>
<TI>Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo</TI>
<SO>Cancer Gene Therapy</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>6</NO>
<PG>513-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shi-2003" NAME="Shi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Shi W, Teschendorf C, Muzyczka N, Siemann DW</AU>
<TI>Gene therapy delivery of endostatin enhances the treatment efficacy of radiation</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2003</YR>
<VL>66</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shih-2006" NAME="Shih 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shih T, Lindley C</AU>
<TI>Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.</TI>
<SO>Clin Ther</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1779-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shpitz-2003" NAME="Shpitz 2003" TYPE="JOURNAL_ARTICLE">
<AU>Shpitz B, Gochberg S, Neufeld D, Grankin M, Buklan G, Klein E, Bernheim J</AU>
<TI>Angiogenic Switch in Earliest Stages of Human Colonic Tumorigenesis</TI>
<SO>Anticancer Research</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6 D</NO>
<PG>5153-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sivridis-2005" NAME="Sivridis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sivridis E, Giatromanolaki A, Koukourakis MI</AU>
<TI>Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>10</NO>
<PG>1033-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sledge-2005" NAME="Sledge 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sledge Jr GW</AU>
<TI>VEGF-targeting therapy for breast cancer</TI>
<SO>Journal of Mammary Gland Biology and Neoplasia</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>4</NO>
<PG>319-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slevin-2004" NAME="Slevin 2004" TYPE="JOURNAL_ARTICLE">
<AU>Slevin M, Payne S</AU>
<TI>New treatments for colon cancer.</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>329</VL>
<NO>7458</NO>
<PG>124-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2003" NAME="Smith 2003" TYPE="JOURNAL_ARTICLE">
<AU>Smith K A, Kirkpatrick N, Madden L A, Topping K P, Monson J R, Greenman J</AU>
<TI>Isolation and characterisation of vascular endothelial growth factor-165 specific scFv fragments by phage display.</TI>
<SO>Int J Oncol</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>2</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobrero-2005" NAME="Sobrero 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sobrero A, Bruzzi P</AU>
<TI>Bevacizumab plus fluorouracil: The value of being part of a developing story</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16</NO>
<PG>3660-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sonpavde-2004" NAME="Sonpavde 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sonpavde G</AU>
<TI>Bevacizumab in colorectal cancer.</TI>
<SO>N Engl J Med</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>16</NO>
<PG>1690-1; author reply 1690-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorscher-2007" NAME="Sorscher 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sorscher SM</AU>
<TI>Biological therapy update in colorectal cancer</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>4</NO>
<PG>509-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sparano-2004" NAME="Sparano 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sparano J A, Gray R, Giantonio B, O'Dwyer P, Comis R L, Eastern Cooperative Oncology Group Portfolio of Clinical Trials</AU>
<TI>Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.</TI>
<SO>Clin Cancer Res</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>1206-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiesbach-2005" NAME="Spiesbach 2005" TYPE="JOURNAL_ARTICLE">
<AU>Spiesbach K, Tannapfel A, Mossner J, Engeland K</AU>
<TI>TAp63&lt; gamma &gt; can substitute for p53 in inducing expression of the maspin tumor suppressor</TI>
<SO>International Journal of Cancer</SO>
<YR>2005</YR>
<VL>114</VL>
<NO>4</NO>
<PG>555-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-St-2000" NAME="St 2000" TYPE="JOURNAL_ARTICLE">
<AU>St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montegomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW</AU>
<TI>Genes expressed in human tumor endothelium</TI>
<SO>Science</SO>
<YR>2000</YR>
<VL>289</VL>
<NO>5482</NO>
<PG>1197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staib-2002" NAME="Staib 2002" TYPE="JOURNAL_ARTICLE">
<AU>Staib L, Link KH, Henne-Bruns D</AU>
<TI>[Interferon-alpha in adjuvant treatment of colorectal carcinoma]</TI>
<TO>Interferon-alpha in der adjuvanten Behandlung des kolorektalen Karzinoms.</TO>
<SO>Kongressband / Deutsche Gesellschaft f|r Chirurgie. Deutsche Gesellschaft f|r Chirurgie. Kongress</SO>
<YR>2002</YR>
<VL>119</VL>
<PG>142-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Starling-2004" NAME="Starling 2004" TYPE="JOURNAL_ARTICLE">
<AU>Starling N, Cunningham D</AU>
<TI>Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: Present and future directions</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>4</NO>
<PG>385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stathopoulou-2003" NAME="Stathopoulou 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E, Georgoulias V</AU>
<TI>Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: Comparison of CK-19, CEA and maspin as detection markers</TI>
<SO>Anticancer Research</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>2 C</NO>
<PG>1883-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staton-2003" NAME="Staton 2003" TYPE="JOURNAL_ARTICLE">
<AU>Staton CA, Brown NJ, Lewis CE</AU>
<TI>The role of fibrinogen and related fragments in tumour angiogenesis and metastasis</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>7</NO>
<PG>1105-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stenger-2004" NAME="Stenger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stenger M, Lichtman SM</AU>
<TI>Bevacizumab in metastatic colorectal cancer and other settings</TI>
<SO>Community Oncology</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>4</NO>
<PG>205+207-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stephen-2004" NAME="Stephen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stephen RL, Gustafsson MCU, Jarvis M, Tatoud R, Marshall BR, Knight D, Ehrenborg E, Harris AL, Wolf CR, Palmer CNA</AU>
<TI>Activation of Peroxisome Proliferator-Activated Receptor &lt; delta &gt; Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines</TI>
<SO>Cancer Research</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>9</NO>
<PG>3162-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stessels-2004" NAME="Stessels 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stessels F, Van Den Eynden G, Van Der Auwera I, Salgado R, Van Den Heuvel E, Harris AL, Jackson DG, Colpaert CG, Van Marck EA, Dirix LY, Vermeulen PB</AU>
<TI>Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>90</VL>
<NO>7</NO>
<PG>1429-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stockwin-2003" NAME="Stockwin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stockwin LH, Holmes S</AU>
<TI>Antibodies as therapeutic agents: Vive la renaissance!</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>7</NO>
<PG>1133-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoeltzing-2003" NAME="Stoeltzing 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM</AU>
<TI>Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors</TI>
<SO>Cancer Research</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>12</NO>
<PG>3370-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stone-2007" NAME="Stone 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stone A, Wheeler C, Barge A</AU>
<TI>Improving the design of phase II trials of cytostatic anticancer agents</TI>
<SO>Contemporary Clinical Trials</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>2</NO>
<PG>138-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stow-2006" NAME="Stow 2006" TYPE="JOURNAL_ARTICLE">
<AU>Stow W, Wilde MI</AU>
<TI>The 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO): 2-6 June 2006, Atlanta, Georgia, USA</TI>
<SO>American Journal of Cancer</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>4</NO>
<PG>273-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strumberg-2005" NAME="Strumberg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S</AU>
<TI>Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>5</NO>
<PG>965-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strumberg-2006" NAME="Strumberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B</AU>
<TI>Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?</TI>
<SO>European Journal of Cancer</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>4</NO>
<PG>548-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sulkowska-2006" NAME="Sulkowska 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sulkowska M, Famulski W, Wincewicz A, Moniuszko T, Kedra B, Koda M, Zalewski B, Baltaziak M, Sulkowski S</AU>
<TI>Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer</TI>
<SO>Tumori</SO>
<YR>2006</YR>
<VL>92</VL>
<NO>1</NO>
<PG>67-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-2005" NAME="Sun 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sun W, Haller DG</AU>
<TI>Adjuvant therapy for colon cancer</TI>
<SO>Current Oncology Reports</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>3</NO>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-X_x002c_-Feng-Z_x002c_-2" NAME="Sun X, Feng Z, 2" TYPE="JOURNAL_ARTICLE">
<AU>Sun X, Feng Z, Chen F, Sui H, Bai Y</AU>
<TI>Expression of basic fibroblast growth factor, transforming growth factor &lt; beta &gt;&lt;inf&gt;1&lt;/inf&gt;, its receptor and their relationship to clinicopathological characteristics of colorectal cancer</TI>
<SO>Chinese Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>6</NO>
<PG>336-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Susman-2005" NAME="Susman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Susman E</AU>
<TI>Bevacizumab adds survival benefit in colorectal cancer</TI>
<SO>Lancet Oncology</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>3</NO>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suzuki-2007" NAME="Suzuki 2007" TYPE="JOURNAL_ARTICLE">
<AU>Suzuki R, Rao P, Sasaguri S</AU>
<TI>Current status and future of target-based therapeutics</TI>
<SO>Current Cancer Drug Targets</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>3</NO>
<PG>273-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swensen-2004" NAME="Swensen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Swensen RE, Garcia RL, Goff BA</AU>
<TI>Ovarian metastasis from gastrointestinal tract cancer: A review</TI>
<SO>CME Journal of Gynecologic Oncology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>2</NO>
<PG>115-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sxrensen-1995" NAME="Sxrensen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sxrensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF</AU>
<TI>Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil</TI>
<SO>Cancer</SO>
<YR>1995</YR>
<VL>75</VL>
<NO>10</NO>
<PG>2592-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sxrensen-1997" NAME="Sxrensen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sxrensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF</AU>
<TI>[Reversible liver steatosis in patients treated with 5-fluorouracil and interferon-alpha]</TI>
<TO>Reversibel leversteatose hos patienter behandlet med 5-fluoruracil og interferon-alpha.</TO>
<SO>Ugeskrift for laeger</SO>
<YR>1997</YR>
<VL>159</VL>
<NO>6</NO>
<PG>765-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takahashi-2001" NAME="Takahashi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi N, Kawanishi Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK</AU>
<TI>Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin</TI>
<SO>Clinical Cancer Research</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>3</NO>
<PG>524-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takahashi-Y_x002c_-Ma2" NAME="Takahashi Y, Ma2" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi Y, Mai M</AU>
<TI>[Significance of angiogenesis and clinical application of anti-angiogenesis]</TI>
<SO>Nippon Geka Gakkai Zasshi</SO>
<YR>2001</YR>
<VL>102</VL>
<NO>5</NO>
<PG>381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takebayashi-1995" NAME="Takebayashi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Takebayashi Y, Yamada K, Maruyama I, Fujii i R, Akiyama i S, Aikou T</AU>
<TI>The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas</TI>
<SO>Cancer Letters</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takebayashi-Y_x002c_-2" NAME="Takebayashi Y, 2" TYPE="JOURNAL_ARTICLE">
<AU>Takebayashi Y, Yamada K, Ohmoto Y, Sameshima T, Miyadera K, Yamada Y, Akiyama S I, Aikou T</AU>
<TI>The correlation of thymidine phosphorylase activity with the expression of interleukin 1alpha, interferon alpha and interferon gamma in human colorectal carcinoma</TI>
<SO>Cancer Letters</SO>
<YR>1995</YR>
<VL>95</VL>
<NO>1-2</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takeda-2000" NAME="Takeda 2000" TYPE="JOURNAL_ARTICLE">
<AU>Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T</AU>
<TI>Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers.</TI>
<SO>Oncol Rep</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>2</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takeuchi-2004" NAME="Takeuchi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, Mukogawa T, Matsumoto H, Kondo S, Takahashi C, Noda M, Nakajima Y</AU>
<TI>The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>16</NO>
<PG>5572-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2005" NAME="Tan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tan B R, McLeod H L</AU>
<TI>Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.</TI>
<SO>Semin Oncol</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>1</NO>
<PG>113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanaka-2001" NAME="Tanaka 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka T, Konno H, Baba S, Kanai T, Matsumoto K, Matsuda I, Ohba K, Ohta M, Kamiya K, Nakamura S</AU>
<TI>Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor FR-118487 after removal of growing tumor in mice</TI>
<SO>Japanese Journal of Cancer Research</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>1</NO>
<PG>88-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanigawa-1997" NAME="Tanigawa 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R</AU>
<TI>Tumor angiogenesis and mode of metastasis in patients with colorectal cancer.</TI>
<SO>Cancer Res</SO>
<YR>1997</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1043-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanigawa-N_x002c_-Ama2" NAME="Tanigawa N, Ama2" TYPE="JOURNAL_ARTICLE">
<AU>Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R</AU>
<TI>Tumor anglogenesis and mode of metastasis in patients with colorectal cancer</TI>
<SO>Cancer Research</SO>
<YR>1997</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1043-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanwar-2002" NAME="Tanwar 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tanwar MK, Gilbert MR, Holland EC</AU>
<TI>Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma</TI>
<SO>Cancer Research</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>15</NO>
<PG>4364-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarhini-2005" NAME="Tarhini 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tarhini AA, Agarwala SS</AU>
<TI>Novel agents in development for the treatment of melanoma</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>7</NO>
<PG>885-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarta-2002" NAME="Tarta 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tarta C, Teixeira C R, Tanaka S, Haruma K, Chiele Neto C, da Silva V D</AU>
<TI>Angiogenesis in advanced colorectal adenocarcinoma with special reference to tumoral invasion.</TI>
<SO>Arq Gastroenterol</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>1</NO>
<PG>32-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarta-2004" NAME="Tarta 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tarta C, Da Silva VD, Teixeira CR, Prolla JC, Meurer L, Neto CC, Tanaka S</AU>
<TI>Digital image analysis and stereology of angiogenesis in polypoid and nonpolypoid colorectal adenomas</TI>
<SO>Analytical and Quantitative Cytology and Histology</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>4</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Te-2005" NAME="Te 2005" TYPE="JOURNAL_ARTICLE">
<AU>Te Velde EA, Reijerkerk A, Brandsma D, Vogren JM, Wu Y, Kranenburg O, Voest EE, Gebbink M, Borel Rinkes IHM</AU>
<TI>Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells</TI>
<SO>British Journal of Cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>4</NO>
<PG>729-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tedesco-2004" NAME="Tedesco 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tedesco K L, Lockhart A C, Berlin J D</AU>
<TI>The epidermal growth factor receptor as a target for gastrointestinal cancer therapy.</TI>
<SO>Curr Treat Options Oncol</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>5</NO>
<PG>393-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Theodoropoulos-2006" NAME="Theodoropoulos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Theodoropoulos GE, Lazaris AC, Theodoropoulos VE, Papatheodosiou K, Gazouli M, Bramis J, Patsouris E, Panoussopoulos D</AU>
<TI>Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>3</NO>
<PG>248-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2003" NAME="Thomas 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP</AU>
<TI>Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584</TI>
<SO>Seminars in Oncology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>3 SUPPL. 6</NO>
<PG>32-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2005" NAME="Thomas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio Pick M, Laurent D, Steward WP</AU>
<TI>Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4162-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2007" NAME="Thomas 2007" TYPE="JOURNAL_ARTICLE">
<AU>Thomas AL, Trarbach T, Bartel C, Laurent D, Henry A, Poethig M, Wang J, Masson E, Steward W, Vanhoefer U, Wiedenmann B</AU>
<TI>A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>4</NO>
<PG>782-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorne-2006" NAME="Thorne 2006" TYPE="JOURNAL_ARTICLE">
<AU>Thorne SH, Tam BYY, Kirn DH, Contag CH, Kuo CJ</AU>
<TI>Selective Intratumoral Amplification of an Antiangiogenic Vector by an Oncolytic Virus Produces Enhanced Antivascular and Anti-tumor Efficacy</TI>
<SO>Molecular Therapy</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>5</NO>
<PG>938-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornton-2006" NAME="Thornton 2006" TYPE="JOURNAL_ARTICLE">
<AU>Thornton AD, Ravn P, Winslet M, Chester K</AU>
<TI>Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer</TI>
<SO>British Journal of Surgery</SO>
<YR>2006</YR>
<VL>93</VL>
<NO>12</NO>
<PG>1456-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thun-2002" NAME="Thun 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thun MJ, Henley SJ, Patrono C</AU>
<TI>Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>4</NO>
<PG>252-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thuss-2006" NAME="Thuss 2006" TYPE="JOURNAL_ARTICLE">
<AU>Thuss Patience P C, Reichardt P, Riess H, Kretzschmar A</AU>
<TI>Jungste Fortschritte in der Therapie des Kolonkarzinoms. [Recent progress in the treatment of colorectal cancer]</TI>
<SO>Med Klin (Munich)</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>2</NO>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tien-2004" NAME="Tien 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tien Y W, Jeng Y M, Hu R H, Chang K J, Hsu S M, Lee P H</AU>
<TI>Intravasation-related metastatic factors in colorectal cancer</TI>
<SO>Tumor Biology</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>1-2</NO>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tien-2006" NAME="Tien 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tien Y W, Chang K J, Chiu Y F, Huang K W, Lee P H</AU>
<TI>Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>11</NO>
<PG>1357-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tocchi-2000" NAME="Tocchi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tocchi A, Mazzoni G, Lepre L, Costa G, Liotta G, Agostini N, Miccini M</AU>
<TI>Prospective evaluation of omentoplasty in preventing leakage of colorectal anastomosis</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>7</NO>
<PG>951-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tol-2006" NAME="Tol 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tol J, Punt CJA</AU>
<TI>Treatment of liver metastases from colorectal cancer</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>5</NO>
<PG>133-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tomisaki-1996" NAME="Tomisaki 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tomisaki S I, Ohno S, Ichiyoshi Y, Kuwano H, Maehara Y, Sugimachi K</AU>
<TI>Microvessel quantification and its possible relation with liver metastasis in colorectal cancer</TI>
<SO>Cancer</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>8 SUPPL.</NO>
<PG>1722-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toyota-2000" NAME="Toyota 2000" TYPE="JOURNAL_ARTICLE">
<AU>Toyota M, Itoh F, Imai K</AU>
<TI>DNA methylation and gastrointestinal malignancies: Functional consequences and clinical implications</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>10</NO>
<PG>727-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Troiani-2006" NAME="Troiani 2006" TYPE="JOURNAL_ARTICLE">
<AU>Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG</AU>
<TI>Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases</TI>
<SO>Molecular Cancer Therapeutics</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>7</NO>
<PG>1883-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuji-2004" NAME="Tsuji 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tsuji T, Sawai T, Yamashita H, Takeshita H, Nakagoe T, Shindou H, Fukuoka H, Yoshinaga M, Hidaka S, Yasutake T, Nagayasu T, Tagawa Y</AU>
<TI>Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>3</NO>
<PG>296-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsukagoshi-2003" NAME="Tsukagoshi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tsukagoshi S</AU>
<TI>Recent development of anticancer agents including biotherapeutics in Japan</TI>
<SO>Biotherapy</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsunoda-2001" NAME="Tsunoda 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tsunoda T, Nakamura T, Ishimoto K, Yamaue H, Tanimura H, Saijo N, Nishio K</AU>
<TI>Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray</TI>
<SO>Anticancer Research</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1 A</NO>
<PG>137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsushima-2004" NAME="Tsushima 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tsushima Y, Funabasama S, Aoki J, Sanada S, Endo K</AU>
<TI>Quantitative Perfusion Map of Malignant Liver Tumors, Created from Dynamic Computed Tomography Data</TI>
<SO>Academic Radiology</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>2</NO>
<PG>215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tutton-2003" NAME="Tutton 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM</AU>
<TI>Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients</TI>
<SO>International Journal of Cancer</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>4</NO>
<PG>541-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuynman-2003" NAME="Tuynman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tuynman JB, Hulscher JBF, Steller EPh, Van Lanschot JJB, Richel DJ</AU>
<TI>Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2003</YR>
<VL>147</VL>
<NO>45</NO>
<PG>2207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuynman-2004" NAME="Tuynman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tuynman JB, Peppelenbosch MP, Richel DJ</AU>
<TI>COX-2 inhibition as a tool to treat and prevent colorectal cancer</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2004</YR>
<VL>52</VL>
<NO>2</NO>
<PG>81-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tyagi-2006" NAME="Tyagi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tyagi P</AU>
<TI>Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.</TI>
<SO>Clin Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>189-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tyagi-P_x002c_-Grothe2" NAME="Tyagi P, Grothe2" TYPE="JOURNAL_ARTICLE">
<AU>Tyagi P, Grothey A</AU>
<TI>Commentary on a phase III trial of Bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>4</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Umekita-2006" NAME="Umekita 2006" TYPE="JOURNAL_ARTICLE">
<AU>Umekita Y, Souda M, Hiroki Y</AU>
<TI>Expression of maspin in colorectal cancer</TI>
<SO>In Vivo</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>6 B</NO>
<PG>797-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vallbohmer-2005" NAME="Vallbohmer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vallbohmer D, Lenz H J</AU>
<TI>Epidermal growth factor receptor as a target for chemotherapy.</TI>
<SO>Clin-Colorectal-Cancer. 2005 Apr; 5 Suppl 1: S19-27</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vallbohmer-2006" NAME="Vallbohmer 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD, Lenz H J</AU>
<TI>Molecular determinants of irinotecan efficacy</TI>
<SO>International Journal of Cancer</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>10</NO>
<PG>2435-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-2005" NAME="Van 2005" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Verslype C, Tejpar S</AU>
<TI>Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment</TI>
<SO>Seminars in Oncology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>1 SPEC. ISS.</NO>
<PG>43-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-2006" NAME="Van 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E</AU>
<TI>Progress with biological agents in metastatic colorectal cancer leads to many challenges.</TI>
<SO>J Clin Oncol</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>21</NO>
<PG>3325-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-2007" NAME="Van 2007" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Verslype C, Grusenmeyer PA</AU>
<TI>Lessons learned in the management of advanced pancreatic cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>15</NO>
<PG>1949-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vanhoefer-2005" NAME="Vanhoefer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vanhoefer U</AU>
<TI>Molecular mechanisms and targeting of colorectal cancer.</TI>
<SO>Semin Oncol</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>6 Suppl 8</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vannoni-2002" NAME="Vannoni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Vannoni D, Bernini A, Carlucci F, Civitelli S, Di Pietro MC, Leoncini R, Mancini A, Marinello E, Rosi F, Tabucchi A, Tanzini G</AU>
<TI>Metabolism of adenosine in human colorectal tumors</TI>
<SO>Rivista Italiana di Biologia e Medicina</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3-4</NO>
<PG>72-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vannoni-2004" NAME="Vannoni 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vannoni D, Bernini A, Carlucci F, Civitelli S, Di Pietro M C, Leoncini R, Rosi F, Tabucchi A, Tanzini G, Marinello E</AU>
<TI>Enzyme activities controlling adenosine levels in normal and neoplastic tissues.</TI>
<SO>Med Oncol</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>2</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Varadhachary-2005" NAME="Varadhachary 2005" TYPE="JOURNAL_ARTICLE">
<AU>Varadhachary G R, Hoff P M</AU>
<TI>Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.</TI>
<SO>Semin Oncol</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>6 Suppl 9</NO>
<PG>S40-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vauthey-2006" NAME="Vauthey 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vauthey J N, Pawlik TM, Ribero D, Wu T T, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK</AU>
<TI>Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2065-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venook-2005" NAME="Venook 2005" TYPE="JOURNAL_ARTICLE">
<AU>Venook AP, Blanke CD, Niedzwiecki D, Lenz H J, Taylor JR, Hollis DR, Sutherland S, Goldberg RM</AU>
<TI>Cancer and leukemia group b/southwest oncology group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>4</NO>
<PG>292-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verbeek-2005" NAME="Verbeek 2005" TYPE="JOURNAL_ARTICLE">
<AU>Verbeek W, Graeven U</AU>
<TI>Welche Rolle spielen die neuen Therapieoptionen in der palliativen Therapie des Kolonkarzinoms? [Which role do new therapeutic options play in palliative care of colorectal cancer?]</TI>
<SO>Internist (Berl)</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>12</NO>
<PG>1339-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verbeek-W_x002c_-Grae2" NAME="Verbeek W, Grae2" TYPE="JOURNAL_ARTICLE">
<AU>Verbeek W, Graeven U</AU>
<TI>Which role play new therapeutic options in palliative care of colorectal cancer?</TI>
<SO>Internist</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>12</NO>
<PG>1339-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verheul-2005" NAME="Verheul 2005" TYPE="JOURNAL_ARTICLE">
<AU>Verheul H M, Pinedo H M</AU>
<TI>Inhibition of angiogenesis in cancer patients.</TI>
<SO>Expert Opin Emerg Drugs</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>403-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-1995" NAME="Vermeulen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen PB, Verhoeven D, Fierens H, Hubens G, Goovaerts G, Van Marck E, De Bruijn EA, Van Oosterom AT, Dirix LY</AU>
<TI>Microvessel quantification in primary colorectal carcinoma: An immunohistochemical study</TI>
<SO>British Journal of Cancer</SO>
<YR>1995</YR>
<VL>71</VL>
<NO>2</NO>
<PG>340-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-1996" NAME="Vermeulen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen PB, Roland L, Mertens V, Van Marck E, De Bruijn EA, Van Oosterom AT, Dirix LY</AU>
<TI>Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma</TI>
<SO>Microvascular Research</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>2</NO>
<PG>164-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-1999" NAME="Vermeulen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY</AU>
<TI>Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>79</VL>
<NO>2</NO>
<PG>316-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-2001" NAME="Vermeulen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van den Heuvel E, Goovaerts G, Dirix LY, Van Marck E</AU>
<TI>Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia</TI>
<SO>Journal of Pathology</SO>
<YR>2001</YR>
<VL>195</VL>
<NO>3</NO>
<PG>336-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-PB_x002c_-V2" NAME="Vermeulen PB, V2" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen PB, Verhoeven D, Hubens G, van Marck E, Goovaerts G, Huyghe M, De Bruijn EA, Van Oosterom AT, Dirix LY</AU>
<TI>Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas</TI>
<SO>Annals of Oncology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>1</NO>
<PG>59-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Veronese-2004" NAME="Veronese 2004" TYPE="JOURNAL_ARTICLE">
<AU>Veronese M L, O'Dwyer P J</AU>
<TI>Monoclonal antibodies in the treatment of colorectal cancer.</TI>
<SO>Eur J Cancer</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>9</NO>
<PG>1292-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar_x002d_Grimalt-1999" NAME="Villar-Grimalt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Villar-Grimalt A, Candel MT, Massuti B, Lizsn J, Sanchez B, Frau A, Gorostidi B, Goedkoop R</AU>
<TI>A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer</TI>
<SO>British journal of cancer</SO>
<YR>1999</YR>
<VL>80</VL>
<NO>5-6</NO>
<PG>786-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vincenzi-2006" NAME="Vincenzi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G</AU>
<TI>Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>5</NO>
<PG>835-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vogelaar-2006" NAME="Vogelaar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vogelaar I, Van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JDF, Zauber AG</AU>
<TI>How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment</TI>
<SO>Cancer</SO>
<YR>2006</YR>
<VL>107</VL>
<NO>7</NO>
<PG>1624-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-2004" NAME="Von 2004" TYPE="JOURNAL_ARTICLE">
<AU>Von Pawel J</AU>
<TI>Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.</TI>
<SO>Bull Cancer</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>5</NO>
<PG>E70-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-von-2006" NAME="von 2006" TYPE="JOURNAL_ARTICLE">
<AU>von Mehren M</AU>
<TI>Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.</TI>
<SO>Clin-Colorectal-Cancer. 2006 Nov; 6 Suppl 1: S30-4</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-2006" NAME="Von 2006" TYPE="JOURNAL_ARTICLE">
<AU>Von Eyben F</AU>
<TI>Epidermal growth factor receptor inhibition and non-small cell lung cancer</TI>
<SO>Critical Reviews in Clinical Laboratory Sciences</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>4</NO>
<PG>291-323</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wadler-1998" NAME="Wadler 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wadler S, Haynes H, Rozenblit A, Hu X, Kaleya R, Wiernik PH</AU>
<TI>Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma</TI>
<SO>The cancer journal from Scientific American</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>5</NO>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wadler-2007" NAME="Wadler 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wadler S</AU>
<TI>Targeted therapy in colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>5</NO>
<PG>357-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagsater-2006" NAME="Wagsater 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wagsater D, Lofgren S, Hugander A, Dimberg J</AU>
<TI>Expression of interleukin-17 in human colorectal cancer</TI>
<SO>Anticancer Research</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>6 B</NO>
<PG>4213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wainberg-2006" NAME="Wainberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wainberg Z, Hecht JR</AU>
<TI>A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>5</NO>
<PG>363-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wallace-2002" NAME="Wallace 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wallace JM</AU>
<TI>Nutritional and botanical modulation of the inflammatory cascade - Eicosanoids, cyclooxygenases, and lipoxygenases - As an adjunct in cancer therapy</TI>
<SO>Integrative Cancer Therapies</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>1</NO>
<PG>7-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2002" NAME="Wang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wang JH, Wu QD, Bouchier Hayes D, Redmond HP</AU>
<TI>Hypoxia upregulates Bcl-2 expression and suppresses interferon-&lt; gamma &gt; induced antiangiogenic activity in human tumor derived endothelial cells</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>10</NO>
<PG>2745-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2003" NAME="Wang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Yu J, Ni J, Xu X M, Wang J, Ning H, Pei X F, Chen J, Yang S, Underhill CB, Liu L, Liekens J, Merregaert J, Zhang L</AU>
<TI>Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors</TI>
<SO>Cancer Letters</SO>
<YR>2003</YR>
<VL>200</VL>
<NO>1</NO>
<PG>57-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2004" NAME="Wang 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Fei D, Vanderlaan M, Song A</AU>
<TI>Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro</TI>
<SO>Angiogenesis</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>4</NO>
<PG>335-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2005" NAME="Wang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wang H M, Zhang G Y</AU>
<TI>Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>340-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2006" NAME="Wang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN</AU>
<TI>CXCL1 induced by prostaglandin E&lt;inf&gt;2&lt;/inf&gt; promotes angiogenesis in colorectal cancer</TI>
<SO>Journal of Experimental Medicine</SO>
<YR>2006</YR>
<VL>203</VL>
<NO>4</NO>
<PG>941-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2007" NAME="Wang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wang H L, Deng C S, Yuan Y F, Qian Q</AU>
<TI>[Effects of anti-angiopoietin-2 antibody on vascularization of an implanted model of human colonic carcinoma on chick embryo]</TI>
<SO>Zhonghua Wei Chang Wai Ke Za Zhi</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>3</NO>
<PG>278-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-H_x002c_-Deng-C_x002c_2" NAME="Wang H, Deng C,2" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Deng C, Lin J</AU>
<TI>Relationship between expressions of angiopoietin-2 and c-myc in colorectal adenocarcinoma tissues</TI>
<SO>Medical Journal of Wuhan University</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>1</NO>
<PG>36-7+90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waters-1997" NAME="Waters 1997" TYPE="JOURNAL_ARTICLE">
<AU>Waters JS, Ross PJ, Popescu RA, Cunningham D</AU>
<TI>New approaches to the treatment of gastro-intestinal cancer</TI>
<SO>Digestion</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>6</NO>
<PG>508-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-2001" NAME="Weiss 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weiss H, Amberger A, Widschwendter M, Margreiter R, Ofner D, Dietl P</AU>
<TI>Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells</TI>
<SO>International Journal of Cancer</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>6</NO>
<PG>877-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wendum-2005" NAME="Wendum 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wendum D, Comperat E, Boelle P Y, Parc R, Masliah J, Trugnan G, Flejou J F</AU>
<TI>Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer</TI>
<SO>Modern Pathology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>212-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Werther-2000" NAME="Werther 2000" TYPE="JOURNAL_ARTICLE">
<AU>Werther K, Christensen I J, Brunner N, Nielsen H J</AU>
<TI>Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.</TI>
<SO>Eur J Surg Oncol</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>7</NO>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Werther-K_x002c_-Chri2" NAME="Werther K, Chri2" TYPE="JOURNAL_ARTICLE">
<AU>Werther K, Christensen IJ, Brunner N, Nielsen HJ, Schulze S, Thorup J, Wille Jorgensen P, Bentzen E, Christoffersen I, Moller P, Banke L, Froberg D, Henriksen FW, Crone P, Hesselfeldt P, Hempel Sparso B, Lindorff Larsen K, Asmussen T, Heiner J, Hart Hansen O, Flyger H, Jess P, Iversen J, La Cour Andersen J, Vennits B, Moesgaard F, Hammer J, Fischer A, Galatius H, Naver L, Telium D, Holbraad L, Iversen O, Nymark J, Roikjaer O, Svendsen LB, Vedel L, Palm L, Rasmussen KC, Friis J, Lanng C, Wiboltt K, Jensen NC, Hoffman N, Larsen T, Packler J</AU>
<TI>Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>7</NO>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weyn-2004" NAME="Weyn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Weyn B, Tjalma W A, Vermeylen P, van Daele A, Van Marck E, Jacob W</AU>
<TI>Determination of tumour prognosis based on angiogenesis-related vascular patterns measured by fractal and syntactic structure analysis.</TI>
<SO>Clin Oncol (R Coll Radiol)</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>4</NO>
<PG>307-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weyn-B_x002c_-Tjalma-2" NAME="Weyn B, Tjalma 2" TYPE="JOURNAL_ARTICLE">
<AU>Weyn B, Tjalma WAA, Vermeylen P, van Daele A, Van Marck E, Jacob W</AU>
<TI>Determination of tumour prognosis based on angiogenesis-related vascular patterns measured by fractal and syntactic structure analysis</TI>
<SO>Clinical Oncology</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>4</NO>
<PG>307-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2002" NAME="White 2002" TYPE="JOURNAL_ARTICLE">
<AU>White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, Murray JC</AU>
<TI>Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma</TI>
<SO>Cancer Research</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1669-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiedmann-2005" NAME="Wiedmann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wiedmann MW, Caca K</AU>
<TI>Molecularly targeted therapy for gastrointestinal cancer</TI>
<SO>Current Cancer Drug Targets</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>3</NO>
<PG>171-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilke-2003" NAME="Wilke 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wilke H J, Van Cutsem E</AU>
<TI>Current treatments and future perspectives in colorectal and gastric cancer.</TI>
<SO>Ann-Oncol. 2003; 14 Suppl 2: ii49-55</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2003" NAME="Williams 2003" TYPE="JOURNAL_ARTICLE">
<AU>Williams EA, Coxhead JM, Mathers JC</AU>
<TI>Anti-cancer effects of butyrate: Use of micro-array technology to investigate mechanisms</TI>
<SO>Proceedings of the Nutrition Society</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>1</NO>
<PG>107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2007" NAME="Williams 2007" TYPE="JOURNAL_ARTICLE">
<AU>Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR</AU>
<TI>Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit</TI>
<SO>Molecular Cancer Therapeutics</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>2</NO>
<PG>599-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wils-2006" NAME="Wils 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wils J</AU>
<TI>Adjuvant treatment of colon cancer - Past, present and future</TI>
<SO>Archive of Oncology</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>SUPPL. 1</NO>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2005" NAME="Wilson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA</AU>
<TI>Macrophage migration inhibitory factor promotes intestinal tumorigenesis</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>5</NO>
<PG>1485-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wittig-1996" NAME="Wittig 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wittig B M, Kaulen H, Thees R, Schmitt C, Knolle P, Stock J, Meyer zum Buschenfelde K H, Dippold W</AU>
<TI>Elevated serum E-selectin in patients with liver metastases of colorectal cancer.</TI>
<SO>Eur J Cancer</SO>
<YR>1996</YR>
<VL>32A</VL>
<NO>7</NO>
<PG>1215-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolmark-2005" NAME="Wolmark 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wolmark N</AU>
<TI>Provocative optimism in the treatment of early stage disease</TI>
<SO>Oncologist</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>SUPPL. 2</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolpin-2007" NAME="Wolpin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ</AU>
<TI>Adjuvant treatment of colorectal cancer</TI>
<SO>CA Cancer Journal for Clinicians</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>3</NO>
<PG>168-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-1999" NAME="Wong 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP</AU>
<TI>Vascular endothelial growth factor is up-regulated in the early pre- malignant stage of colorectal tumour progression</TI>
<SO>International Journal of Cancer</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>6</NO>
<PG>845-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2005" NAME="Wong 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wong SCC, Chan ATC, Lo ESF, Lo YMD</AU>
<TI>Nuclear &lt; beta &gt;-catenin expression is rare and its potential association with short survival in colorectal signet-ring cell carcinoma</TI>
<SO>Applied Immunohistochemistry and Molecular Morphology</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>3</NO>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woo-2006" NAME="Woo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Woo KJ, Lee T J, Park J W, Kwon TK</AU>
<TI>Desferrioxamine, an iron chelator, enhances HIF-1&lt; alpha &gt; accumulation via cyclooxygenase-2 signaling pathway</TI>
<SO>Biochemical and Biophysical Research Communications</SO>
<YR>2006</YR>
<VL>343</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2003" NAME="Wu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wu FP, Boelens PG, van Leeuwen PA, Hoekman K, Hansma AH, Wiezer MJ, Meijer C, Meijer S, Scotti M, Cuesta MA</AU>
<TI>Effects of major liver resection, with or without recombinant bactericidal/permeability-increasing protein (rBPI21), on the angiogenic profile of patients with metastatic colorectal carcinoma</TI>
<SO>Journal of surgical oncology</SO>
<YR>2003</YR>
<VL>84</VL>
<NO>3</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2004" NAME="Wu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wu A W, Gu J, Li Z F, Ji J F, Xu G W</AU>
<TI>COX-2 expression and tumor angiogenesis in colorectal cancer</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>16</NO>
<PG>2323-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-FP_x002c_-Westphal2" NAME="Wu FP, Westphal2" TYPE="JOURNAL_ARTICLE">
<AU>Wu FP, Westphal JR, Hoekman K, Mels AK, Muller MG, de Waal RW, Beelen RH, van Leeuwen PA, Meijer S, Cuesta MA</AU>
<TI>The effects of surgery, with or without rhGM CSF, on the angiogenic profile of patients treated for colorectal carcinoma</TI>
<SO>Cytokine</SO>
<YR>2004</YR>
<VL>25</VL>
<PG>&lt;25 Location in Work&gt;</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-FP_x002c_-Westphal3" NAME="Wu FP, Westphal3" TYPE="JOURNAL_ARTICLE">
<AU>Wu FP, Westphal JR, Hoekman K, Mels AK, Statius Muller MG, de Waal RW, Beelen RH, van Leeuwen PA, Meijer S, Cuesta MA</AU>
<TI>The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma</TI>
<SO>Cytokine</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>2</NO>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-FPK_x002c_-Boelens2" NAME="Wu FPK, Boelens2" TYPE="JOURNAL_ARTICLE">
<AU>Wu FPK, Boelens PG, Van Leeuwen PAM, Hoekman K, Hansma AHG, Wiezer MJ, Meijer C, Meijer S, Scotte M, Cuesta MA</AU>
<TI>Effects of Major Liver Resection, With or Without Recombinant Bactericidal/Permeability-Increasing Protein (rBPI&lt;inf&gt;21&lt;/inf&gt;), on the Angiogenic Profile of Patients With Metastatic Colorectal Carcinoma</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>2003</YR>
<VL>84</VL>
<NO>3</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-FPK_x002c_-Westpha2" NAME="Wu FPK, Westpha2" TYPE="JOURNAL_ARTICLE">
<AU>Wu FPK, Westphal JR, Hoekman K, Mels AK, Muller MGS, De Waal RW, Beelen RHJ, Van Leeuwen PAM, Meijer S, Cuesta MA</AU>
<TI>The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma</TI>
<SO>Cytokine</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>2</NO>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiao-2006" NAME="Xiao 2006" TYPE="JOURNAL_ARTICLE">
<AU>Xiao H, Lichtman SM</AU>
<TI>Management of colorectal cancer in older patients</TI>
<SO>ONCOLOGY</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>7</NO>
<PG>741-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xie-1999" NAME="Xie 1999" TYPE="JOURNAL_ARTICLE">
<AU>Xie Z, Huang X, Li J, Zhou L</AU>
<TI>[Liver metastasis in colorectal cancer and tumor angiogenesis]</TI>
<SO>Zhonghua Wai Ke Za Zhi</SO>
<YR>1999</YR>
<VL>37</VL>
<NO>6</NO>
<PG>336-7, 21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiong-2002" NAME="Xiong 2002" TYPE="JOURNAL_ARTICLE">
<AU>Xiong B, Gong L L, Zhang F, Hu M B, Yuan H Y</AU>
<TI>TGF &lt; beta &gt;&lt;inf&gt;1&lt;/inf&gt; expression and angiogenesis in colorectal cancer tissue</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>496-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiong-2003" NAME="Xiong 2003" TYPE="JOURNAL_ARTICLE">
<AU>Xiong B, Sun T J, Yuan H Y, Hu M B, Hu W D, Cheng F L</AU>
<TI>Cyclooxygenase-2 expression and angiogenesis in colorectal cancer</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiong-2005" NAME="Xiong 2005" TYPE="JOURNAL_ARTICLE">
<AU>Xiong B, Sun T J, Hu W D, Cheng F L, Mao M, Zhou Y F</AU>
<TI>Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>8</NO>
<PG>1105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiong-2006" NAME="Xiong 2006" TYPE="JOURNAL_ARTICLE">
<AU>Xiong Z F, Yan Z H</AU>
<TI>Expression of leptin receptor and nuclear factor kappa B and their significances in colorectal adenocarcinoma</TI>
<SO>World Chinese Journal of Digestology</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>28</NO>
<PG>2759-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-2003" NAME="Xu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Xu M H, Deng C S, Zhu Y Q, Lin J</AU>
<TI>Role of inducible nitric oxide synthase expression in aberrant crypt foci-adenoma-carcinoma sequence</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1246-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-2005" NAME="Xu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Xu Q, Chen R X, Wang Z W, Ni Q C, Qian J J, Sheng H X</AU>
<TI>Clinical research on angiogenesis in colorectal carcinoma and expression of CK&lt;inf&gt;2&lt;/inf&gt;0 mRNA in peripheral blood</TI>
<SO>National Medical Journal of China</SO>
<YR>2005</YR>
<VL>85</VL>
<NO>17</NO>
<PG>1205-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamamoto-2002" NAME="Yamamoto 2002" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto H, Imsumran A, Fukushima H, Adachi Y, Min Y, Iku S, Horiuchi S, Yoshida M, Shimada K, Sasaki S, Itoh F, Endo T, Imai K</AU>
<TI>Analysis of gene expression in human colorectal cancer tissues by cDNA array</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>SUPPL. 14</NO>
<PG>83-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yan-2006" NAME="Yan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yan TD</AU>
<TI>Peritoneal carcinomatosis of colorectal origin: Standard of care [5]</TI>
<SO>Annals of Surgery</SO>
<YR>2006</YR>
<VL>244</VL>
<NO>4</NO>
<PG>632-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2003" NAME="Yang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Yang Y J, Zhang Y L, Li X, Dan H L, Lai Z S, Wang J D, Wang Q Y, Cui H H, Sun Y, Wang Y D</AU>
<TI>Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1707-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2005" NAME="Yang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yang J, Liu F X, Yan X C, He G Y, Liu L M</AU>
<TI>[Clinical significance of survivin expression in colorectal cancer and its relationship with cell apoptosis and angiogenesis.]</TI>
<SO>Ai Zheng</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>1</NO>
<PG>116-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2006" NAME="Yang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yang D, Schneider S, Azuma M, Iqbal S, El Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz H J</AU>
<TI>Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecularmarkers of lymph node involvement in patients with locally advanced rectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>4</NO>
<PG>305-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-S-H_x002c_-Lin-J2" NAME="Yang S H, Lin J2" TYPE="JOURNAL_ARTICLE">
<AU>Yang S H, Lin J K, Huang C J, Chen W S, Li S Y, Chiu J H</AU>
<TI>Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation</TI>
<SO>Journal of Surgical Research</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>1</NO>
<PG>140-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yao-2005" NAME="Yao 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM</AU>
<TI>Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer</TI>
<SO>Clinical Cancer Research</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>1618-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yasuno-2005" NAME="Yasuno 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yasuno M, Mori T, Koike M, Takahashi K, Toi M, Takizawa T, Shimizu S, Yamaguchi T, Matsumoto H</AU>
<TI>Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.</TI>
<SO>Oncol Rep</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>3</NO>
<PG>405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ye-2005" NAME="Ye 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ye YN, Wu WKK, Shin VY, Cho CH</AU>
<TI>A mechanistic study of colon cancer growth promoted by cigarette smoke extract</TI>
<SO>European Journal of Pharmacology</SO>
<YR>2005</YR>
<VL>519</VL>
<NO>1-2</NO>
<PG>52-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yonenaga-2005" NAME="Yonenaga 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T, Imamura M</AU>
<TI>Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients.</TI>
<SO>Oncology</SO>
<YR>2005</YR>
<VL>69</VL>
<NO>2</NO>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoon-2006" NAME="Yoon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK, DeMatteo RP</AU>
<TI>Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>3</NO>
<PG>353-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshimura-2000" NAME="Yoshimura 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimura H, Chikamoto A, Honda T, Tashiro K, Nakamoto T, Takano M, Takagi K, Nagasue N, Soma G I</AU>
<TI>Relationship between microvessel quantification and inducibility of endogenous tumor necrosis factor in colorectal adenocarcinoma</TI>
<SO>Anticancer Research</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>1 C</NO>
<PG>629-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshimura-2001" NAME="Yoshimura 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S</AU>
<TI>Expression of cyclooxygenase-2 in patients with bladder carcinoma</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>165</VL>
<NO>5 I</NO>
<PG>1468-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshimura-2004" NAME="Yoshimura 2004" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M, Nagasue N</AU>
<TI>Prognostic impact of hypoxia-inducible factors 1&lt; alpha &gt; and 2&lt; alpha &gt; in colorectal cancer patients: Correlation with tumor angiogenesis and cyclooxygenase-2 expression</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>24</NO>
<PG>8554-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yost-2005" NAME="Yost 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, West DW</AU>
<TI>Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>12</NO>
<PG>1241-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2006" NAME="Young 2006" TYPE="JOURNAL_ARTICLE">
<AU>Young N, Hahn CN, Poh A, Dong C, Wilhelm D, Olsson J, Muscat GEO, Parsons P, Gamble JR, Koopman P</AU>
<TI>Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>15</NO>
<PG>1060-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Youssef-2006" NAME="Youssef 2006" TYPE="JOURNAL_ARTICLE">
<AU>Youssef MMS, Symonds P, Ellis IO, Murray JC</AU>
<TI>EMAP-II-dependent lymphocyte killing is associated with hypoxia in colorectal cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>2006</YR>
<VL>95</VL>
<NO>6</NO>
<PG>735-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2002" NAME="Yu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS</AU>
<TI>Effect of p53 status on tumor response to antiangiogenic therapy</TI>
<SO>Science</SO>
<YR>2002</YR>
<VL>295</VL>
<NO>5559</NO>
<PG>1526-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2003" NAME="Yu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Yu J X, Zhang X T, Liao Y Q, Zhang Q Y, Chen H, Lin M, Kumar S</AU>
<TI>Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal and its significance</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>12</NO>
<PG>2866-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2004" NAME="Yu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Yu H G, Zhong X, Yang Y N, Luo H S, Yu J P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F</AU>
<TI>Increased expression of nuclear factor-&lt; Kappa &gt;B/ReIA is correlated with tumor angiogenesis in human colorectal cancer</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>1</NO>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2005" NAME="Yu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW</AU>
<TI>Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>4</NO>
<PG>1734-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2006" NAME="Yu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yu J X, Cui L, Zhang Q Y, Chen H, Ji P, Wei H J, Ma H Y</AU>
<TI>Expression of NOS and HIF-1&lt; alpha &gt; in human colorectal carcinoma and implication in tumor angiogenesis</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>29</NO>
<PG>4660-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2007" NAME="Yu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Yu X Q</AU>
<TI>Preoperative administration of xeloda on the angiogenesis and expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in colorectal cancer</TI>
<SO>World Chinese Journal of Digestology</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>1</NO>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zaman-2006" NAME="Zaman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Ruegg C</AU>
<TI>Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy</TI>
<SO>International Journal of Cancer</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>3</NO>
<PG>755-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2005" NAME="Zhang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y C, Chen Y P, Li J, Wang X D, Deng C S, Zhu Y Q, Gong L</AU>
<TI>CpG island methylation and expression of thrombospondin 1 gene in colorectal adenocarcinoma</TI>
<SO>World Chinese Journal of Digestology</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>2</NO>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2006" NAME="Zhang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Gordon M, Lenz H J</AU>
<TI>Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies</TI>
<SO>Annals of Medicine</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>8</NO>
<PG>545-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhao-2002" NAME="Zhao 2002" TYPE="JOURNAL_ARTICLE">
<AU>Zhao W, Kobayashi M, Hosokawa M, Seth P</AU>
<TI>Adenoviral vectors for cancer gene therapy</TI>
<SO>Current Genomics</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>3</NO>
<PG>163-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zheng-2003" NAME="Zheng 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zheng S, Han M Y, Xiao Z X, Peng J P, Dong Q</AU>
<TI>Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1227-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zheng-2007" NAME="Zheng 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K, Takano Y</AU>
<TI>Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors</TI>
<SO>Anticancer Research</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>1 A</NO>
<PG>259-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhong-2003" NAME="Zhong 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zhong S S, Zhang Z S, Li S M, Deng H J, Ma Q</AU>
<TI>[Study of angiogenesis in human colorectal carcinoma and its modulation by p53 and K-ras gene]</TI>
<SO>Zhonghua Nei Ke Za Zhi</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>2</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2006" NAME="Zhou 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Z W, Wan D S, Wang G Q, Ren J Q, Lu Z H, Lin S X, Tang S X, Ye Y L, Chen G</AU>
<TI>[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]</TI>
<SO>Ai Zheng</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>7</NO>
<PG>818-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-Z-W_x002c_-Wan-D2" NAME="Zhou Z W, Wan D2" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Z W, Wan D S, Wang G Q, Ren J Q, Lu Z H, Tang S X, Ye Y L, Chen G, Lin S X</AU>
<TI>[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]</TI>
<SO>Zhonghua Wei Chang Wai Ke Za Zhi</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>2</NO>
<PG>161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhuang-2007" NAME="Zhuang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhuang J L, Su Z J, Pan Q X, Xu R Y, Li M Z</AU>
<TI>Expression of CD24 and its relationship with angiogenesis and tumor cell proliferation in colorectal carcinoma</TI>
<SO>World Chinese Journal of Digestology</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>3</NO>
<PG>260-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zimmer-2002" NAME="Zimmer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Zimmer R, Thomas P</AU>
<TI>Expression profiling and interferon-beta regulation of liver metastases in colorectal cancer cells</TI>
<SO>Clinical and Experimental Metastasis</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>6</NO>
<PG>541-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zipin-2007" NAME="Zipin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zipin Roitman A, Meshel T, Sagi Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben Baruch A</AU>
<TI>CXCL10 promotes invasion-related properties in human colorectal carcinoma cells</TI>
<SO>Cancer Research</SO>
<YR>2007</YR>
<VL>67</VL>
<NO>7</NO>
<PG>3396-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zondor-2004" NAME="Zondor 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zondor SD, Medina PJ</AU>
<TI>Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>7-8</NO>
<PG>1258-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zucker-2004" NAME="Zucker 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zucker S, Vacirca J</AU>
<TI>Role of matrix metalloproteinases (MMPs) in colorectal cancer.</TI>
<SO>Cancer Metastasis Rev</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>1-2</NO>
<PG>101-17</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-13 16:14:47 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-11 14:21:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giantonio-2007">
<CHAR_METHODS MODIFIED="2009-03-29 22:33:12 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter RCT<BR/>3 arms<BR/>Quality Score A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-29 22:40:49 +0200" MODIFIED_BY="[Empty name]">
<P>n=829<BR/>Patients pretreated with a fluoropyrimidine and irinotecan<BR/>median age: 61.4<BR/>&gt;1 metastatic organ: 70%<BR/>ECOG 1-3: 50%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:21:07 +0200" MODIFIED_BY="[Empty name]">
<P>Second-line chemotherapy (CTX) with or without bevacizumab:<BR/>FOLFOX 4+bevacizumab: oxaliplatin 85mg/m≤ d1 q d15+ Leucovorin 200mg/m≤ d1+2 q d15 + fluorouracil 400mg/m≤ bolus d1+ fluorouracil 600mg/m≤ over 22 hrs d1+2 + bevacizumab 10mg/kg d1<BR/>versus FOLFOX4,<BR/>versus bevacizumab 10mg/kg d1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, progression-free survival, tumour response, toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-26 12:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>The bevacizumab-alone arm was closed to accrual after an interim analysis that suggested inferior survival. This arm will not be included in the analysis (n=243).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-11 14:22:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hecht-2007">
<CHAR_METHODS MODIFIED="2009-03-29 22:40:30 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter RCT<BR/>2 arms<BR/>Quality Score D</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-29 22:40:45 +0200" MODIFIED_BY="[Empty name]">
<P>n=1168<BR/>median age: 60 years<BR/>&gt;1 metastatic organs: 52%<BR/>ECOG 1-3: 43%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:22:05 +0200" MODIFIED_BY="[Empty name]">
<P>First-line CTX with or without PTK/ZK<BR/>FOLFOX 4 + PTK/ZK: oxaliplatin 85mg/m≤ d1 q d15 + Leucovorin 200mg/m≤ d1+2 + 5-FU 400mg/m≤ bolus d1+2 + 5-FU 600mg/m≤ d1+2 +vatalinib 1250 mg daily<BR/>versus FOLFOX4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression-free survival, overall survival, tumour response, toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-29 22:42:23 +0200" MODIFIED_BY="[Empty name]">
<P>Final results are published as oral presentation only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-11 14:24:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hurwitz-2004">
<CHAR_METHODS MODIFIED="2009-03-29 22:42:30 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter RCT<BR/>3 arms<BR/>Quality score A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-29 22:47:12 +0200" MODIFIED_BY="[Empty name]">
<P>n=923<BR/>mean age: 59<BR/>&gt;1 metastatic organs: 62%<BR/>ECOG 1-3: 43%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:23:20 +0200" MODIFIED_BY="[Empty name]">
<P>First-line CTX with or without bevacizumab<BR/>IFL : irinotecan 125mg/m≤+fluorouracil 500mg/m≤ + Leucovorin 20mg/m≤ once weekly for 4 wk q 6 wk<BR/>versus<BR/>IFL+Bev 5mg/kg every 2 wk<BR/>versus<BR/>FU/LV+Bev: fluorouracil 500mg/m≤+Leucovorin 500mg/m≤ once weekly for 6 wk, cycle repeated every 8 wk+bevacizumab 5mg/kg every 2 wk</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-29 22:46:00 +0200" MODIFIED_BY="[Empty name]">
<P>Overall survival, progression-free survival, tumour response, duration or response, toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-11 14:24:18 +0200" MODIFIED_BY="[Empty name]">
<P>Treatment with FU/LV/bevacizumab was discontinued after the safety of the IFL+bevacizumab regimen was confirmed (110 patients).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-11 14:26:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kabbinavar-2003">
<CHAR_METHODS MODIFIED="2009-03-29 22:47:23 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter RCT<BR/>3 arms<BR/>Quality score A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>n=104<BR/>&gt;1 metastatic organs: 42%<BR/>ECOG 1-3: 42%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:25:02 +0200" MODIFIED_BY="[Empty name]">
<P>First-line CTX with or without bevacizumab<BR/>FU/LV: 5-FU 500mg/m≤ bolus + Leucovorin 500mg/m≤ once weekly x 6 wk q 8 wk<BR/>versus FU/LV+bevacizumab 5mg/kg every 2 wk,<BR/>versus FU/LV+bevacizumab10mg/kg every 2 wk</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-29 22:48:02 +0200" MODIFIED_BY="[Empty name]">
<P>Time to disease progression, tumour response, overall survival, duration of response, toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-11 14:26:08 +0200" MODIFIED_BY="[Empty name]">
<P>Patients in the bevacizumab groups with complete or partial response or stable disease at the end of the treatment period were eligible to receive additional bevacizumab in an open label extension study if their disease progressed within 6 weeks after their last bevacizumab dose in the study. Patients in the control arm who experienced disease progression where given the option of receiving monotherapy with bevacizumab 10mg/kg every two weeks. Bevacizumab as single-agent without chemotherapy is nearly ineffective. For this reason this form of cross-over is unlikely to have any impact on survival. Both bevacizumab arms have been combined in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-11 14:26:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kabbinavar-2005">
<CHAR_METHODS MODIFIED="2009-03-29 22:50:03 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter RCT<BR/>2 arms<BR/>Quality score A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-24 18:34:19 +0100" MODIFIED_BY="[Empty name]">
<P>n=209<BR/>mean age: 71<BR/>&gt;1 metastatic organs: 66%<BR/>ECOG 1-3: 72%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:26:41 +0200" MODIFIED_BY="[Empty name]">
<P>First-line CTX with or without bevacizumab<BR/>FU/LV: 5-FU 500mg/m≤ bolus +Leucovorin 500mg/m≤ once weekly x 6 wk q 8 wk<BR/>versus FU/LV+bevacizumab 5mg/kg every 2 wk</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>overall survival, progression-free survival, tumour response, response duration, quality of life, safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-11 14:28:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltz-2008">
<CHAR_METHODS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>multicenter RCT<BR/>4 arms<BR/>Quality score A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-26 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>n=1401<BR/>median age: 60 years<BR/>&gt;1 metastatic organs: 58%<BR/>ECOG 1-3: 41%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:28:07 +0200" MODIFIED_BY="[Empty name]">
<P>First-line CTX plus bevacizumab<BR/>XELOX: oxaliplatin 130mg/m≤ d1 q d 22+capecitabine 1000mg/m≤ d 1-14 q d 22<BR/>versus<BR/>FOLFOX4: oxaliplatin 85mg/m≤ d1 q d 15+ Leucovorin 5-FU 200mg /m≤ d1 q d 15+5-FU 400mg/m≤ d1q d 15+5-FU 600mg/m≤ d1 q d 15<BR/>versus<BR/>XELOX + bevacizumab 7.5 mg/kg d 1 q d22<BR/>FOLFOX 5 + bevacizumab 5mg/kg d 1 q d15<BR/>treatment continuation until PD or for 48 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression -free survival (2 definitions), overall survival, tumour response, duration of response, time to treatment failure, safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-11 14:28:40 +0200" MODIFIED_BY="[Empty name]">
<P>This study has originally been planned for a comparison of FOLFOX versus XELOX. After publication of the results of the Hurwitz-study, the protocol has been amended to include as a second question the effect of bevacizumab or placebo in both treatment groups, thus resulting in a 2x2 factorial design. 2x2 factorial designs may only be used if there is no interaction between the two questions studied. In this case it must be considered as unclear whether any interactions exist between the treatments studied</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-05-13 16:08:25 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:38:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:38:19 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bekaii_x002d_Saab-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]">
<P>No randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:49:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergsland-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:49:47 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:52:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergsland-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:52:39 +0200" MODIFIED_BY="[Empty name]">
<P>Editorial, no study report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berry-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]">
<P>No randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:55:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buyse-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:55:31 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CALGB_x002f_SWOG-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to either bevacizumab or cetuximab or both - no comparison of chemotherapy with or without angiogenesis inhibitor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]">
<P>No randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cunningham-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:47:24 +0200" MODIFIED_BY="[Empty name]">
<P>This study randomised patients to either cediranib or bevacizumab. Both are anti-angiogenic agents. Because of this design the trial is not eligible for the analysis according to our pre-specified comparisons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:05:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fyfe-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:05:22 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis of Hurwitz 2004.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:24:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giantonio-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:24:27 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 16:08:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hecht-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 16:08:14 +0200" MODIFIED_BY="[Empty name]">
<P>Not eligible because they had no arm with chemotherapy alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:44:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hochster-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:44:11 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization of chemotherapy, no randomisation to bevacizumab.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:12:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hurwitz-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:12:21 +0200" MODIFIED_BY="[Empty name]">
<P>This publication is a report of the third arm (5FU/LV/bevacizumab) of the trial published by Hurwitz 2004. As only studies randomizing patients to chemotherapy with versus the same chemotherapy without angiogenesis inhibitor were eligible for our review, this arm was not included. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:49:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-King-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:49:00 +0200" MODIFIED_BY="[Empty name]">
<P>Patients in this trial were randomised to the matrix-metalloproteinase-inhibitor marimastat, which is an agent primarily involved in the degradation and remodeling of extracellular matrix proteins with secondary effects on angiogenesis and not included for this reason.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:44:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koopman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:44:03 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization to chemotherapy, but no angiogenesis inhibitor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:43:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koukourakis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:43:58 +0200" MODIFIED_BY="[Empty name]">
<P>No randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-06 06:43:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kozloff-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 06:43:55 +0200" MODIFIED_BY="[Empty name]">
<P>No randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:26:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-K_x00f6_hne-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:26:39 +0200" MODIFIED_BY="[Empty name]">
<P>Celecoxib was primarily developed for other indications but subsequently reported to have unspecific anti-angiogenic activity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:26:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Punt-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:26:49 +0200" MODIFIED_BY="[Empty name]">
<P>No randomization to angiogenesis inhibitor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:27:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reinacher_x002d_Schick-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:27:10 +0200" MODIFIED_BY="[Empty name]">
<P>No randomization to angiogenesis inhibitor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:27:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:27:27 +0200" MODIFIED_BY="[Empty name]">
<P>No randomization to angiogenesis inhibitor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-29 23:27:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltz-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-29 23:27:32 +0200" MODIFIED_BY="[Empty name]">
<P>No randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sobrero-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sobrero-2007a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 16:08:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tol-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 16:08:25 +0200" MODIFIED_BY="[Empty name]">
<P>Not eligible because they had no arm with chemotherapy alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-30 00:00:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wainberg-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-30 00:00:53 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were randomized to chemotherapy plus bevacizumab, with or without panitumumab.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-11 14:29:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-11 14:29:14 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were randomized to chemotherapy with or without thalidomide. Thalidomide is an agent which has been developed for another indication and was subsequently reported to have anti-angiogenic activity. It was not included for this reason.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-05-13 16:10:02 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-05-11 14:29:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-K_x00f6_hne-2007">
<CHAR_METHODS MODIFIED="2009-03-30 00:01:59 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-11 14:29:43 +0200" MODIFIED_BY="[Empty name]">
<P>855 pts. with metastatic colorectal cancer with pretreatment for metastatic disease with irinotecan/fluoropyrimidine based therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:29:29 +0200" MODIFIED_BY="[Empty name]">
<P>FOLFOX4 plus vatalinib (1250mg/day orally) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-30 00:21:49 +0200" MODIFIED_BY="[Empty name]">
<P>Progression-free-survival, overall survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-30 00:22:43 +0200" MODIFIED_BY="[Empty name]">
<P>The study has been presented at ASCO 2007 (abstract 4033). Final results are still pending.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-05-11 14:30:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Price-2008">
<CHAR_METHODS MODIFIED="2009-03-30 00:02:50 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-30 00:04:08 +0200" MODIFIED_BY="[Empty name]">
<P>Pts. with metastatic colorectal cancer without prior chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:30:42 +0200" MODIFIED_BY="[Empty name]">
<P>Arm A: capecitabine 2000 or 2500mg/m2/day d1-14, q d 22 (Cape)</P>
<P>Arm B: capecitabine as above + bevacizumab 7.5mg/m2 q d 2 (Bev)</P>
<P>Arm C: mitomycin C 7mg/m2 (max. 4 X 14mg absolute) every 6 weeks + capecitabine/bevacizumab</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-30 00:10:11 +0200" MODIFIED_BY="[Empty name]">
<P>Progression-free-survival, toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-30 00:10:37 +0200" MODIFIED_BY="[Empty name]">
<P>At present only safety data available</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-05-13 16:14:47 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-03-30 21:28:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EORTC40051_x002d_BOS">
<CHAR_STUDY_NAME>
<P>Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:27:37 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 patients with resectable liver metastases from colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-30 21:27:47 +0200" MODIFIED_BY="[Empty name]">
<P>arm1: FOLFOX (5-FU+Folinic acid+oxaliplatin)+cetuximab<BR/>arm2: FOLFOX +cetuximab + bevacizumab</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>feasibility + tolerance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>4.1.2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-03-30 21:28:28 +0200" MODIFIED_BY="[Empty name]">
<P>Bernd Nordlinger (study coordinator), C.H.U. Ambriose pare, Boulogne -Billancourt, Michel Prat (project manager) EORTC, Brussels, michel.praet (at) eortc.be, +32 2774672</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:31:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00004252">
<CHAR_STUDY_NAME MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:28:55 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>710 patients (355 per treatment arm)<BR/>with histologically confirmed, newly diagnosed or recurrent, metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-30 21:36:35 +0200" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm I: leucovorin calcium IV over 2 hours and fluorouracil IV bolus 1 hour into leucovorin calcium administration weekly for 6 wks.<BR/>arm II: leucovorin calcium IV over 2 hours and fluorouracil IV bolus 1 hour into leucovorin calcium administration weekly for 6 wks + SU5416 twice weekly for 8 wks.<BR/>repeats every 8 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>median survival,<BR/>time to progression, duration of response, objective response,<BR/>percentage 6 month, 9 month and one year survival,<BR/>time to treatment failure, health related quality of life, palliative and biologic effects, safety and tolerability</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Investigators<BR/>Study Chair: Alison L. Hannah, MBBS</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-05-11 14:31:16 +0200" MODIFIED_BY="[Empty name]">
<P>Sponsored by:<BR/>SUGEN Incorporated - South San Francisco,</P>
<P>study ID numbers: CDR0000067499, SUGEN-SU5416.031, UCLA-9909008</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:32:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00021281">
<CHAR_STUDY_NAME>
<P>Combination chemotherapy with or without SU5416 in Treating patients with metastatic colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:29:25 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1,270 patients<BR/>(635 per treatment arm) with previously untreated metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:31:59 +0200" MODIFIED_BY="[Empty name]">
<P>first line therapy<BR/>Regimen I (Saltz)<BR/>arm IA: SU5416,<BR/>d1, 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, 39, irinotecan, leucovorin calcium IV, fluorouracil IV, d1, 8, 15, 22.<BR/>arm IIA: irinotecan, leucovorin calcium, and fluorouracil as in arm I, repeats every 6 weeks,<BR/>Regimen II(de Gramont): Arm IB: SU5416 as in arm IA, irinotectan IV, d1, 15, 29. leucovorin calcium IV on d1, 2, 15, 16, 29, 30.<BR/>Arm IIB: irinotecan, leucovorin calcium, and fluorouracil as in arm IB,<BR/>repeats every 6 weeks,<BR/>Phase III<BR/>semaxanib, antiangiogenesis therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>survival, antitumor efficacy, clinical benefit, relative safety profile, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-03-30 21:39:05 +0200" MODIFIED_BY="[Empty name]">
<P>December 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-05-11 14:32:18 +0200" MODIFIED_BY="[Empty name]">
<P>Jonsson Comprehensive Cancer Center, UCLA<BR/>Los Angeles, California, United States, 90095-1781</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsors and Collaborators:<BR/>Jonsson Comprehensive Cancer Center<BR/>National Cancer Institute (NCI), CDR0000068766, UCLA-oo1oo3701, SUGEN-SU5416.035, NCI-G01-1980</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:32:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00070122">
<CHAR_STUDY_NAME>
<P>Combination chemotherapy and Bevacizumab In treating patients with locally advanced, metastatic or recurrent Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:39:29 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2,200 patients (1,100 per treatment arm) with histologically or cytologically confirmed locally advanced, recurrent, or metastatic colorectal adenocarcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm1: oxaliplatin IV, leucovorin calcium IV d1, fluorouracil IV d1 + bevacizumab every 2 weeks<BR/>arm2: chemo as in arm1 + placebo IV d 1 every 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:32:38 +0200" MODIFIED_BY="[Empty name]">
<P>overall survival, progression-free survival, response and toxicity rates, patient-reported functional status and convenience of therapy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>April 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-05-11 14:32:59 +0200" MODIFIED_BY="[Empty name]">
<P>Trial contact information<BR/>Southwest Oncology Group<BR/>- Charles Blanke, MD, FACP, Study coordinator<BR/>- Heinz-Josef Lenz, MD, Study coordinator<BR/>lenz_h@ccnt.usc.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab,<BR/>Sudy ID numbers: CDR00000330000, SWOG-S0303, ECOG-S0303</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:33:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00109070">
<CHAR_STUDY_NAME MODIFIED="2009-05-11 14:33:13 +0200" MODIFIED_BY="[Empty name]">
<P>A study to evaluate Avastin in Combination with Standard Chemotherapy to treat Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:41:32 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>900 patients with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:33:23 +0200" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm1: standard chemotherapy<BR/>arm2: arm1+rhu MAb VEGF (bevacizumab)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>efficacy<BR/>safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>April 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Genentech</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsored by:<BR/>Genentech, Study ID numbers: AVG2107g</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-03-30 21:42:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00109226">
<CHAR_STUDY_NAME>
<P>A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:42:01 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>patients with previously untreated metastatic colorectal cancer who are not optimal candidates to receive first-line CPT-11 (irinotecan)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm1 (experimental): rhuMAb VEGF (Avastin) 5 mg/kg every 2 wks + 5 FU (fluorouracil) leucovorin<BR/>arm2: 5 FU/leucovorin alone<BR/>max. 48 doses of rhuMAb VEGF (96 weeks of therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>efficacy<BR/>safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>J Natl. Cancer Inst.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Study ID number: AVG2192g</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:34:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00200200">
<CHAR_STUDY_NAME MODIFIED="2009-05-11 14:33:51 +0200" MODIFIED_BY="[Empty name]">
<P>Hepatic Arterial Infusion W/Floxuridine &amp; Dexamethasone Combination W/ Chemo W/W/out bevacizumab for hepatic metastases from colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:44:25 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-11 14:34:18 +0200" MODIFIED_BY="[Empty name]">
<P>80 patients W/resectd hepatic metastases from colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:34:38 +0200" MODIFIED_BY="[Empty name]">
<P>arm A : bevacizumab + HAI plus systematic chemotherapy,<BR/>arm B HAI+ systematic chemotherapy alone,<BR/>chemo-naive, or who have not received oxaliplatin and received prior CPT_11will received oxaliplantin + 5FU/LV and HAI,<BR/>prior oxaliplantin will receive CPT-11 + 5FU/LV and HAI,<BR/>6 cycles (7.5 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:34:46 +0200" MODIFIED_BY="[Empty name]">
<P>time to progression,<BR/>toxicity, survival, expression pattern of VEGFR1, VEGFR2,<BR/>VEGFR3 and their cognate ligands</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Contact:<BR/>Nancy Kemeny, M.D.<BR/>212-639-8068</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Memorial Sloan-Kettering Cancer Center<BR/>Weill Medical College of Cornell University, Study ID numbers: 04-086</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:35:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00265850">
<CHAR_STUDY_NAME MODIFIED="2009-05-11 14:35:15 +0200" MODIFIED_BY="[Empty name]">
<P>Cetuximab and/or Bevacizumab combined with combination Chemotherapy in treating patients with untreated metastatic colon cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:44:50 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2300 patients<BR/>with untreated metastatic adenocarcinoma of the colon or rectum</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm 1: oxaliplatin IV or irinotecan hydrochloride IV, leucovorin calcium IV, fluorouracil IV +bevacizumab IV, d1, 15, 29, 43<BR/>arm 2: chemo as in arm1+ cetuximab IV, d 1 ,8, 15, 22, 29, 36, 43, 50<BR/>arm 3: chemo as in arm 1+bevacizumab as in arm1+cetuximab as in arm2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:35:30 +0200" MODIFIED_BY="[Empty name]">
<P>overall survival,<BR/>response (complete response and partial response),<BR/>progression-free survival,<BR/>time to treatment failure,<BR/>duration of tumour response</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study Chair:<BR/>Alan P. Venook, MD University of California, San Francisco<BR/>Study Chair: Charles D. Blanke,<BR/>MD, FACP Oregon Health and Science University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Cancer and Leukemia Group B<BR/>National Cancer Institute<BR/>Southwest Oncology Group, Study ID numbers: CDR0000455161, CALGB-C80405, SWOG-C80405</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-03-30 21:45:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00294359">
<CHAR_STUDY_NAME>
<P>The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:45:50 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>333 patients<BR/>Patients with untreated metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm1: capecitabine d1-d14 q3 weekly,<BR/>arm2: capecitabine as in arm1+<BR/>bevacizumab q3 weekly,<BR/>arm3: capecitabine +<BR/>bevacizumab as in arm2+ Mitomycin C q6weekly (maximum dose 14 mg, maximum 4 treatments)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary outcome: phase II: treatment related toxicity<BR/>phase III:<BR/>progression free survival<BR/>Secondary Outcomes:<BR/>Phase II: treatment response<BR/>Phase III:<BR/>treatment related toxicity, treatment response, overall survival, symptoms of disease, treatment and quality of life,<BR/>cost of therapy and assessment of gain in quality-adjusted progression free survival</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Juni 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Principal Investigator:<BR/>Niall C Tebbutt, BA (Hons) BM BCh PhD MRCP FRAC<BR/>Ludwig Oncology Unit, Austin Health</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsored by:<BR/>Australasian Gastro-Intestinal Trials Group, study ID numbers: AG0501CR</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:35:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00321100">
<CHAR_STUDY_NAME MODIFIED="2009-03-30 21:46:30 +0200" MODIFIED_BY="[Empty name]">
<P>Phase II - Combination of Cetuximab, Capecetabine, and Oxaliplatin with or without Bevacizumab</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:46:33 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>80 patients with previously untreated metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm1: cetuximab +capecetabine + oxaliplatin<BR/>arm2: arm1+ bevacizumab</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-30 21:46:48 +0200" MODIFIED_BY="[Empty name]">
<P>objective response rate (RECIST) after every second cycle,<BR/>time to progression, overall survival, safety and toxicity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>April 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Principal Investigator:<BR/>Steven Cohen, MD<BR/>215-728-2450<BR/>United States, Pennsylvania<BR/>Fox Chase Cancer Center<BR/>Philadelphia,<BR/>Pennsylvania, United States, 19111<BR/>Holly Tuttle, RN, MSN<BR/>215-728-2451<BR/>holly.tuttle@fccc.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-05-11 14:35:46 +0200" MODIFIED_BY="[Empty name]">
<P>Sponsors and Collaborators:<BR/>Fox Chase Cancer Center, Study ID numbers: FRN-GI-002</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:37:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00399035">
<CHAR_STUDY_NAME MODIFIED="2008-11-26 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy in patients with untreated Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:47:23 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1050 patients with previously untreated metastatic CRC</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:37:11 +0200" MODIFIED_BY="[Empty name]">
<P>arm 1 (placebo comparator)<BR/>(FOLFOX + placebo cediranib):<BR/>FOLFOX (5-fluorouracil, Leucovorin, oxaliplatin) intravenous infusion<BR/>arm 2 (placebo comparator):<BR/>(XELOX + placebo cediranib):<BR/>XELOX (capecitabine and oxaliplatin), intravenous oxaliplatin 130 mg/m(2) (d 1) followed by oral<BR/>capecitabine 1,000 mg/m(2)<BR/>twice daily (d1-15)<BR/>arm 3 (Experimental: FOLFOX + cediranib): cediranib oral tablet,<BR/>FOLFOX (5-fluorouracil, Leucovorin, oxaliplatin) intravenous infusion<BR/>arm 4: (experimental: XELOX + cediranib): cediranib oral tablet, XELOX (capecitabine and oxaliplatin), intravenous oxaliplatin 130 mg/m(2) (d1)<BR/>followed by oral<BR/>capecitabine 1,000 mg/m(2) twice daily (d1-15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:37:21 +0200" MODIFIED_BY="[Empty name]">
<P>progression-free survival, overall survival , overall response rate, duration of response, rate of resection of liver metastases, incidence of wound healing complications, safety of cediranib</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Contact:<BR/>AstraZeneca Clinical study Information<BR/>1-800-236-9933<BR/>information.center@astrazeneca.com<BR/>AZD2171 Trials Enquiries<BR/>AZD2171Trials@astrazeneca.com<BR/>Investigators:<BR/>Study Director:<BR/>Cediranib Medical Science<BR/>Director, MD</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>AstraZeneca, study ID numbers: D08480C00051, EUDRACT No 2006-001194-14, HORIZON II</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-03-30 21:54:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00437268">
<CHAR_STUDY_NAME>
<P>A Study of Irinotecan plus Cetuximab With or Without Enzastaurin in patients with colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:54:18 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>115 patients with recurrent Colorectal Cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>second-line therapy<BR/>arm A (experimental):<BR/>enzastaurin 1125 mg loading dose then 500 mg, oral daily, q 3 wks until progressive disease, irinotecan<BR/>300 mg/m2, IV, d 1 q 3 wks until progressive disease, cetuximab<BR/>400 mg/m2, IV,d1, 250 mg/m2 d8, d15 cycle 1 then 250 mg/m2, IV, d1, 8,15 of each cycle, IV, 21 day cycles until progressive disease<BR/>arm B (active comparator):<BR/>irinotecan 300 mg/m2, IV, d1 q 3 wks until progressive disease, cetuximab 400 mg/m2, IV,d1, 250 mg/m2 d8, d15 cycle 1 then 250 mg/m2, IV, d1, 8,15 of each cycle, IV, q 3 wks until progressive disease</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression-free survival (PFS) rate (at 6 months),<BR/>tumour response rate,<BR/>duration of response, Overall survival, safety and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>M‰rz 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-03-30 21:54:38 +0200" MODIFIED_BY="[Empty name]">
<P>Investigators:<BR/>Study Director:<BR/>Call 1-877-285-4559 or 1-317-615-4559<BR/>Mon - Fri 9 AM - 5 PM Eastern time</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Eli Lilly and Company<BR/>Study ID numbers: 10538, H6Q-MC-S018</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:40:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00438737">
<CHAR_STUDY_NAME MODIFIED="2009-05-11 14:38:39 +0200" MODIFIED_BY="[Empty name]">
<P>Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil with or without bevacizumab in treating patients with resectable liver metastases from colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:54:46 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 patients with resectable liver metastases secondary to colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:40:07 +0200" MODIFIED_BY="[Empty name]">
<P>arm 1: leucovorin calcium IV over 2 hours and oxaliplantin IV over 2 hours d1+ fluorouracil IV over 46 hours (FOLFOX) beginning on d1 + cetuximab IV over 1-2 hours d1+d8, q 2 wks for 6 courses in the absence of disease progression or unacceptable toxicity.<BR/>Between 3-5 wks after completion of FOLFOX and cetuximab, patients undergro liver resection.<BR/>Beginning between 4-8 wks after surgery, patients receive another 6 courses of FOLFOX and cetuximab as in neoadjuvant therapy.<BR/>arm 2: FOLFOX + cetuximab as in arm I + bevacizumab IV over 30-90 minutes on d1. q 2 wks for 6 courses in the absence of disease progression or unacceptable toxicity.<BR/>NOTE: *Patients do not receive bevacizumab during course 6,<BR/>Between 3-5 wks after completion of FOLFOX, cetuximab, and bevacizumab, patients undergo liver resection. Beginning between 4-8 wks after surgery, patients receive another 6 courses of FOLFOX, cetuximab + bevacizumab as in neoadjuvant therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response rate (preoperative response rate), Safety (rate of perioperative safety findings)<BR/>progression-free survival,<BR/>pathological resection rate,<BR/>Overall survival</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-11 14:40:15 +0200" MODIFIED_BY="[Empty name]">
<P>January 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Investigator:<BR/>Bernard Nordlinger, MD<BR/>Hopital Ambroise Pare</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>European Organization for Research and Treatment of Cancer<BR/>Study ID CDR0000530116, EORTC-40051, EUDRACT-2005-002825-29</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:40:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00454116">
<CHAR_STUDY_NAME MODIFIED="2009-05-11 14:40:22 +0200" MODIFIED_BY="[Empty name]">
<P>A phase II, double-blind study of 2 doses of ZACTIMA (ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:55:16 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-30 21:55:10 +0200" MODIFIED_BY="[Empty name]">
<P>96 patients with histologically confirmed colorectal cancer,<BR/>have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>second-line therapy<BR/>arm1: ZD6474 (2 doses)+ FOLFIRI<BR/>arm2: FOLFIRI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:40:30 +0200" MODIFIED_BY="[Empty name]">
<P>safety + efficacy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>AstraZeneca Cancer Support Network<BR/>1-866-992-9276<BR/>information.center@astrazeneca.com<BR/>Outside US<BR/>001-886-992-9276</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>AstraZeneca, Study ID numbers: D4200C00048</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:40:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00457691">
<CHAR_STUDY_NAME MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Study of FOLFIRI chemotherapy with or without Sunitinib In Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:55:22 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>720 patients with confirmed (histologically or cytologically) colorectal andenocarcinoma with metastatic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>first-line therapy<BR/>arm1: Irinotecan, 5-Fluorouracil+Leucovorin (FOLFIRI )<BR/>arm2: FOLFIRI + sunitinib</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression-free survival,<BR/>Overall survival,<BR/>Objective Response rate,<BR/>Duration of Response,<BR/>Adverse Events,<BR/>Patient Reported Outcomes</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-11 14:40:42 +0200" MODIFIED_BY="[Empty name]">
<P>June 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Pfizer Oncology Clinical Trial Information Service<BR/>1-877-369-9753<BR/>PfizerCancerTrials@emergingmed.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsored by: Pfizer, Study ID numbers: A681122</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:40:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00484939">
<CHAR_STUDY_NAME>
<P>A Study of Avastin in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:55:43 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>100 - 500 patients<BR/>(&gt;=70 years) with metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-30 21:57:16 +0200" MODIFIED_BY="[Empty name]">
<P>First-line therapy<BR/>arm1: Avastin (7.5 mg/kg iv on d1 q3 wks + Xeloda (1000mg/m2 po bid on d1-14 q3 wks)<BR/>arm2: Xeloda as in arm1 alone,</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>Progression-free survival,<BR/>Best overall response, duration of response, time to response, overall survival<BR/>Safety: Adverse events, laboratory parameters, vital signs.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-11 14:40:51 +0200" MODIFIED_BY="[Empty name]">
<P>July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Please reference Study ID Number<BR/>or<BR/>800-526-6367<BR/>(for US only)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Hoffmann-La Roche,<BR/>Study ID Numbers:<BR/>PDO_MO19286, MO19286</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:41:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00499369">
<CHAR_STUDY_NAME MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Irinotecan and Cetuximab<BR/>with or without Bevacizumab<BR/>in treating patients with metastatic colorectal cancer that progressed during first-line therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:57:29 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>1260 patients with metastatic colorectal cancer who have progressed on Bevacizumab<BR/>with either FOLFOX, OPTIMOX or<BR/>XELOX</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>second-line therapy<BR/>arm I (active comparator):<BR/>single-agent irinotecan hydrochloride IV or FOLFIRI IV, cetuximab IV d1, q 14-21 ds<BR/>Arm II (experimental):<BR/>arm I + bevacizumab IV d1,<BR/>Arm III (experimental):<BR/>arm I + bevacizumab (higher than in arm II) d1, q 14-21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:41:03 +0200" MODIFIED_BY="[Empty name]">
<P>overall survival, Progression-free survival, objective tumour response,<BR/>Tolerability and safety profile</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-11 14:41:10 +0200" MODIFIED_BY="[Empty name]">
<P>June 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Study Chair:<BR/>Philip J. Gold, MD<BR/>Swedish Cancer Institute at Swedish Medical Center - First Hill Campus,<BR/>Axel Grothey, MD<BR/>Mayo Clinic,<BR/>Leonard B. Saltz, MD,<BR/>Memorial Sloan-Kettering Cancer Center<BR/>Steven J. Cohen, MD,<BR/>Fox Chase Cancer Center<BR/>Scott Berry, MD,<BR/>Edmond Odette Cancer Centre at Sunnybrook</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Southwest Oncology Group NCI, North Central Cancer Treatment Group,<BR/>Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, NCI of Canada,<BR/>Studa ID numbers: CDR0000551934, SWOG-S0600, CALB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-03-30 21:58:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00500292">
<CHAR_STUDY_NAME>
<P>A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:58:08 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>103 patients with colorectal cancer who have failed therapy with an irinotecan and fluoropyrimidine<BR/>regimen</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>second-line therapy<BR/>arm 1 (placebo comparator):<BR/>oxaliplatin, fluorouracil, folinic acid iv (FOLFOX)+ placebo<BR/>arm2 (experimental):<BR/>arm1 + low dose vandetanib (daily oral)<BR/>arm3 (experimental):<BR/>FOLFOX + high dose vandetanib<BR/>(daily oral)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>efficacy<BR/>safety and tolerability</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-03-30 21:58:19 +0200" MODIFIED_BY="[Empty name]">
<P>march 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>Study Director:<BR/>Gill Pover, MD<BR/>AstraZeneca<BR/>Peter Langmuir, MD,<BR/>AstraZeneca<BR/>more information:<BR/>AstraZeneca Clinical Trial Information -<BR/>Outside US</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>AstraZeneca, Study ID numbers: D4200C00047</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-03-30 21:58:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00544700">
<CHAR_STUDY_NAME>
<P>Bevacizumab in treating patients who have undergone first-line therapy for metastatic colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:58:30 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>238 patients with metastatic colorectal cancer and stable or responding disease after completion of standard first-line chemotherapy /bevacizumab treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>second-line therapy<BR/>arm I: bevacizumab IV d1 q 3wks,<BR/>arm II: no further treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time to progression<BR/>Overall survival,<BR/>Progression-free survival,<BR/>Adverse events,<BR/>Long-term bevacizumab treatment costs</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Oktober 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study Chair:<BR/>Dieter Koeberle, MD,<BR/>Kantonspital -<BR/>St. Gallen,<BR/>Investigator:<BR/>Peter Moosmann, MD, PhD,<BR/>Kantonspital Aarau</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored by:<BR/>Swiss Group for Clinical Cancer Research, Study ID numbers: : CDR0000569866, SWS-SAKK-41/06, EU-20762</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:41:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00561470">
<CHAR_STUDY_NAME>
<P>Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:59:18 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1200 patients with histologically or cytologically proven adenocarcinoma of the colon or rectum</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>second-line therapy<BR/>arm1: Irinotecan+5-FU combination (FOLFIRI)<BR/>arm2: arm1 + Aflibercept once q 2 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-11 14:41:41 +0200" MODIFIED_BY="[Empty name]">
<P>Overall survival,<BR/>Progression-free survival,<BR/>Tumour reponse rate,<BR/>Safety, Immunogenicity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-03-30 21:58:44 +0200" MODIFIED_BY="[Empty name]"/>
<CHAR_CONTACT_INFORMATION>
<P>Public ICD Registry<BR/>GV-Contact-us@sanofi-aventis.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Sanofi-Aventis<BR/>Regeneron Pharmaceuticals<BR/>(NSABP),<BR/>study ID numbers EFC10262, AVE 0005, EudraCT 2007-000820-42</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:41:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00642577">
<CHAR_STUDY_NAME>
<P>A Study of Avastin (Bevacizumab) in combination with chemotherapy chinese patients with metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:59:40 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>210 patients with metastatic colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>first-line therapy<BR/>arm 1 (active comparator):<BR/>irinotecan 125mg/m2 iv cycle + leucovorin 20mg/m2 iv + fluorouracil<BR/>500mg/m2 iv weekly for 4 ws q 6 wks<BR/>arm 2 (experimental):<BR/>arm1+bevacizumab 5mg/kg iv q 2 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression-free survival<BR/>Overall response rate, time to response, duration of response, overall survival,<BR/>Adverse events, laboratory tests</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-11 14:41:49 +0200" MODIFIED_BY="[Empty name]">
<P>July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-05-11 14:41:54 +0200" MODIFIED_BY="[Empty name]">
<P>Please reference Study ID Number:<BR/>PDO_BO20696<BR/>973-235-5000<BR/>or<BR/>800-526-6367<BR/>(for US only)<BR/>Investigators:<BR/>Study Director:<BR/>Clinical Trials<BR/>Hoffmann-La Roche,<BR/>+1 973 235 5000</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Hoffmann-La Roche<BR/>Study ID number: BO020696</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:42:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00700102">
<CHAR_STUDY_NAME>
<P>A Study of Avastin (Bevacizumab) plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 21:59:57 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>808 patients with metastatic colorectal cancer who have experienced disease progression under first line treatment with standard chemotherapy plus Avastin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-11 14:42:07 +0200" MODIFIED_BY="[Empty name]">
<P>second-line therapy<BR/>arm 1 (experimental)<BR/>bevacizumab [Avastin] 5mg/kg on d1+14 q 4 wks or 7.5mg/kg on d1+22 q 6 wks<BR/>+ AIO-IRI, FOLFIRI, CAPIRI or XELIRI<BR/>arm 2 (experimental):<BR/>bevacizumab [Avastin]<BR/>5mg/kg on d1+14 q 4 wks or 7.5mg/kg on d1+22 q 6 wks+ FUFOX, FOLFOX, CAPOX or XELOX<BR/>arm 3 (active comparator):<BR/>AIO-IRI, FOLFIRI, CAPIRI or XELIRI<BR/>arm4 (active comparator):<BR/>FUFOX, FOLFOX, CAPOX or XELOX</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression-free survival<BR/>Overall survival,<BR/>response rate,<BR/>AEs, laboratory parameters</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>September 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-05-11 14:42:20 +0200" MODIFIED_BY="[Empty name]">
<P>Please reference Study ID Number</P>
<P>973-235-5000<BR/>or<BR/>800-526-6367<BR/>(for US only)<BR/>Investigators:<BR/>Study Director:<BR/>Clinical Trials<BR/>Hoffmann-La Roche<BR/>+1 973 235 5000</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsors and Collaborators:<BR/>Hoffmann-La Roche, Study ID numbers: RLI_ML 18147, ML 18147</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-03-30 22:00:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00707889">
<CHAR_STUDY_NAME>
<P>Phase 2 Study of ABT-869 in combination with mFOLFOX6 versus Bevacizumab in combination with mFOLFOX6 to treat advanced colorectal cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 22:00:20 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>102 patients with advanced colorectal cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>second-line therapy<BR/>arm A (active comparator):<BR/>ABZ-869 0.20 mg/kg QD, tablets taken orally d1-14 q 2wks+ mFOLFOX6 (oxaliplatin 85 mg/m2 IV, 120 minutes on d 1 q 2wks + folinic acid<BR/>400 mg/m2IV, 120 minutes d1 q 2wks<BR/>+ fluorouracil 400 mg/m2 IV bolus on d1 q 2wks followed by 2400 mg/m2 IV infusion 46-48 hours)<BR/>arm B (Active Comparator):<BR/>bevacizumab 10 mg/kg QD, IV d1 q 2wks + mFOLFOX6 as in arm1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Progression-free survival<BR/>Overall survival<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>August 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Christi Kosogof, M.S.<BR/>847-937-7481<BR/>christi.kosogof@abbott. com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Abbott<BR/>Genetech<BR/>Study ID numbers: M10-300, EudraCT: 2007-007081-38</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-05-11 14:42:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00720512">
<CHAR_STUDY_NAME>
<P>Second-Line Combination Chemotherapy with or without Bevacizumab in treating patients with Metastatic Colorectal Cancer patients who have received First-Line Chemotherapy and Bevacizumab</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-03-30 22:00:28 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>262 patients with metastatic colorectal cancer who have received first-line chemotherapy with bevacizumab</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-26 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>second-line therapy<BR/>arm I (active comparator):<BR/>irinotecan hydrochloride or<BR/>oxaliplatin d1, leucovorin calcium IV,<BR/>fluorouracil IV, continuously beginning on d1 q 2 wks up to 12 courses<BR/>arm 2 (experimental):<BR/>combination chemotherapy as in arm 1+ bevacizumab IV on d1,</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Progression-free survival<BR/>Overall survival<BR/>Response rate<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-05-11 14:42:39 +0200" MODIFIED_BY="[Empty name]">
<P>June 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-26 12:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Please refer to this study by its ClinicalTrials.gov identifier<BR/>Locations:<BR/>Presidio Ospedaliero di<BR/>Livorno<BR/>Livorno, Italy<BR/>57100<BR/>Contact Person<BR/>39-058-622-3189<BR/>Principal<BR/>Investigator:<BR/>Alfredo Falcone, MD<BR/>Presidio Ospedaliero di Livorno</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsors and Collaborators:<BR/>Gruppo Oncologico del Nord-Ovest<BR/>Stdy ID numbers: CDR0000598567, GONO-BEBYP-ASL607LIOM03, GONO-AIFA-FARM5C4FB4 EUDRACT:2007-002886-11</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 16:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hecht-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-31 09:01:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurwitz-2004">
<DESCRIPTION>
<P>interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kabbinavar-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-31 09:02:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kabbinavar-2005">
<DESCRIPTION>
<P>interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-31 09:02:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saltz-2008">
<DESCRIPTION>
<P>interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-05-13 13:59:30 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hecht-2007">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hurwitz-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kabbinavar-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kabbinavar-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Saltz-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-03-26 16:39:19 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-03-26 16:40:44 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-03-26 16:40:44 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-03-29 23:33:55 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-03-29 23:33:55 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-26 16:45:34 +0100" MODIFIED_BY="[Empty name]">Quality assessment of trials</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Kabbinavar 2003</P>
</TD>
<TD>
<P>Hurwitz 2004</P>
</TD>
<TD>
<P>Kabbinavar 2005</P>
</TD>
<TD>
<P>Giantonio 2007</P>
</TD>
<TD>
<P>Hecht 2007</P>
</TD>
<TD>
<P>Saltz 2008</P>
</TD>
</TR>
<TR>
<TD>
<P>(1) Was the allocation truly random?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>(2) Were groups similar at baseline regarding the most important prognostic factors ?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>(3) Were the number of withdrawals, dropouts and losses to follow-up in each group completely described ?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>(4) Was the analysis done by intention-to-treat ?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>(5) Were type and schedule of the follow up similar in the comparison group ?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Hurwitz 2004 describes the randomization by a dynamic randomization algorithm.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-04-06 09:44:21 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-04-06 09:44:21 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>First-line CTX with versus without Bevacizumab</NAME>
<IV_OUTCOME CHI2="18.412445442270815" CI_END="0.8297404220687616" CI_START="0.44678911998640003" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.608866974792726" ESTIMABLE="YES" I2="83.70667269914796" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.08105775207596314" LOG_CI_START="-0.3498974111772907" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21547758162662695" MODIFIED="2009-04-06 09:33:04 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.615739423681319E-4" P_Q="1.0" P_Z="0.001678782280407703" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0743707927957751" TOTALS="YES" TOTAL_1="1273" TOTAL_2="1253" WEIGHT="100.00000000000001" Z="3.1418601026033883">
<NAME>Progression Free Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev.</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.6539584126869914" CI_START="0.44588755334749014" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="-0.18444986897669233" LOG_CI_START="-0.3507746505208752" LOG_EFFECT_SIZE="-0.26761225974878383" ORDER="1" SE="0.0977" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="402" TOTAL_2="411" WEIGHT="29.717801212235575"/>
<IV_DATA CI_END="0.9388513081762129" CI_START="0.310583703814025" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="-0.027403184253551392" LOG_CI_START="-0.5078213352440162" LOG_EFFECT_SIZE="-0.26761225974878383" ORDER="2" SE="0.2822" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="68" TOTAL_2="36" WEIGHT="16.192713450386588"/>
<IV_DATA CI_END="0.7326383960038507" CI_START="0.3412646576493325" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.13511032463456848" LOG_CI_START="-0.4669086861797193" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-03-25 14:44:35 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.1949" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="104" TOTAL_2="105" WEIGHT="22.195375847132237"/>
<IV_DATA CI_END="0.9369042163120472" CI_START="0.735337446499652" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.028304806607897717" LOG_CI_START="-0.13351331734925395" LOG_EFFECT_SIZE="-0.08090906197857582" ORDER="4" SE="0.061799999999999994" STUDY_ID="STD-Saltz-2008" TOTAL_1="699" TOTAL_2="701" WEIGHT="31.89410949024561"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.90212588222369" CI_END="0.9015984603465099" CI_START="0.731883535022049" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.8123207915157904" ESTIMABLE="YES" I2="49.170857079894795" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.044986838603016555" LOG_CI_START="-0.13555802293267813" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09027243076784737" MODIFIED="2009-03-25 14:52:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11647056796019817" P_Q="1.0" P_Z="9.344996879744718E-5" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1273" TOTAL_2="1253" WEIGHT="99.99999999999999" Z="3.9069978914678365">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.8082856756313742" CI_START="0.5389350178041085" EFFECT_SIZE="0.6600101930934101" ESTIMABLE="YES" ESTIMATE="-0.4155" LOG_CI_END="-0.09243511766238502" LOG_CI_START="-0.2684635967992172" LOG_EFFECT_SIZE="-0.18044935723080113" ORDER="5" SE="0.10339999999999999" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="402" TOTAL_2="411" WEIGHT="26.473674203727672"/>
<IV_DATA CI_END="1.68416796123767" CI_START="0.4391687030590904" EFFECT_SIZE="0.8600196853970379" ESTIMABLE="YES" ESTIMATE="-0.1508" LOG_CI_END="0.22638540129736373" LOG_CI_START="-0.35736861703938444" LOG_EFFECT_SIZE="-0.06549160787101034" ORDER="6" SE="0.3429" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="68" TOTAL_2="36" WEIGHT="2.4072451879493073"/>
<IV_DATA CI_END="1.107168436676331" CI_START="0.5637153811909568" EFFECT_SIZE="0.7900176436786672" ESTIMABLE="YES" ESTIMATE="-0.2357" LOG_CI_END="0.04421369635700178" LOG_CI_START="-0.24894011512619466" LOG_EFFECT_SIZE="-0.10236320938459643" ORDER="7" SE="0.1722" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="104" TOTAL_2="105" WEIGHT="9.545287269941314"/>
<IV_DATA CI_END="1.0165205376401043" CI_START="0.7792794579077884" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="0.007116157488238431" LOG_CI_START="-0.10830677177169605" LOG_EFFECT_SIZE="-0.050595307141728815" ORDER="8" SE="0.0678" STUDY_ID="STD-Saltz-2008" TOTAL_1="699" TOTAL_2="701" WEIGHT="61.573793338381705"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="12.45535479019243" CI_END="2.149102229767045" CI_START="0.9212343624525492" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4070631906509372" ESTIMABLE="YES" EVENTS_1="557" EVENTS_2="509" I2="75.91397394506775" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.33225707475981286" LOG_CI_START="-0.035629871027825874" LOG_EFFECT_SIZE="0.14831360186599352" METHOD="MH" MODIFIED="2009-04-06 09:44:21 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.005975506116308815" P_Q="0.0" P_Z="0.11403388938374688" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11954434736606843" TOTALS="YES" TOTAL_1="1268" TOTAL_2="1250" WEIGHT="100.0" Z="1.5803187441315685">
<NAME>Tumour Response</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours without bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.01573903350279" CI_START="1.1455189254928513" EFFECT_SIZE="1.5195615195615195" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="143" LOG_CI_END="0.3044343057269135" LOG_CI_START="0.05900226870587541" LOG_EFFECT_SIZE="0.18171828721639446" ORDER="9" O_E="0.0" SE="0.14416799345433487" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="402" TOTAL_2="411" VAR="0.020784410336649142" WEIGHT="33.27800467701408"/>
<DICH_DATA CI_END="6.730473327854288" CI_START="0.8662775672178393" EFFECT_SIZE="2.4146341463414633" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" LOG_CI_END="0.8280456075295985" LOG_CI_START="-0.06234293177396976" LOG_EFFECT_SIZE="0.3828513378778144" ORDER="10" O_E="0.0" SE="0.5230186354812687" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="63" TOTAL_2="33" VAR="0.2735484930606882" WEIGHT="11.879791679952326"/>
<DICH_DATA CI_END="3.886796941466216" CI_START="0.9788007053427047" EFFECT_SIZE="1.9504870129870129" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.5895918523101256" LOG_CI_START="-0.00930572635913877" LOG_EFFECT_SIZE="0.2901430629754934" ORDER="11" O_E="0.0" SE="0.3517954023011526" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="104" TOTAL_2="105" VAR="0.1237600050802298" WEIGHT="19.193495752121144"/>
<DICH_DATA CI_END="1.131621994179108" CI_START="0.7439059553446972" EFFECT_SIZE="0.9175076788064941" ESTIMABLE="YES" EVENTS_1="328" EVENTS_2="344" LOG_CI_END="0.053701379804566324" LOG_CI_START="-0.1284819645299738" LOG_EFFECT_SIZE="-0.037390292362703706" MODIFIED="2009-04-06 09:18:13 +0200" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.10701539828420772" STUDY_ID="STD-Saltz-2008" TOTAL_1="699" TOTAL_2="701" VAR="0.011452295469927608" WEIGHT="35.64870789091244"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8857153575039662" CI_END="1.1142602002037296" CI_START="0.4359175136702366" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6969401237226265" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" I2="48.529425961743044" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.04698661841171889" LOG_CI_START="-0.36059568216940874" LOG_EFFECT_SIZE="-0.15680453187884494" METHOD="MH" MODIFIED="2009-03-25 09:34:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.14329402617643427" P_Q="0.0" P_Z="0.13153671899961744" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1187" TOTAL_2="1176" WEIGHT="100.0" Z="1.5080695832817492">
<NAME>Toxicity - 60-day mortality</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.308840447735959" CI_START="0.2999868590045026" EFFECT_SIZE="0.626605884790717" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.116886707749238" LOG_CI_START="-0.5228977692364343" LOG_EFFECT_SIZE="-0.20300553074359806" ORDER="12" O_E="0.0" SE="0.37581256876562136" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.1412350868422149" WEIGHT="43.33193020752828"/>
<DICH_DATA CI_END="0.9776056064699107" CI_START="0.11710031466269606" EFFECT_SIZE="0.3383458646616541" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.009836316459168984" LOG_CI_START="-0.9314419379243153" LOG_EFFECT_SIZE="-0.47063912719174217" ORDER="13" O_E="0.0" SE="0.5413557040700285" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.29306599832915625" WEIGHT="30.83031934121139"/>
<DICH_DATA CI_END="2.757295710997248" CI_START="0.5601517396510979" EFFECT_SIZE="1.2427807486631015" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4404833452742466" LOG_CI_START="-0.2516943109106583" LOG_EFFECT_SIZE="0.09439451718179412" ORDER="14" O_E="0.0" SE="0.40658858157767047" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.16531427466934198" WEIGHT="25.837750451260334"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7113661407608305" CI_END="1.5796395031948889" CI_START="0.5462872308682896" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9289439649249552" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.19855798591854523" LOG_CI_START="-0.2625789507361079" LOG_EFFECT_SIZE="-0.03201048240878132" METHOD="MH" MODIFIED="2009-03-25 22:41:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4249931066617445" P_Q="0.0" P_Z="0.7855394193783775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1187" TOTAL_2="1176" WEIGHT="100.0" Z="0.27210742693531">
<NAME>Toxicity - treatment related deaths</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1824548453378374" CI_START="0.38463289535665773" EFFECT_SIZE="0.9162117256112035" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.33894526698311644" LOG_CI_START="-0.4149535758933021" LOG_EFFECT_SIZE="-0.03800415445509281" ORDER="15" O_E="0.0" SE="0.4428439121650672" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.19611073054166173" WEIGHT="37.68488405901694"/>
<DICH_DATA CI_END="6.637188253379483" CI_START="0.5334897311796357" EFFECT_SIZE="1.881720430107527" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8219841358949339" LOG_CI_START="-0.27287393563021517" LOG_EFFECT_SIZE="0.27455510013235934" ORDER="16" O_E="0.0" SE="0.6431250508487334" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.41360983102918586" WEIGHT="12.885924667420516"/>
<DICH_DATA CI_END="1.564923120631141" CI_START="0.30446798791087365" EFFECT_SIZE="0.6902673350041771" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1944930069905945" LOG_CI_START="-0.5164583628160225" LOG_EFFECT_SIZE="-0.16098267791271398" ORDER="17" O_E="0.0" SE="0.4176163538904453" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.1744034190367497" WEIGHT="49.429191273562544"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1959665886253448" CI_END="1.8555530944964187" CI_START="1.2104314618763532" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4986726943400588" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="183" I2="6.131684521446586" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.26847338569472523" LOG_CI_START="0.08294020346664496" LOG_EFFECT_SIZE="0.1757067945806851" METHOD="MH" MODIFIED="2009-03-25 09:35:43 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3623866249801657" P_Q="0.0" P_Z="2.0537057758159095E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1254" TOTAL_2="1211" WEIGHT="99.99999999999999" Z="3.7123169567993206">
<NAME>Toxicity - treatment discontinuation</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0403037332337353" CI_START="0.71526129331579" EFFECT_SIZE="1.2080357142857143" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.30969482421433886" LOG_CI_START="-0.14553527635945607" LOG_EFFECT_SIZE="0.08207977392744137" ORDER="18" O_E="0.0" SE="0.2674044145023878" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.0715051208953648" WEIGHT="18.404062201806163"/>
<DICH_DATA CI_END="14.01948815981509" CI_START="0.5977038027008879" EFFECT_SIZE="2.8947368421052633" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.1467321581794505" LOG_CI_START="-0.22351398109662063" LOG_EFFECT_SIZE="0.4616090885414149" ORDER="19" O_E="0.0" SE="0.8048893650385456" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="67" TOTAL_2="35" VAR="0.6478468899521531" WEIGHT="1.6120738424901406"/>
<DICH_DATA CI_END="2.070413146229128" CI_START="0.35048636491951796" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.3160570165797203" LOG_CI_START="-0.45532887286250906" LOG_EFFECT_SIZE="-0.06963592814139442" ORDER="20" O_E="0.0" SE="0.45311588988010093" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.20531400966183574" WEIGHT="7.636139253900666"/>
<DICH_DATA CI_END="2.060270468907226" CI_START="1.2577745985243056" EFFECT_SIZE="1.609768884617065" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="141" LOG_CI_END="0.31392423757469357" LOG_CI_START="0.09960281965622625" LOG_EFFECT_SIZE="0.20676352861545994" ORDER="21" O_E="0.0" SE="0.12589346179343652" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.015849163722335458" WEIGHT="72.34772470180302"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.545379158915061" CI_END="1.9973906233958083" CI_START="1.3575050418691292" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6466535281721935" ESTIMABLE="YES" EVENTS_1="1027" EVENTS_2="892" I2="54.16613878030453" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.3004630067814156" LOG_CI_START="0.1327414512641074" LOG_EFFECT_SIZE="0.21660222902276147" METHOD="MH" MODIFIED="2009-03-25 09:36:22 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.08789010954353815" P_Q="0.0" P_Z="4.1412091209172613E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1254" TOTAL_2="1211" WEIGHT="100.00000000000001" Z="5.062349517881724">
<NAME>Toxicity - any adverse event (grade 3 or 4)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.832288739435178" CI_START="1.3887727080571506" EFFECT_SIZE="1.9832814481724894" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="294" LOG_CI_END="0.45213752569545135" LOG_CI_START="0.14263117322941896" LOG_EFFECT_SIZE="0.2973843494624352" ORDER="22" O_E="0.0" SE="0.18180556351970129" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.03305326292671614" WEIGHT="27.1315801537646"/>
<DICH_DATA CI_END="6.409869439924265" CI_START="1.1240456950195878" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" LOG_CI_END="0.8068491836377082" LOG_CI_START="0.05078396665250654" LOG_EFFECT_SIZE="0.4288165751451074" ORDER="23" O_E="0.0" SE="0.4441164510402911" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="67" TOTAL_2="35" VAR="0.1972394220846233" WEIGHT="3.6827840117561745"/>
<DICH_DATA CI_END="5.578567715241958" CI_START="1.3194962536179915" EFFECT_SIZE="2.713097713097713" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="74" LOG_CI_END="0.746522709114472" LOG_CI_START="0.12040816148646397" LOG_EFFECT_SIZE="0.433465435300468" ORDER="24" O_E="0.0" SE="0.36778278459368785" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.135264176643487" WEIGHT="5.827036544916842"/>
<DICH_DATA CI_END="1.7336295361694587" CI_START="1.0421138185393208" EFFECT_SIZE="1.344112828549042" ESTIMABLE="YES" EVENTS_1="555" EVENTS_2="505" LOG_CI_END="0.2389562975308089" LOG_CI_START="0.017915154725578503" LOG_EFFECT_SIZE="0.12843572612819373" ORDER="25" O_E="0.0" SE="0.1298406614550958" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.0168585973670968" WEIGHT="63.35859928956239"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.772604393935895" CI_END="7.896698453570117" CI_START="2.9858527412046056" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.855757276065033" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.8974455541899723" LOG_CI_START="0.47506838501684107" LOG_EFFECT_SIZE="0.6862569696034067" METHOD="MH" MODIFIED="2009-03-25 09:36:55 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6209147203789376" P_Q="0.0" P_Z="1.9038887052874228E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1254" TOTAL_2="1211" WEIGHT="100.0" Z="6.36889984937111">
<NAME>Toxicity - hypertension (grade 3 or 4)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="22.7577765010219" CI_START="1.8069735824314033" EFFECT_SIZE="6.412698412698413" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.3571298279994528" LOG_CI_START="0.2569518033145938" LOG_EFFECT_SIZE="0.8070408156570232" ORDER="4" O_E="0.0" SE="0.6462500176689399" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.41763908533710514" WEIGHT="13.144433558512757"/>
<DICH_DATA CI_END="11.021839599134767" CI_START="2.54521906884707" EFFECT_SIZE="5.296507936507936" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="9" LOG_CI_END="1.0422540864465242" LOG_CI_START="0.40572516832186234" LOG_EFFECT_SIZE="0.7239896273841933" ORDER="26" O_E="0.0" SE="0.3739002373753876" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.13980138750937118" WEIGHT="42.42823490406016"/>
<DICH_DATA CI_END="252.9408291444898" CI_START="0.825651063532492" EFFECT_SIZE="14.451327433628318" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.4030189378495694" LOG_CI_START="-0.08320345534307265" LOG_EFFECT_SIZE="1.1599077412532484" ORDER="27" O_E="0.0" SE="1.460419340760689" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="67" TOTAL_2="35" VAR="2.132824650867885" WEIGHT="2.890391124759959"/>
<DICH_DATA CI_END="7.219655737342714" CI_START="1.4586428775101052" EFFECT_SIZE="3.245134730538922" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" LOG_CI_END="0.8585164891296135" LOG_CI_START="0.1639489757101415" LOG_EFFECT_SIZE="0.5112327324198777" ORDER="29" O_E="0.0" SE="0.4079923955472394" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.16645779482437503" WEIGHT="41.536940412667114"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8173639578300758" CI_END="2.0806749253345203" CI_START="0.5501822224134877" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0699300699300698" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" I2="44.97524859060178" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.31820423342578014" LOG_CI_START="-0.25949344672070634" LOG_EFFECT_SIZE="0.02935539335253693" METHOD="MH" MODIFIED="2009-03-25 09:39:03 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.17762752936482884" P_Q="0.0" P_Z="0.8421148981242623" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="139" WEIGHT="100.0" Z="0.19918900733127282">
<NAME>Toxicity - thrombembolic events (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="33.61720397452372" CI_START="0.4680473859863108" EFFECT_SIZE="3.966666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.5265615892660844" LOG_CI_START="-0.32971017592034785" LOG_EFFECT_SIZE="0.5984257066728683" MODIFIED="2009-03-25 09:39:03 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="1.0903832235639412" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="67" TOTAL_2="35" VAR="1.1889355742296916" WEIGHT="6.993006993006993"/>
<DICH_DATA CI_END="1.7686006271846408" CI_START="0.4105653254961673" EFFECT_SIZE="0.8521303258145363" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.2476297746895065" LOG_CI_START="-0.3866177319784928" LOG_EFFECT_SIZE="-0.06949397864449314" ORDER="31" O_E="0.0" SE="0.37256012499257524" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.1388010467344833" WEIGHT="93.006993006993"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.43636220843651014" CI_END="3.705954349531324" CI_START="1.1370075843460765" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.052729451890201" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.5689000653151103" LOG_CI_START="0.05576336163466896" LOG_EFFECT_SIZE="0.3123317134748896" METHOD="MH" MODIFIED="2009-03-25 09:40:15 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8039799486551005" P_Q="0.0" P_Z="0.017035130035338953" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1187" TOTAL_2="1176" WEIGHT="99.99999999999999" Z="2.3859486380521804">
<NAME>Toxicity - arterial thrombembolic event (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.595909506536902" CI_START="0.9470477019859858" EFFECT_SIZE="2.6821052631578945" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8805797821516341" LOG_CI_START="-0.023628145402704213" LOG_EFFECT_SIZE="0.428475818374465" ORDER="32" O_E="0.0" SE="0.5311362125468462" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.2821056762786086" WEIGHT="29.609261266217374"/>
<DICH_DATA CI_END="6.059997175359121" CI_START="0.6327908533215651" EFFECT_SIZE="1.9582417582417582" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7824724217362148" LOG_CI_START="-0.19873980697669" LOG_EFFECT_SIZE="0.2918663073797624" ORDER="33" O_E="0.0" SE="0.5763689202248263" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.33220113220113223" WEIGHT="27.458846651552722"/>
<DICH_DATA CI_END="4.290871738317003" CI_START="0.6570600385143262" EFFECT_SIZE="1.679095098449937" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6325455329028206" LOG_CI_START="-0.18239494519795107" LOG_EFFECT_SIZE="0.22507529385243472" ORDER="34" O_E="0.0" SE="0.47870007085681965" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.22915375783832417" WEIGHT="42.93189208222989"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8398077739182095" CI_END="7.397895009005954" CI_START="0.6942215913254028" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.266225594597848" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.8691081635118274" LOG_CI_START="-0.15850188324936812" LOG_EFFECT_SIZE="0.35530314013122966" METHOD="MH" MODIFIED="2009-03-25 09:44:16 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.3985573977763285" P_Q="0.0" P_Z="0.17530872465345088" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1187" TOTAL_2="1176" WEIGHT="100.0" Z="1.3553416696266087">
<NAME>Toxicity - proteinuria (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.03604051613051" CI_START="0.20266278859256875" EFFECT_SIZE="1.0102564102564102" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.70208921545114" LOG_CI_START="-0.6932259858529902" LOG_EFFECT_SIZE="0.0044316147990749" ORDER="35" O_E="0.0" SE="0.8196150561676859" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.671768840296759" WEIGHT="75.01301238746143"/>
<DICH_DATA CI_END="78.25728596216754" CI_START="0.1268539943576022" EFFECT_SIZE="3.150753768844221" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8935247820761212" LOG_CI_START="-0.8966958532341016" LOG_EFFECT_SIZE="0.4984144644210098" ORDER="36" O_E="0.0" SE="1.6389894129961238" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="2.6862862959133786" WEIGHT="12.23217541846404"/>
<DICH_DATA CI_END="163.84619869513676" CI_START="0.4731207435957839" EFFECT_SIZE="8.804489500362056" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.214436370009657" LOG_CI_START="-0.325028010244209" LOG_EFFECT_SIZE="0.9447041798827241" ORDER="37" O_E="0.0" SE="1.4916939475125386" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="2.2251508330455403" WEIGHT="12.754812194074534"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.679951624205848" CI_END="2.6230811350579604" CI_START="0.8706891737862559" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.511253898674187" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.4188117240493706" LOG_CI_START="-0.06013685555670701" LOG_EFFECT_SIZE="0.1793374342463318" METHOD="MH" MODIFIED="2009-03-25 09:44:17 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8779091055240121" P_Q="0.0" P_Z="0.1421647416949125" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1254" TOTAL_2="1211" WEIGHT="100.0" Z="1.4677772402696154">
<NAME>Toxicity - bleeding (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.854769481535562" CI_START="0.520431320648611" EFFECT_SIZE="1.2188976377952756" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4555710453528096" LOG_CI_START="-0.2836365745709757" LOG_EFFECT_SIZE="0.08596723539091693" ORDER="38" O_E="0.0" SE="0.43421421507996394" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="0.1885419845775092" WEIGHT="45.88982178686731"/>
<DICH_DATA CI_END="76.71822830203465" CI_START="0.19347942676370458" EFFECT_SIZE="3.852713178294574" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.88489856486732" LOG_CI_START="-0.7133652079991536" LOG_EFFECT_SIZE="0.5857666784340831" ORDER="39" O_E="0.0" SE="1.5262330017948718" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="67" TOTAL_2="35" VAR="2.329387175767785" WEIGHT="2.9506307656342416"/>
<DICH_DATA CI_END="7.618490963514761" CI_START="0.4121203684832754" EFFECT_SIZE="1.7719298245614035" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8818689567568914" LOG_CI_START="-0.38497592053658886" LOG_EFFECT_SIZE="0.24844651811015117" ORDER="40" O_E="0.0" SE="0.7441509519054699" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="0.553760639221817" WEIGHT="13.2933114293052"/>
<DICH_DATA CI_END="3.8648022303806617" CI_START="0.6554459729766406" EFFECT_SIZE="1.5915932452276065" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5871272751102514" LOG_CI_START="-0.18346310047293743" LOG_EFFECT_SIZE="0.201832087318657" ORDER="41" O_E="0.0" SE="0.45264860110144345" STUDY_ID="STD-Saltz-2008" TOTAL_1="694" TOTAL_2="675" VAR="0.20489075607909366" WEIGHT="37.86623601819324"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1893089449149809" CI_END="49.56787891923325" CI_START="1.690588331843065" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="9.154172695283041" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="1.6952003352178084" LOG_CI_START="0.22803786722234964" LOG_EFFECT_SIZE="0.9616191012200791" METHOD="MH" MODIFIED="2009-03-25 09:44:17 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.9096872606747626" P_Q="0.0" P_Z="0.010192482733792906" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="560" TOTAL_2="536" WEIGHT="100.00000000000001" Z="2.569229851977055">
<NAME>Toxicity - gastrointestinal perforation</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="237.52437343653293" CI_START="0.7487026594361639" EFFECT_SIZE="13.335483870967742" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.375708181143508" LOG_CI_START="-0.12569062422951457" LOG_EFFECT_SIZE="1.1250087784569969" ORDER="42" O_E="0.0" SE="1.4693340403998965" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="393" TOTAL_2="397" VAR="2.1589425222778846" WEIGHT="31.58289908020104"/>
<DICH_DATA CI_END="158.77445651264384" CI_START="0.4879191234074579" EFFECT_SIZE="8.801652892561984" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.2007806348171033" LOG_CI_START="-0.3116521599004904" LOG_EFFECT_SIZE="0.9445642374583065" ORDER="43" O_E="0.0" SE="1.4758154603600258" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="67" TOTAL_2="35" VAR="2.178031273037675" WEIGHT="37.55151842002266"/>
<DICH_DATA CI_END="111.8749247060598" CI_START="0.2515170163583786" EFFECT_SIZE="5.304568527918781" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0487327560356667" LOG_CI_START="-0.5994326274647072" LOG_EFFECT_SIZE="0.7246500642854798" ORDER="44" O_E="0.0" SE="1.5555454548981813" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="100" TOTAL_2="104" VAR="2.41972166225439" WEIGHT="30.865582499776306"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-03-25 14:53:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Second-line CTX with versus without Bevacizumab</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.7319644370707021" CI_START="0.5083542913556687" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.6099977563111423" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.13551001888579575" LOG_CI_START="-0.2938335059237589" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21467176240477734" MODIFIED="2009-03-25 14:52:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0662584043536638E-7" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="280" TOTAL_2="279" WEIGHT="100.0" Z="5.31505376344086">
<NAME>Progression Free Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.7319644370707021" CI_START="0.5083542913556687" EFFECT_SIZE="0.6099977563111423" ESTIMABLE="YES" ESTIMATE="-0.4943" LOG_CI_END="-0.13551001888579575" LOG_CI_START="-0.2938335059237589" LOG_EFFECT_SIZE="-0.21467176240477734" ORDER="45" SE="0.09300000000000001" STUDY_ID="STD-Giantonio-2007" TOTAL_1="280" TOTAL_2="279" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.891341923177532" CI_START="0.6310483297640086" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.04995566648633671" LOG_CI_START="-0.19993737840079437" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2009-03-25 14:53:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0010922962721707417" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="286" TOTAL_2="291" WEIGHT="100.0" Z="3.2656072644721905">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.891341923177532" CI_START="0.6310483297640086" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.04995566648633671" LOG_CI_START="-0.19993737840079437" LOG_EFFECT_SIZE="-0.12494652244356551" ORDER="46" SE="0.08810000000000001" STUDY_ID="STD-Giantonio-2007" TOTAL_1="286" TOTAL_2="291" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.760359194717415" CI_START="1.732835274991134" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.872093023255814" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.6776397238125467" LOG_CI_START="0.2387572802196496" LOG_EFFECT_SIZE="0.458198502016098" METHOD="MH" MODIFIED="2009-03-25 09:07:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="4.268365013448268E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="237" TOTAL_2="215" WEIGHT="100.0" Z="4.092451520137726">
<NAME>Tumour Response</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.760359194717415" CI_START="1.732835274991134" EFFECT_SIZE="2.872093023255814" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="25" LOG_CI_END="0.6776397238125467" LOG_CI_START="0.2387572802196496" LOG_EFFECT_SIZE="0.458198502016098" ORDER="47" O_E="0.0" SE="0.2578017198696012" STUDY_ID="STD-Giantonio-2007" TOTAL_1="237" TOTAL_2="215" VAR="0.06646172676772433" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8636602859073337" CI_START="0.5698033995230333" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2773892773892774" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.45692149662933423" LOG_CI_START="-0.24427496403004442" LOG_EFFECT_SIZE="0.10632326629964492" METHOD="MH" MODIFIED="2009-03-25 09:46:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.5522557031692465" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="0.59438341280275">
<NAME>Toxicity -60- day mortality</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8636602859073337" CI_START="0.5698033995230333" EFFECT_SIZE="1.2773892773892774" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.45692149662933423" LOG_CI_START="-0.24427496403004442" LOG_EFFECT_SIZE="0.10632326629964492" ORDER="49" O_E="0.0" SE="0.4118862719697785" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.16965030103716233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="73.69370871397975" CI_START="0.12127605703322221" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.9895287958115184" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.8674304134027784" LOG_CI_START="-0.9162249314065369" LOG_EFFECT_SIZE="0.4756027409981205" METHOD="MH" MODIFIED="2009-03-25 09:47:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.5030228294187666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="0.6697411337528227">
<NAME>Toxicity - treatment related deaths</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.69370871397975" CI_START="0.12127605703322221" EFFECT_SIZE="2.9895287958115184" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8674304134027784" LOG_CI_START="-0.9162249314065369" LOG_EFFECT_SIZE="0.4756027409981205" ORDER="48" O_E="0.0" SE="1.6351329288571785" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="2.673659695033055" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4296765700837648" CI_START="0.6606448991436698" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9718582887700534" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.15523779990213477" LOG_CI_START="-0.18003191386030806" LOG_EFFECT_SIZE="-0.012397056979086633" METHOD="MH" MODIFIED="2009-03-25 09:47:59 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.884754528175752" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="0.14494470687869562">
<NAME>Toxicity - treatment discontinuation</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4296765700837648" CI_START="0.6606448991436698" EFFECT_SIZE="0.9718582887700534" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="68" LOG_CI_END="0.15523779990213477" LOG_CI_START="-0.18003191386030806" LOG_EFFECT_SIZE="-0.012397056979086633" ORDER="50" O_E="0.0" SE="0.1969390894759079" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.038785004963599656" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.682656537940027E-31" CI_END="2.777764696713201" CI_START="1.3559473036440834" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9407479358912092" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="174" I2="100.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.4436954540555984" LOG_CI_START="0.13224281181622827" LOG_EFFECT_SIZE="0.2879691329359133" METHOD="MH" MODIFIED="2009-03-25 09:48:45 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="2.896715481521031E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="3.6243656509411455">
<NAME>Toxicity - any adverse event (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.777764696713201" CI_START="1.3559473036440837" EFFECT_SIZE="1.9407479358912094" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="174" LOG_CI_END="0.4436954540555984" LOG_CI_START="0.13224281181622832" LOG_EFFECT_SIZE="0.28796913293591336" ORDER="51" O_E="0.0" SE="0.18294882376684954" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.03347027211767377" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.875778826781864E-31" CI_END="10.235411537157958" CI_START="1.3718644279108447" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.7472118959107803" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="100.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="1.0101053091112426" LOG_CI_START="0.1373111951029543" LOG_EFFECT_SIZE="0.5737082521070984" METHOD="MH" MODIFIED="2009-03-25 09:49:17 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.009975958009203747" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="2.5766615372767294">
<NAME>Toxicity - hypertension (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.235411537157958" CI_START="1.371864427910845" EFFECT_SIZE="3.7472118959107807" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="1.0101053091112426" LOG_CI_START="0.1373111951029544" LOG_EFFECT_SIZE="0.5737082521070984" ORDER="52" O_E="0.0" SE="0.5126835829690114" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.2628444562459432" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8205206351638163" CI_START="0.5380361098592495" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4337287261474987" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.5821225497105872" LOG_CI_START="-0.26918857603184554" LOG_EFFECT_SIZE="0.15646698683937088" METHOD="MH" MODIFIED="2009-03-25 09:49:48 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.4712391464569804" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="0.7204643512845469">
<NAME>Toxicity - thromboembolic event (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.820520635163818" CI_START="0.5380361098592494" EFFECT_SIZE="1.4337287261474987" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5821225497105874" LOG_CI_START="-0.2691885760318456" LOG_EFFECT_SIZE="0.15646698683937088" ORDER="53" O_E="0.0" SE="0.500064369319141" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.2500643734625502" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="36.13648257583404" CI_START="0.4459004538939234" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.014134275618375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="1.5579458772716914" LOG_CI_START="-0.35076208557027166" LOG_EFFECT_SIZE="0.6035918958507098" METHOD="MH" MODIFIED="2009-03-25 09:50:12 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.21512294614530258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="1.2396012383855644">
<NAME>Toxicity - arterial thromboembolic event (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.13648257583404" CI_START="0.4459004538939234" EFFECT_SIZE="4.014134275618375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5579458772716914" LOG_CI_START="-0.35076208557027166" LOG_EFFECT_SIZE="0.6035918958507098" ORDER="54" O_E="0.0" SE="1.1211845056301648" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="1.2570546956651572" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="104.60895764931949" CI_START="0.23898527011240725" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="2.0195688746947775" LOG_CI_START="-0.6216288660227404" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2009-03-25 09:50:43 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.29956121658171164" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="1.0373748346462197">
<NAME>Toxicity - proteinuria (gade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="104.60895764931959" CI_START="0.23898527011240714" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.019568874694778" LOG_CI_START="-0.6216288660227406" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="55" O_E="0.0" SE="1.551452627037144" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="2.4070052539404556" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="80.62605704207554" CI_START="1.3037722121435458" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="10.252707581227437" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="1.9064754214669677" LOG_CI_START="0.11520172049821058" LOG_EFFECT_SIZE="1.0108385709825891" METHOD="MH" MODIFIED="2009-03-25 09:51:05 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.026962153702834307" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="2.212065294363818">
<NAME>Toxicity - bleeding (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="80.62605704207562" CI_START="1.3037722121435453" EFFECT_SIZE="10.252707581227437" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.906475421466968" LOG_CI_START="0.11520172049821044" LOG_EFFECT_SIZE="1.0108385709825891" ORDER="56" O_E="0.0" SE="1.0522030388968722" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="1.1071312350638125" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="136.61287864671382" CI_START="0.3612036423324707" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="7.024604569420035" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="2.1354916426951394" LOG_CI_START="-0.44224787896507195" LOG_EFFECT_SIZE="0.8466218818650336" METHOD="MH" MODIFIED="2009-03-25 09:51:37 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.1979393720033387" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="285" WEIGHT="100.0" Z="1.2874445870390159">
<NAME>Toxicity - gastrointestinal perforation</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with bev</GRAPH_LABEL_2>
<DICH_DATA CI_END="136.61287864671382" CI_START="0.3612036423324707" EFFECT_SIZE="7.024604569420035" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1354916426951394" LOG_CI_START="-0.44224787896507195" LOG_EFFECT_SIZE="0.8466218818650336" ORDER="57" O_E="0.0" SE="1.5141769550396313" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="2.29273185117309" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-03-26 10:26:22 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>First-line CTX with versus without Vatalanib (PTK 787/ZK 222584)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0227156041423022" CI_START="0.7745589979422007" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.009754882272204498" LOG_CI_START="-0.11094549655566215" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-03-25 14:53:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.10034996184890788" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="585" TOTAL_2="583" WEIGHT="100.0" Z="1.6431593794076162">
<NAME>Progression Free Survival</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="1.0227156041423022" CI_START="0.7745589979422007" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="0.009754882272204498" LOG_CI_START="-0.11094549655566215" LOG_EFFECT_SIZE="-0.050595307141728815" ORDER="58" SE="0.0709" STUDY_ID="STD-Hecht-2007" TOTAL_1="585" TOTAL_2="583" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.2405681419872725" CI_START="0.9402876370094687" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.09362062421184073" LOG_CI_START="-0.02673927399873993" LOG_DATA="YES" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-03-25 14:53:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.2761058776967771" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="585" TOTAL_2="583" WEIGHT="100.0" Z="1.0891089108910892">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="1.2405681419872725" CI_START="0.9402876370094687" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.09362062421184073" LOG_CI_START="-0.02673927399873993" LOG_EFFECT_SIZE="0.03344067510655043" ORDER="59" SE="0.0707" STUDY_ID="STD-Hecht-2007" TOTAL_1="585" TOTAL_2="583" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2111714989641698" CI_START="0.7582189201671365" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9582970030641987" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="274" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.08320564254881055" LOG_CI_START="-0.12020538263490341" LOG_EFFECT_SIZE="-0.018499870043046415" METHOD="MH" MODIFIED="2009-03-26 10:19:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7214583213293214" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="562" TOTAL_2="560" WEIGHT="100.0" Z="0.3565104592565173">
<NAME>Tumour Response</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2111714989641698" CI_START="0.7582189201671365" EFFECT_SIZE="0.9582970030641987" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="274" LOG_CI_END="0.08320564254881055" LOG_CI_START="-0.12020538263490341" LOG_EFFECT_SIZE="-0.018499870043046415" MODIFIED="2009-03-26 10:19:40 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.11948464309372733" STUDY_ID="STD-Hecht-2007" TOTAL_1="562" TOTAL_2="560" VAR="0.014276579935235404" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.222217967417833" CI_START="0.44505053187892984" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7375288173836269" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.08714866384875858" LOG_CI_START="-0.351590675602769" LOG_EFFECT_SIZE="-0.1322210058770052" METHOD="MH" MODIFIED="2009-03-26 10:26:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.2374708828774379" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="1.1813319947217547">
<NAME>Toxicity - 28-day mortality</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.222217967417833" CI_START="0.44505053187892984" EFFECT_SIZE="0.7375288173836269" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" LOG_CI_END="0.08714866384875858" LOG_CI_START="-0.351590675602769" LOG_EFFECT_SIZE="-0.1322210058770052" MODIFIED="2009-03-26 10:24:32 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.25771765978858385" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="0.06641839216690426" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.793182925871226" CI_START="2.7357654080882865" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.981053811659193" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.7629172420226542" LOG_CI_START="0.4370788538884216" LOG_EFFECT_SIZE="0.599998047955538" METHOD="MH" MODIFIED="2009-03-26 10:26:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="5.270103391762273E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="7.218146219792465">
<NAME>Toxicity - hypertension (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat.</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.793182925871226" CI_START="2.7357654080882865" EFFECT_SIZE="3.981053811659193" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="40" LOG_CI_END="0.7629172420226542" LOG_CI_START="0.4370788538884216" LOG_EFFECT_SIZE="0.599998047955538" ORDER="61" O_E="0.0" SE="0.19139908211608245" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="0.03663360863487888" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.697982752634758" CI_START="0.8492160421578155" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5136612021857923" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.43103916903510936" LOG_CI_START="-0.07098181036707121" LOG_EFFECT_SIZE="0.18002867933401906" METHOD="MH" MODIFIED="2009-03-26 10:26:18 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.15980815894136594" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="1.4057170602677609">
<NAME>Toxicity - thromboembolic events (DVT) (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat.</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.697982752634758" CI_START="0.8492160421578155" EFFECT_SIZE="1.5136612021857923" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" LOG_CI_END="0.43103916903510936" LOG_CI_START="-0.07098181036707121" LOG_EFFECT_SIZE="0.18002867933401906" MODIFIED="2009-03-25 13:54:21 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.2948896083447672" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="0.08695988110973019" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7065047657531876E-31" CI_END="7.191352492475454" CI_START="1.7215215389177938" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.5185321100917437" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="10" I2="100.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.8568105767223204" LOG_CI_START="0.23591246077558967" LOG_EFFECT_SIZE="0.546361518748955" METHOD="MH" MODIFIED="2009-03-26 10:26:13 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="5.619281724206472E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="3.4493546421984305">
<NAME>Toxicity - thromboembolic events (pulmonary embolism) (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat.</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.191352492475454" CI_START="1.7215215389177936" EFFECT_SIZE="3.5185321100917433" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="10" LOG_CI_END="0.8568105767223204" LOG_CI_START="0.2359124607755896" LOG_EFFECT_SIZE="0.546361518748955" MODIFIED="2009-03-25 13:57:13 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.3647186268023523" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="0.13301967673659354" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.431689711304073" CI_START="0.5470582535047432" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3701584507042253" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.5355080126380573" LOG_CI_START="-0.2619664253509894" LOG_EFFECT_SIZE="0.13677079364353398" METHOD="MH" MODIFIED="2009-03-26 10:26:07 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.5014010390141461" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="0.6722869521793207">
<NAME>Toxicity - arterial thromboembolic events (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat.</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.431689711304073" CI_START="0.5470582535047432" EFFECT_SIZE="1.3701584507042253" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5355080126380573" LOG_CI_START="-0.2619664253509894" LOG_EFFECT_SIZE="0.13677079364353398" ORDER="62" O_E="0.0" SE="0.46844043243689953" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="0.21943643874166943" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6982410168418058" CI_START="0.4651355138180599" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8887700534759359" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.22999932598830428" LOG_CI_START="-0.3324205001651178" LOG_EFFECT_SIZE="-0.05121058708840677" METHOD="MH" MODIFIED="2009-03-26 10:26:03 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.721147799460392" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="0.35692520659130916">
<NAME>Toxicity - bleeding (grade 3 or 4)</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat.</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6982410168418058" CI_START="0.4651355138180599" EFFECT_SIZE="0.8887700534759359" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.22999932598830428" LOG_CI_START="-0.3324205001651178" LOG_EFFECT_SIZE="-0.05121058708840677" ORDER="63" O_E="0.0" SE="0.3303681899055598" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="0.109143140901476" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="103.83347149003698" CI_START="0.2382751345519539" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.974025974025974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="2.0163373741309427" LOG_CI_START="-0.6229212765386613" LOG_EFFECT_SIZE="0.6967080487961408" METHOD="MH" MODIFIED="2009-03-26 10:25:58 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.300772865655079" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="574" WEIGHT="100.0" Z="1.034777461491442">
<NAME>Toxicity - gastrointestional perforation</NAME>
<GROUP_LABEL_1>with Vatalanib</GROUP_LABEL_1>
<GROUP_LABEL_2>without Vatalanib</GROUP_LABEL_2>
<GRAPH_LABEL_1>decreased risk with vat.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>increased risk with vat.</GRAPH_LABEL_2>
<DICH_DATA CI_END="103.83347149003698" CI_START="0.238275134551954" EFFECT_SIZE="4.974025974025974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0163373741309427" LOG_CI_START="-0.622921276538661" LOG_EFFECT_SIZE="0.6967080487961408" MODIFIED="2009-03-25 13:59:16 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.5503135959443481" STUDY_ID="STD-Hecht-2007" TOTAL_1="579" TOTAL_2="574" VAR="2.403472245769896" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-03-25 21:34:34 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>First-line 5-FU/LV with versus without Bevacizumab</NAME>
<IV_OUTCOME CHI2="0.05027603055018656" CI_END="0.7019128668841039" CI_START="0.3743422981247909" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.5125969914784478" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.1537167963888299" LOG_CI_START="-0.4267310978005686" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.29022394709469923" MODIFIED="2009-03-25 14:48:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8225836555430325" P_Q="1.0" P_Z="3.0860290467029904E-5" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="141" WEIGHT="100.0" Z="4.167023345043059">
<NAME>Progression Free Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.9388513081762129" CI_START="0.310583703814025" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="-0.027403184253551392" LOG_CI_START="-0.5078213352440162" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-03-25 14:19:47 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SE="0.2822" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="68" TOTAL_2="36" WEIGHT="32.294753952994675"/>
<IV_DATA CI_END="0.7326383960038507" CI_START="0.3412646576493325" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.13511032463456848" LOG_CI_START="-0.4669086861797193" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-03-25 14:20:24 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SE="0.1949" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="104" TOTAL_2="105" WEIGHT="67.70524604700533"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.04895640081299571" CI_END="1.0865515032097268" CI_START="0.5943950405258172" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8036422243658762" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.03605031697008061" LOG_CI_START="-0.22592482287005244" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09493725294998587" MODIFIED="2009-03-25 14:48:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8248892675127485" P_Q="1.0" P_Z="0.15544939054422993" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="141" WEIGHT="100.0" Z="1.420543924027985">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="1.68416796123767" CI_START="0.4391687030590904" EFFECT_SIZE="0.8600196853970379" ESTIMABLE="YES" ESTIMATE="-0.1508" LOG_CI_END="0.22638540129736373" LOG_CI_START="-0.35736861703938444" LOG_EFFECT_SIZE="-0.06549160787101034" MODIFIED="2009-03-25 14:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="76" SE="0.3429" STUDY_ID="STD-Kabbinavar-2003" TOTAL_1="68" TOTAL_2="36" WEIGHT="20.140043094885158"/>
<IV_DATA CI_END="1.107168436676331" CI_START="0.5637153811909568" EFFECT_SIZE="0.7900176436786672" ESTIMABLE="YES" ESTIMATE="-0.2357" LOG_CI_END="0.04421369635700178" LOG_CI_START="-0.24894011512619466" LOG_EFFECT_SIZE="-0.10236320938459643" MODIFIED="2009-03-25 14:31:14 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SE="0.1722" STUDY_ID="STD-Kabbinavar-2005" TOTAL_1="104" TOTAL_2="105" WEIGHT="79.85995690511484"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-03-25 21:34:44 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>First-line IFL with versus without Bevacizumab</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.6539584126869914" CI_START="0.44588755334749014" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.18444986897669233" LOG_CI_START="-0.3507746505208752" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-03-25 14:49:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.8438113348616766E-10" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="411" WEIGHT="100.0" Z="6.30706243602866">
<NAME>Progression Free Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.6539584126869914" CI_START="0.44588755334749014" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="-0.18444986897669233" LOG_CI_START="-0.3507746505208752" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-03-25 14:16:41 +0100" MODIFIED_BY="[Empty name]" ORDER="70" SE="0.0977" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="402" TOTAL_2="411" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.8082856756313742" CI_START="0.5389350178041085" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.6600101930934101" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.09243511766238502" LOG_CI_START="-0.2684635967992172" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.18044935723080113" MODIFIED="2009-03-25 14:49:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.860082268163134E-5" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="411" WEIGHT="100.0" Z="4.018375241779497">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.8082856756313742" CI_START="0.5389350178041085" EFFECT_SIZE="0.6600101930934101" ESTIMABLE="YES" ESTIMATE="-0.4155" LOG_CI_END="-0.09243511766238502" LOG_CI_START="-0.2684635967992172" LOG_EFFECT_SIZE="-0.18044935723080113" MODIFIED="2009-03-25 14:33:32 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SE="0.1034" STUDY_ID="STD-Hurwitz-2004" TOTAL_1="402" TOTAL_2="411" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-03-25 21:34:52 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>First-line Oxaliplatin with versus without Bevacizumab</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.9369042163120472" CI_START="0.735337446499652" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.028304806607897717" LOG_CI_START="-0.13351331734925395" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2009-03-25 14:50:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0025734966689185896" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="699" TOTAL_2="701" WEIGHT="100.0" Z="3.0145631067961163">
<NAME>Progression Free Survival</NAME>
<GROUP_LABEL_1>with Bev</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="0.9369042163120472" CI_START="0.735337446499652" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.028304806607897717" LOG_CI_START="-0.13351331734925395" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2009-03-25 14:25:23 +0100" MODIFIED_BY="[Empty name]" ORDER="75" SE="0.0618" STUDY_ID="STD-Saltz-2008" TOTAL_1="699" TOTAL_2="701" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0165205376401043" CI_START="0.7792794579077884" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.007116157488238431" LOG_CI_START="-0.10830677177169605" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-03-25 14:50:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.08574389917200377" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="699" TOTAL_2="701" WEIGHT="100.0" Z="1.718289085545723">
<NAME>Overall Survival</NAME>
<GROUP_LABEL_1>with Bev.</GROUP_LABEL_1>
<GROUP_LABEL_2>without Bev.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours with bev</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours without bev</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="1.0165205376401043" CI_START="0.7792794579077884" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="0.007116157488238431" LOG_CI_START="-0.10830677177169605" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-03-25 14:37:24 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.0678" STUDY_ID="STD-Saltz-2008" TOTAL_1="699" TOTAL_2="701" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-04-06 09:33:05 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="flowchart.bmp.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-03-25 15:25:28 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flowchart of the search process</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoAAAAIACAIAAACdH0qsAAAhfklEQVR42u3dy5HbSBZAUalCC0Uv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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-04-06 09:33:05 +0200" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 First-line CTX with versus without Bevacizumab, outcome: 1.1 Progression Free Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAACwCAMAAABzaNKeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-03-25 23:20:46 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 First-line CTX with versus without Bevacizumab, outcome: 1.2 Overall Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvIAAACwCAMAAABaSnowAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAARhElEQVR42u1dy67sthHUPRi44Z0Bw94F+SHu8p3Oij8UOIsggAGv
bLQ3ycxIovhoUnzpNaqy7zlzJLL5UKnZ5JSobzQAwJ3whS4AQHkAAOUB4FPwuFuD1aAHpd+/5gMv
6LrMzkldaq57w14/DqvAVSp6O8rrmZXuIaUrM1tXstjchk1U+iLXYv+K3oTyi3tWxiH7vvp1Rs8u
KCvzO8d4enHzq+YAxPJ7sV4Z36JHgiqP2Drqw8XMTg49BPdJ3ByAWP6YUdX2x/PR50ib4ZV18t4q
Ntfrpg4rcFLvc2RFb0R5rVZCSlWTuc7cptOU048ux1b0JoHN2Lkr/lY/UZ0539xuzb3MdQHlDxxx
1TwdLbsSqq85AJTvG737rkW9qalHhhZknnLocanGnMgyBzd/WEW/QVYGwMsDACgPAKA8AIDyAADK
AwAoDwBHwhYcTF8CB4rA+OrynGM95SqCzMoSIs7SapWlyXC+zNZ5ya1WNLYnz9ykSLB1lraEX3t5
B0uQYs6+yxEr6T4NoJe085cIy6muXx5coY425dWkDlFlNN1O8azdz8+Csuq21EpnFqM8jVljrSvN
afnmsRJM0h1t59CrfaGUSWf333Kq6zU7fx0fwgUbRvXf/M/6Ye66wWmTSWk98aLtpFMCNaRlheZ2
b1cf6koXpYyqWPfweHFzs2tRQicN89CmcsYo62INEXm+CkcdNehhP4nnmeroxPJqqpB26upWa6q1
tnI4w7WyAhEdqMZV6gvmKbEqkS3KhlTddRlH1NfPdq17jrn50RLTSabpas5bXGKk+9Q5ZD5nqOOX
6xjDQseLJodTQQ695mMzr6EOukHlK1aWWqnKTuysAysypxP95F+IqXmBnEe6VOPwvT2xzl/HRxjU
FLZv2PTpxRpptamVbnBGqq9vUxlT3urobY4DlRRaWwnfSxNK7+rvz1fHhzTSlpJ+n74rmMc01qqz
BFIyp0e55eT6dGsBg4qYOeJRlZPX8SsaAav1ZSIrh3K8lYo5MpXdPztH8oczQuU0fV5PUIM4wzIB
nRXauYGV0u5QuEFXnb6OX27IOSm9LQ24DqJSLeXQy+il3UqHCZIxrw4KLXXd2gT+RbH8UnqXWL7A
3NKrbtMLxyqp+/S8Wqv8jXuOEfSfoY55evmiclV0H4s8MyqxTvnh+2OozC1AckK8o3eyOW0dH1mE
LyKablzVNvnV6pczn4bMrgPjt/fyAAAAQBv+cVC5D3h54CAcRD2Ih4GbAZQHQHkAAOUB4GNgr8sz
LT8DPA/bZ3icfbi/oplzwdacxq4Nj5Md9uc8VnqTsKU+LLWpoTl2h4pVCcoyLSUxh5PQbenzd2DG
sRHkfZ/kzWaRf42/vjsz5Qum10zmJlh+jT3dSBG2LtpikMQ5vpWehWoV14clG0038FIHTjTYLouM
f5EYT/Z95OYUzDilBnnHk8TDzfBIXgnjbF4XgKcOpGG39SUmXvOTTkLx9qwD9W4CpwupGJUoWtMs
M7wJ25cvyP/pHziJWOSR3ymj20n1ZsdOHE1RbPzPI2hhfTpzwGkCrQ0IFEQfeVnkwGTusFSLtnFb
evXAqSjPQacQT/9VepJOmMaa/FijS4S6SwtnP2LCk9en1/DK6Ua4YWWkwyK9yYd9DXQ6ytOwGv+m
nXyfiWtgKs9TujkiXNiP4VxUXe8DDcNKC5J9kh4oOkxTPi6Wz7mOouOv70rqZ6raiJe8tfys0qMp
ukRZfCS3v7sY5dkK4GNrB0WjaVUk4xaWbdwJEirLbG4K1TC+U//VdcCdvfwYSspOY55I8hjqv//s
FRxOdoLLFCsmSN+jPrPRYYeI1+1GpqXmU0Af7SCppYIZ6waInb0doJf/ECRXcA+fpEs46iEWCA4+
hvO7ZrvP9BU4K6jq1B0jHHh5AJQHAFAeAEB5ALj+9NXTy7tfAOWJ8yQVfcEqsKR/n4TyoqVQAt5B
8t5PL59tLnhOoFUvL142llR6fLsJbLBiw0VaxTBvoKIvUHQE+nf7UQbBUigB7yB576eXzzYXPCfQ
rpcXVPosVgl6edtJOvrURT8/eYfp2PSVHkdV9FRHFM4eWsJCmpna0fFRhlXao7L9HykYwttqDd+G
4X/z51/2vRAxyhtJfOipZ+fjOhPaRphHwohffl2rr+EWPc1D2XMbTTJp4cEU2qqFJab+spIf9e3r
Q4hqyG0LeY2bfr49O/nNlgWW1NCdgYIm69J78VFhKNJViMIZUmBfLb2qlyfOURjv1MJ8nEFd+fB8
Q4ZkXg4Qk7zNkBSK3U/RkFcuRCJOpdfqN3bR/HhLZuQ/1yHJZl6emombSc/L7iqb9x4RIedR4ERv
C5+Lgu+Ngja2YrMrfZluL6bM81Nu7weGejjElzBgmnWDqCPnYTAq+jXGN165ooRENCyMP8VaBBcx
fm5A68Aymulk7cNXbF5MngOCaYHG123b8YIbO4gq+oKQcUX/ntDLewJxpx6ldNnkGYCVeQj74V+b
Xj4xT+DuTzlcDdDLfwigl68NbIDLcn7XbJ8U2ADXBPTy8PIAAMoDACgPgPIAcJ/p63Z6+Wy1X0QO
PprgYLrl6+vnFJWSd2eP+g7blXlb3qcW5kv3l/daGtlf3u0AlsT00Mv318sX0C4uBzf6AZbTW/uA
c7XknV2jrct3njnKaXf2/vJuS8cjkhmb517N9t1f/vWChe9OSfn+evkqX+m9GIDWjLma2/JtW10b
XeCa4zJZWWNaptBV2V3EG7TXv9c9fAtO/FJ1lbpTfgu9fI830ISvgYmMQQ3BCPW9A6iqFwr2l6ec
Dgs3Na71CNUtX7y8e+KD9fKVGlW2rhkNlTtnn0dHuO4XrGQZ+8unfarrtIAo5TfRy+c+3BN7jJCP
UQN2pkr6G1AjzsvfX97PKZZ2Irp/d07Kn0kvX/fiEqZuTn5PrTmVzyyYzkbqq+CsenlnuOG63E2U
7aw157yT3Mcsg9j5KzYn0cvn7V8fFYjPW7TUzJw7y8hzeqFif3mpsjE1PdN2AdsFAb38hwB6+drA
Brgs53fN9kmBDXBNQC8PLw8A8PLAsfjL+nzcOj28PIDABgBuE9i4mm7vC+/WveMzlw9EtX5Mcx7R
1wdi8qLSOzXNr4S4GBicNIU37S8vdwD2lw8ob21tJ1ycxr3js1gS7C+f1pzH9PWhmLyg9F5N8yrB
qQYLW7837S8vdgD2l09MXxfp6SJ22tcXhJLubAY2aQ2ocyv8BslFbrH1u7BnGW/Z1pxR75vz5y8H
jS9f4hWY7n16KU0OETL6umUe7wBedUnMDYxn3orx0T5kP1jjwv3lcxl/ePzyYpLz5z8OqpHt5Wnq
fsrvxp22NWSzYfUKEZz5R2ntTOZaNVt1w/wD+fvLJ2u52gG3FNw8gvCThAdMM4LvfhPXqNPPKIha
ajc/+zJShfd4LJQSw1vO/vLpWt51B/nC6esgTKh2cAmbBdHtQdUhlch9DpFayr7n7fAVdbrn6x/e
s5RrLGTwcffkR3h5E8svoyVbi7htWvgslxXRv2fvL++mKKzdNk3LEcovFMzWy2ftLx/Ry8+Hh3tu
MA+9/IcAevnGwAa4HufPHC2edsUGuC6gl4eXBwBQHgBAeQCUBwBQHgBAeQAA5QEAlAcAUB4AQHkA
AOUBAJQHAFAeAEB5AADlAQCUB47Az9+D8sCd8NMfv38PygM38vH//m34/ecz1MR6EFC9f5pncJen
cdV08HlEjSneSbV6fTbJxlPPtEc9xtsANTdKm15Qdl/Um5u6SjLnp9JON9pd6/Sw80nNv+wixCYE
ma2C9mD8r6+fv/7w56m8vNbjP/sG8HpcvRKMF/Gd2r2AM1/U9Ri/NEC/W2Y3p8nc1FWCOTvVcnr+
pMUbyUtkWdRugUETgsxzc3fy8W/GDz+ewc8/5Cv28uDK902B27fGgveh8bNWV2S81c5XW3Qnc1NX
6UiqpB2dV1JsnDnRYPvTHy++/zb89uMJ/PxXxJnocWR1/ISdSKmqS3FOiORQ1S5QD0JXBeb0VhXv
0YT+cfwwjP+O9/Nf6R6NMXu8FdQq+a/F+JEhs2OuDWw8c5Md39waW1Ndqycy6+RkoqEJH71G8rU+
DwvvgSnif44B6lTjZ49JbGdzus5kumtbJhoJP7YZ/vPDK64Z//3tvyeM5VMc0BecnBYyvhfxDwwq
0kUfcA3//Pu/nnH8M5Y/AeMLxxylXDexzLDGQEddn/F2S3vcQKrAnJ0qOnldMbWclop+/qFall9b
/Pwrlj8B4wUvr9V7jez5S2u7u97L8FMMqaxlNOVk6zYzO2jlRg9hc1rMLb0pmgtOS10bVEm0Fhx0
DriZdZcGlvr5czC+ZOfh3JFafVB4/wmzkPRi525X6/vfPcZfYOdh3T0h0HWEqmP8fn7+FD4e+8sD
x92l2F8eAEB5AADlAQCUBwBMX4EqtL6qdsPkjW9xs7LDywM3Q/h274bXeQuvYGfzcvYxwfRqWS/J
dMi8YlZ4Mb2Xy0ozvQc7qKyTxBxg+z2rLOYjuyp4J/wnU74ZJI4nFmNofMVuJNuUmAWWSX+b28i5
q8Qk1gGy00m1YbcqTGD8HSg/+sP3FZ/eD20+vhzf6HanE5Zjfv3FJv1MQ2LbXwavrF5hFE8voqaV
mys5+PjDgLHGA/gc3O975eYdq7ZG+cUfzq5y+Thy3zthPCpN9HKYRFbMw3OcMvjhTDxWWu4age3u
vSAm8e4WpmVcEWpD3HXedC187vQ1QnnO6wqbFGFFSAwFyP3t3RGW1xXKZqksxz+bmJzK+o0SF5rH
oueBC/jIwGae5FnM47xxhns4lpFg2dmcOUK3kZ2cqpA8KQc+LpbPIFNBbC0QRgxAVn10RlHJJDHm
emHWPCGWAx3gU1dsEmuVLIfRZAXL9keJaJRVkDeC0Dp5S2+9IBcNA993XZL2zE07Vs3OLlKezGo6
LXPL6eM05BN7Icn8l7V0OPjJhkRhr0mlKWGJ7yPBzmI3uobomBlvHbMwv8poY3+s1n1uAOtCFtDM
yZWbrcitcD3p/SpVCQ7W1hW7MIS36Lnh1k68pHNKusn7liSXibTPRfPzPVrvma0Ynz9k7brYhRin
U++WzZGo7S5uozxtWb0qMxUxIWi/fWC0D0sqqvTAVQI6DojbRY3VZv0qQUkJHB4O7VslUB64xKyn
X21AeaAjx/h8jA+qZC1SsjgQGP0tlVXQl3v5q9uerIZiUw5rgdyd6yf08a7u3raA9Zqsud6kHcy+
5stXIAXr5yXXoqg2K9PXb7RSC/+5kSrKS8+OUKLccHmYbVU9U04eT37PoqoeuB2kwIaZzS+eZGY8
H+b5gYvx7OCdmfK6tp5n7JOzXY7eaVTkEbi3TwE+GQ+ZHMY7knnKgyn25VwoqvdskaOqf/9vq9ZT
EU5wDzClh62ViTuecQLlyxZ4vGOuNp6ywy2SHHBMDs+yXy/9ghsAopSf3G3+TITjQQavRyAs31gp
WZkoaAOA2lienhh/Za45TRne9CWKnPL/kKYQ/kzgnWe1bAjat4FSdS8CU/P/y9/bF+KeSpX6yFty
iRKOyXfVnPTi4QIQUxjtlG0sAi+/EfQe2fSudZO9PD19LZlfhsLz3+Ff1mdiJsGWb5iWpR8eBOc+
pWS/1GGIPyoY5PHagYWbBm8/zG9WHl3y/MdyxBx7H1TTGw0XC76dzoXYOdRsP1LqQ/CXFP5B/kkn
ETkfyZ7Ikj2x9fLQ2goNheUNBXm8h7lB9krGa+uN1trZF15p/8jkgqej04nxk5iyTyHOeb1S6vUE
B02hO5x8sXtf3tke8tV+N9g7gXLemCcFIYGdXoUkQx87zwXFw3RQ3tvG8snZpc5/y5rao5D1UqGX
B3ICm+R9kfkKHL1HIeulQkkJ5HlK7cUjgRN9v49cJKazXqlj3G0sJPDpsVLh5YE1N6negYUdYViH
IjGH8iJpvRKdtBXi5VA6VSpeqQDcDAhsAFAeAEB5AADlAQCUBwBQHgBAeQAA5QEAlAcAUB4AeuD/
8ICajm3IP5gAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-03-25 23:20:50 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Second-line CTX with versus without Bevacizumab, outcome: 2.1 Progression Free Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt0AAACACAMAAADgZiXAAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-03-25 23:20:55 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Second-line CTX with versus without Bevacizumab, outcome: 2.2 Overall Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuQAAACACAMAAAB0gIwyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-03-25 23:20:58 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 First-line CTX with versus without Vatalanib (PTK 787/ZK 222584), outcome: 3.1 Progression Free Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAx4AAACACAMAAACyYE+iAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-03-25 23:20:59 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 First-line CTX with versus without Vatalanib (PTK 787/ZK 222584), outcome: 3.2 Overall Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAx0AAACACAMAAABZV/ShAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-04-06 09:33:05 +0200" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 First-line CTX with versus without Bevacizumab, outcome: 1.1 Progression Free Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-03-25 23:18:45 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.02" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 First-line CTX with versus without Bevacizumab, outcome: 1.2 Overall Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>